var title_f19_25_19856="Verrucous carcinoma";
var content_f19_25_19856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Verrucous carcinoma of the oral cavity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Verrucous carcinoma of the oral cavity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19856=[""].join("\n");
var outline_f19_25_19856=null;
var title_f19_25_19857="Ingrown toenail 1";
var content_f19_25_19857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ingrown toenail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The nail plate is entering the lateral nail groove, causing erythema, granulation tissue, and discomfort.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19857=[""].join("\n");
var outline_f19_25_19857=null;
var title_f19_25_19858="Treatment protocols for germ cell tumors";
var content_f19_25_19858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19858/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19858/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19858/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19858/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19858/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19858/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19858/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19858/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/25/19858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14151835\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with advanced germ cell tumors.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of both male and female patients with germ cell tumors. Additional regimens may be added over time, particularly as treatment evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with germ cell tumors. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"       \"Overview of the treatment of testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"       \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"       \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"       \"Treatment of malignant germ cell tumors of the ovary\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14152224\">",
"    <span class=\"h2\">",
"     Regimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14152280\">",
"    <span class=\"h3\">",
"     Regimens for advanced germ cell tumors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H937144214\">",
"    <span class=\"h4\">",
"     BEP (bleomycin plus etoposide and cisplatin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H937144239\">",
"    <span class=\"h4\">",
"     EP (etoposide plus cisplatin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef63222 \" href=\"UTD.htm?38/62/39917\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H937144264\">",
"    <span class=\"h4\">",
"     VIP (etoposide plus ifosfamide and cisplatin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef51451 \" href=\"UTD.htm?23/48/24334\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85695 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-CBA3D06F7A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19858=[""].join("\n");
var outline_f19_25_19858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14151835\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14152224\">",
"      Regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14152280\">",
"      - Regimens for advanced germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H937144214\">",
"      BEP (bleomycin plus etoposide and cisplatin)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H937144239\">",
"      EP (etoposide plus cisplatin)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H937144264\">",
"      VIP (etoposide plus ifosfamide and cisplatin)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85695\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85695|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14382\" title=\"table 1\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/62/39917\" title=\"table 2\">",
"      Cisplatin and etoposide for relapsed germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/48/24334\" title=\"table 3\">",
"      VIP germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=related_link\">",
"      Treatment of malignant germ cell tumors of the ovary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_25_19859="Patient information: Long QT syndrome (The Basics)";
var content_f19_25_19859=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86973\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"         Person having an ECG",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/7/39039\">",
"          Holter monitor",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/21/32085\">",
"           Person having a stress test",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/2/6178\">",
"         Patient information: CPR for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/50/26402\">",
"         Patient information: CPR for children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/60/38850\">",
"         Patient information: Implantable cardioverter-defibrillators (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/49/6931\">",
"         Patient information: Pacemakers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/39/34419\">",
"         Patient information: Sudden cardiac arrest (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/5/36946\">",
"         Patient information: Syncope (fainting) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/51/27442\">",
"         Patient information: Ventricular tachycardia (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/10/24738\">",
"         Patient information: Cardioversion (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/20/11589\">",
"         Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/16/20741\">",
"         Patient information: Pacemakers (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/27/34229\">",
"         Patient information: Seizures in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/26/419\">",
"         Patient information: Seizures in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/9/4245\">",
"         Patient information: Syncope (fainting) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Long QT syndrome (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H70626965\">",
"      <span class=\"h1\">",
"       What is long QT syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Long QT syndrome is a condition that affects the heart&rsquo;s electrical system. It sometimes leads to serious heart rhythm problems that can be life threatening.",
"     </p>",
"     <p>",
"      There are 2 main types of long QT syndrome:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A type that people are born with &ndash; This is caused by an abnormal gene.",
"       </li>",
"       <li>",
"        A type that happens later in life that people are not born with &ndash; Certain medicines can cause long QT syndrome. Mineral imbalances in the body, such as having too little potassium or magnesium, can also cause long QT syndrome.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H70626980\">",
"      <span class=\"h1\">",
"       What are the symptoms of long QT syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with long QT syndrome have no symptoms. They find out they have it after they have a test called an electrocardiogram done for another reason. An electrocardiogram (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;) measures the electrical activity in the heart (",
"      <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      When long QT syndrome causes symptoms, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Heartbeat changes called &ldquo;palpitations&rdquo; &ndash; These can feel like your heart is beating hard or fast, or skipping beats.",
"       </li>",
"       <li>",
"        Fainting, or feeling like you are going to faint",
"       </li>",
"       <li>",
"        Seizures &ndash; Seizures are waves of abnormal electrical activity in the brain that can make people pass out or move or behave strangely.",
"       </li>",
"       <li>",
"        Sudden cardiac arrest &ndash; This is when the heart suddenly stops beating. It is a medical emergency that needs to be treated right away.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H70627012\">",
"      <span class=\"h1\">",
"       Is there a test for long QT syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. An ECG usually shows whether someone has long QT syndrome. But some people will have other tests, too. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A Holter monitor &ndash; This is a heart monitor device that records your heart&rsquo;s electrical activity over hours or days. You wear it around at home while you go about your usual activities (",
"        <a class=\"graphic graphic_figure graphicRef76605 \" href=\"UTD.htm?38/7/39039\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        A stress test &ndash; During this test, a doctor, nurse, or physician assistant records your ECG while you exercise on a treadmill or bike, or get medicine to make your heart pump faster (",
"        <a class=\"graphic graphic_figure graphicRef60855 \" href=\"UTD.htm?31/21/32085\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Tests to see how your heartbeat changes when you get certain medicines",
"       </li>",
"       <li>",
"        Blood tests, including tests to check for the abnormal gene that causes long QT syndrome",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H70627073\">",
"      <span class=\"h1\">",
"       How is long QT syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends mostly on whether you were born with long QT syndrome or developed it later in life.",
"     </p>",
"     <p>",
"      For people who were born with long QT syndrome, the main treatment includes medicines called beta blockers. These medicines help keep the heart from beating too fast. Some people need other treatments, too. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Other types of heart medicines",
"       </li>",
"       <li>",
"        A pacemaker &ndash; This is a device that goes under the skin near a person&rsquo;s heart. It sends electrical signals to the heart to control the heartbeat.",
"       </li>",
"       <li>",
"        An implantable cardioverter-defibrillator (called an &ldquo;ICD&rdquo;) &ndash; This is a device that is put under a person&rsquo;s skin near his or her heart. It can sense abnormal heartbeats and then treat them with an electrical shock.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For people who develop long QT syndrome later in life, treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stopping any medicine that could be causing the long QT syndrome",
"       </li>",
"       <li>",
"        Fixing the mineral imbalance that is causing the long QT syndrome",
"       </li>",
"       <li>",
"        A pacemaker",
"       </li>",
"       <li>",
"        Medicines that control the speed or rhythm of the heartbeat",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All people with long QT syndrome who have a sudden cardiac arrest should be treated with defibrillation. This involves using a device to send an electrical shock to the heart. It sometimes works to get a normal heart rhythm started again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H70627088\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have long QT syndrome, you should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Follow all of your doctor&rsquo;s instructions about follow-up tests, so that he or she can monitor your condition.",
"       </li>",
"       <li>",
"        Avoid taking medicines that are likely to cause long QT syndrome. Your doctor can give you a list of these medicines.",
"       </li>",
"       <li>",
"        Let your family members know. Because long QT syndrome can run in families, they might need to be tested for the condition, too.",
"       </li>",
"       <li>",
"        Ask your doctor or nurse whether you need to make any lifestyle changes. With some types of long QT syndrome that people are born with, abnormal heart rhythms are triggered by certain things. These include intense exercise, loud or sudden noises, or diving into cold water. If you have this type of long QT syndrome, you will need to avoid these triggers as much as possible.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H70627103\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=see_link\">",
"       Patient information: Syncope (fainting) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"       Patient information: Sudden cardiac arrest (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=see_link\">",
"       Patient information: Pacemakers (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=see_link\">",
"       Patient information: Ventricular tachycardia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/2/6178?source=see_link\">",
"       Patient information: CPR for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/50/26402?source=see_link\">",
"       Patient information: CPR for children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=see_link\">",
"       Patient information: Syncope (fainting) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=see_link\">",
"       Patient information: Seizures in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=see_link\">",
"       Patient information: Seizures in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"       Patient information: Pacemakers (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=see_link\">",
"       Patient information: Cardioversion (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/25/19859?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86973 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-5480875BC6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19859=[""].join("\n");
var outline_f19_25_19859=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70626965\">",
"      What is long QT syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70626980\">",
"      What are the symptoms of long QT syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70627012\">",
"      Is there a test for long QT syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70627073\">",
"      How is long QT syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70627088\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70627103\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"      Person having an ECG",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/7/39039\">",
"       Holter monitor",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/21/32085\">",
"        Person having a stress test",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/2/6178?source=related_link\">",
"      Patient information: CPR for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/50/26402?source=related_link\">",
"      Patient information: CPR for children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=related_link\">",
"      Patient information: Cardioversion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=related_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=related_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=related_link\">",
"      Patient information: Seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=related_link\">",
"      Patient information: Syncope (fainting) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=related_link\">",
"      Patient information: Syncope (fainting) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=related_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_25_19860="Dalfampridine (fampridine): Patient drug information";
var content_f19_25_19860=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dalfampridine (fampridine): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6725?source=see_link\">",
"     see \"Dalfampridine (fampridine): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9831169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ampyra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13922165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fampyra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat MS (multiple sclerosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705943",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dalfampridine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Kidney disease or seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11646 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19860=[""].join("\n");
var outline_f19_25_19860=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9831169\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13922165\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030558\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030560\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030559\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030564\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030565\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030567\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030562\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030563\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030568\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030569\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6725?source=related_link\">",
"      Dalfampridine (fampridine): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_25_19861="Hydrocortisone (topical): Patient drug information";
var content_f19_25_19861=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydrocortisone (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/54/21352?source=see_link\">",
"     see \"Hydrocortisone (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/33/7702?source=see_link\">",
"     see \"Hydrocortisone (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8116177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ala-Cort;",
"     </li>",
"     <li>",
"      Ala-Scalp;",
"     </li>",
"     <li>",
"      Anu-med HC;",
"     </li>",
"     <li>",
"      Anucort-HC&trade;;",
"     </li>",
"     <li>",
"      Anusol-HC&reg;;",
"     </li>",
"     <li>",
"      Aquanil HC&reg; [OTC];",
"     </li>",
"     <li>",
"      Beta-HC&reg; [OTC];",
"     </li>",
"     <li>",
"      Caldecort&reg; [OTC];",
"     </li>",
"     <li>",
"      Colocort&reg;;",
"     </li>",
"     <li>",
"      Cortaid&reg; Advanced [OTC];",
"     </li>",
"     <li>",
"      Cortaid&reg; Intensive Therapy [OTC];",
"     </li>",
"     <li>",
"      Cortaid&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Cortenema&reg;;",
"     </li>",
"     <li>",
"      CortiCool&reg; [OTC];",
"     </li>",
"     <li>",
"      Cortifoam&reg;;",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Hydratensive Healing [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Hydratensive Soothing [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Intensive Healing Eczema [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength Cooling Relief [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength Easy Relief [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength Intensive Healing Formula [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Plus Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Dermarest&reg; Eczema Medicated [OTC];",
"     </li>",
"     <li>",
"      Hemril&reg; -30;",
"     </li>",
"     <li>",
"      Hydrocortisone Plus [OTC];",
"     </li>",
"     <li>",
"      HydroSKIN&reg; [OTC];",
"     </li>",
"     <li>",
"      Locoid Lipocream&reg;;",
"     </li>",
"     <li>",
"      Locoid&reg;;",
"     </li>",
"     <li>",
"      Pandel&reg;;",
"     </li>",
"     <li>",
"      Pediaderm&trade; HC;",
"     </li>",
"     <li>",
"      Preparation H&reg; Hydrocortisone [OTC];",
"     </li>",
"     <li>",
"      Procto-Pak&trade;;",
"     </li>",
"     <li>",
"      Proctocort&reg;;",
"     </li>",
"     <li>",
"      ProctoCream&reg;-HC;",
"     </li>",
"     <li>",
"      Proctosol-HC&reg;;",
"     </li>",
"     <li>",
"      Proctozone-HC 2.5%&trade;;",
"     </li>",
"     <li>",
"      Recort [OTC];",
"     </li>",
"     <li>",
"      Scalpana [OTC];",
"     </li>",
"     <li>",
"      Texacort&trade;;",
"     </li>",
"     <li>",
"      U-Cort&reg;;",
"     </li>",
"     <li>",
"      Westcort&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8116178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aquacort&reg;;",
"     </li>",
"     <li>",
"      Cortamed&reg;;",
"     </li>",
"     <li>",
"      Cortenema&reg;;",
"     </li>",
"     <li>",
"      Cortifoam&trade;;",
"     </li>",
"     <li>",
"      Emo-Cort&reg;;",
"     </li>",
"     <li>",
"      Hycort&trade;;",
"     </li>",
"     <li>",
"      Hyderm;",
"     </li>",
"     <li>",
"      HydroVal&reg;;",
"     </li>",
"     <li>",
"      Locoid&reg;;",
"     </li>",
"     <li>",
"      Prevex&reg; HC;",
"     </li>",
"     <li>",
"      Sarna&reg; HC;",
"     </li>",
"     <li>",
"      Westcort&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12990658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat signs of hemorrhoids or rectal irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ulcerative colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12990657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydrocortisone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bad infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12990656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12990655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rectal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697930",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Burning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698298",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12990651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding from rectum or rectal pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12990650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rectal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use suppository, rectal cream, foam, or rectal suspension rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695758",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take foil off the rectal suppository and put in, pointed end first. Do not handle too much.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695110",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If using on the groin, use a little bit. Do not wear tight clothing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12990654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12990652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12990660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11697 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19861=[""].join("\n");
var outline_f19_25_19861=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116177\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116178\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031249\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990658\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990657\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990656\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990655\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990651\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990650\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990654\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990652\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990660\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/48/8969?source=related_link\">",
"      Hydrocortisone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/36/35398?source=related_link\">",
"      Hydrocortisone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/46/22249?source=related_link\">",
"      Hydrocortisone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/54/21352?source=related_link\">",
"      Hydrocortisone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/33/7702?source=related_link\">",
"      Hydrocortisone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_25_19862="Cyproheptadine: Drug information";
var content_f19_25_19862=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyproheptadine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/28/35268?source=see_link\">",
"    see \"Cyproheptadine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/2/40996?source=see_link\">",
"    see \"Cyproheptadine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14959840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Euro-Cyproheptadine;",
"     </li>",
"     <li>",
"      PMS-Cyproheptadine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F155750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F155712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Allergic conditions:",
"     </b>",
"     Oral: 4-20 mg/day divided every 8 hours (not to exceed 0.5 mg/kg/day); some patients may require up to 32 mg/day for adequate control of symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Spasticity associated with spinal cord damage (unlabeled use):",
"     </b>",
"     Oral:  Initial: 2-4 mg every 8 hours; maximum: 8 mg every 8 hours (Barbeau, 1982; Wainberg, 1990)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F155731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/2/40996?source=see_link\">",
"      see \"Cyproheptadine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Allergic conditions:",
"     </b>",
"     Oral: Children: 0.25 mg/kg/day or 8 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2-3 divided doses",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-6 years: 2 mg every 8-12 hours (not to exceed 12 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-14 years: 4 mg every 8-12 hours (not to exceed 16 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine headache prophylaxis (unlabeled use):",
"     </b>",
"     Oral: 4 mg every 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F155713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiate therapy at the lower end of the dosage range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, elimination is diminished in renal insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 2 mg/5 mL (473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 4 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F155694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perennial and seasonal allergic rhinitis and other allergic symptoms including urticaria",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F155746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Migraine headache prophylaxis, pruritus, spasticity associated with spinal cord damage",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F155758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cyproheptadine may be confused with cyclobenzaprine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Periactin may be confused with Percodan&reg;, Persantine&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Periactin brand name for cyproheptadine [U.S., multiple international markets] may be confused with Perative brand name for an enteral nutrition preparation [multiple international markets] and brand name for ketoconazole [Argentina]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F155748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Extrasystoles, hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, coordination disturbed, dizziness, excitation, euphoria, faintness, hallucinations, headache, hysteria, insomnia,  irritability, nervousness, neuritis, restlessness, sedation, seizure, sleepiness, tremor, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased, constipation, diarrhea, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficult urination, urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestasis, hepatic failure, hepatitis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Labyrinthitis (acute), tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchial secretions (thickening), nasal congestion, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactic shock, chills, diaphoresis, fatigue",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F155697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyproheptadine or any component of the formulation; narrow-angle glaucoma; bladder neck obstruction; pyloroduodenal obstruction;  symptomatic prostatic hyperplasia; stenosing peptic ulcer; concurrent use of MAO inhibitors; use in debilitated elderly patients; use in premature and term newborns due to potential association with SIDS; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F155682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of this potent anticholinergic agent due to increased risk of confusion, dry mouth, constipation, and other anticholinergic effects; clearance decreases in patients of advanced age (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Cyproheptadine may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F155705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14389393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Maternal antihistamine use has generally not resulted in an increased risk of birth defects; however, information specific to cyproheptadine is limited. Antihistamines are recommended for the treatment of rhinitis, urticaria, and pruritus with rash in pregnant women (although second generation antihistamines may be preferred). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F155717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14389395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if cyproheptadine is excreted into breast milk. Premature infants and newborns have a higher risk of intolerance to antihistamines. Use while breast-feeding is contraindicated by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Cyproheptadine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/5 mL (473 mL): $64.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cyproheptadine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $42.69",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F155701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adekin (GR);",
"     </li>",
"     <li>",
"      Antisemin (TW);",
"     </li>",
"     <li>",
"      Apeton 4 (ID);",
"     </li>",
"     <li>",
"      Cipla-Actin (ZA);",
"     </li>",
"     <li>",
"      Ciplactin (IN);",
"     </li>",
"     <li>",
"      Ciprogal (UY);",
"     </li>",
"     <li>",
"      Ciproral (DE);",
"     </li>",
"     <li>",
"      Ciprovit-A (PE);",
"     </li>",
"     <li>",
"      Complamin (EC);",
"     </li>",
"     <li>",
"      Cyheptine (TH);",
"     </li>",
"     <li>",
"      Cyprodin (TW);",
"     </li>",
"     <li>",
"      Cyprogin (HK, TH);",
"     </li>",
"     <li>",
"      Cypromin (JP, TW);",
"     </li>",
"     <li>",
"      Cyprono (TH);",
"     </li>",
"     <li>",
"      Cyprosian (TH);",
"     </li>",
"     <li>",
"      Cyprotin (SG);",
"     </li>",
"     <li>",
"      Cyprotol (BG);",
"     </li>",
"     <li>",
"      Cytadine (TW);",
"     </li>",
"     <li>",
"      Ennamax (ID);",
"     </li>",
"     <li>",
"      Gubamine (AR);",
"     </li>",
"     <li>",
"      Heptasan (ID);",
"     </li>",
"     <li>",
"      Istam-Far (GR);",
"     </li>",
"     <li>",
"      Kulinet (GR);",
"     </li>",
"     <li>",
"      Pangavit Pedi&aacute;trico (MX);",
"     </li>",
"     <li>",
"      Periactin (AE, AT, AU, BE, BF, BH, BJ, CH, CI, CO, CY, DK, EC, EE, EG, ES, ET, FI, GB, GH, GM, GN, IE, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, OM, PK, PL, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, SY, TH, TN, TR, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Periactine (FR);",
"     </li>",
"     <li>",
"      Periatin (BR);",
"     </li>",
"     <li>",
"      Peritol (BB, BM, BS, BZ, CZ, DE, GY, HN, HU, IN, JM, PL, PR, RU, SR, TT);",
"     </li>",
"     <li>",
"      Petina (MY);",
"     </li>",
"     <li>",
"      Pilian (MY);",
"     </li>",
"     <li>",
"      Poncohist (ID);",
"     </li>",
"     <li>",
"      Prakten (TR);",
"     </li>",
"     <li>",
"      Prohessen (ID);",
"     </li>",
"     <li>",
"      Pronicy (ID);",
"     </li>",
"     <li>",
"      Showmin (TW);",
"     </li>",
"     <li>",
"      Trimetabol (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F155681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A potent antihistamine and serotonin antagonist, competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F155696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily by hepatic glucuronidation via UGT1A (Walker, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Metabolites: ~16 hours (Paton, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 6-9 hours (Paton, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~40% primarily as metabolites); feces (2% to 20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/25/19862/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barbeau H, Richards CL, and Bedard PJ, &ldquo;Action of Cyproheptadine in Spastic Paraparetic Patients,&rdquo;",
"      <i>",
"       J Neurol Neurosurg Psychiatry",
"      </i>",
"      , 1982, 45(10):926-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/25/19862/abstract-text/7143011/pubmed\" id=\"7143011\" target=\"_blank\">",
"        7143011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carlton MC, Kunkel DB, and Curry SC, &ldquo;Ergotism Treated With Cyproheptadine,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):552.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Craven JL and Rodin GM, &ldquo;Cyproheptadine Dependence Associated With an Atypical Somatoform Disorder,&rdquo;",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 1987, 32(2):143-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/25/19862/abstract-text/3567821/pubmed\" id=\"3567821\" target=\"_blank\">",
"        3567821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracies JM, Nance P, Elovic E, et al, &ldquo;Traditional Pharmacological Treatments for Spasticity. Part II: General and Regional Treatments,&rdquo;",
"      <i>",
"       Muscle Nerve Suppl",
"      </i>",
"      , 1997, 6:S92-120.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/25/19862/abstract-text/9826984/pubmed\" id=\"9826984\" target=\"_blank\">",
"        9826984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hintze KL, Wold JS, and Fischer LJ, &ldquo;Disposition of Cyproheptadine in Rats, Mice, and Humans and Identification of a Stable Epoxide Metabolite,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 1975, 3(1):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/25/19862/abstract-text/234828/pubmed\" id=\"234828\" target=\"_blank\">",
"        234828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holland S, Silberstein SD, Freitag F, et al, &ldquo;Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1346-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/25/19862/abstract-text/22529203/pubmed\" id=\"22529203\" target=\"_blank\">",
"        22529203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lappin RI and Auchincloss EL, &ldquo;Treatment of the Serotonin Syndrome With Cyproheptadine,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 331(15):1021-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paton DM and Webster DR, \"Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines),\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1985, 10(6):477-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/25/19862/abstract-text/2866055/pubmed\" id=\"2866055\" target=\"_blank\">",
"        2866055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wainberg M, Barbeau H, and Gauthier S, &ldquo;The Effects of Cyproheptadine on Locomotion and on Spasticity in Patients With Spinal Cord Injuries,&rdquo;",
"      <i>",
"       J Neurol Neurosurg Psychiatry",
"      </i>",
"      , 1990, 53(9):754-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/25/19862/abstract-text/2246657/pubmed\" id=\"2246657\" target=\"_blank\">",
"        2246657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker RB and Kanfer I, \"Pharmacokinetics of Cyclizine Following Intravenous Administration to Human Volunteers,\"",
"      <i>",
"       Eur J Pharm Sci",
"      </i>",
"      , 1996, 4(5):301-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wians FH, Norton JT, and Wirebaugh, &ldquo;False-Positive Serum Tricyclic Antidepressant Screen With Cyproheptadine,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1993, 39(6):1355-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/25/19862/abstract-text/8504557/pubmed\" id=\"8504557\" target=\"_blank\">",
"        8504557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9311 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19862=[""].join("\n");
var outline_f19_25_19862=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959840\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155750\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155712\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155731\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155713\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795920\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795921\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155692\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155678\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155694\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155746\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155758\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155748\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155697\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155682\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299111\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155687\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155705\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155689\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14389393\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155717\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14389395\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323084\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155701\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155681\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155696\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9311\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9311|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/28/35268?source=related_link\">",
"      Cyproheptadine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/2/40996?source=related_link\">",
"      Cyproheptadine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_25_19863="Variant histologies merkel cell";
var content_f19_25_19863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histologic variants of Merkel cell skin cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 459px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHLAOYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDhr7w1rE2uTXGnxyS7pi7ow2HBPJIIrtLDVm07UI7q01OKOVMFUSTczEj5s4HC49a2Jfibql3EI76Kzk25HmiECX8SDj8q828ZeKHstr6Tp8Mmo3TMWyvJhVSzhguCT05J9a9G7SvI+ns6UW5rT7zsdM0a01bW2uZ3V97+azBw7E7gSfY1yL69NpfiG5ivle5025T5o8YCLg4KN2Irs/D8sI0yDV2ure0tbmDdB5jBTK2NwAGf0pPFieHtTgi1TT4IryOVfMSSPKgsODlT7nqOOtF7ltqTtEzQ8NlaRXGj3zGS8ffHJt2lgCMk46EE7SPWpNDszq/jSCxuJpZ1u2CNtbc6sQTuHX3rV0fXdNmSx0bxDoVutltKxTWoMc8THGSDnng/pXaRXfhjwFNLJoO681IxM6yXJwiEj+I+vsP0pSk1olqROcldKOvQYdA8PeCtTa5vry9vry2TzI4UAVUbbxu9TnkfWvN9W1FtZvXvZ7h7m9ZjGI0zuibOR82eR61f1OfVLzwfb6s+ofbzf3EktxIowqEsVKYxkYwPwNZWmtG6rGHS3byml3L8jHb95R6An/0E04q2r3KpQSXNJ3ZFbzm1uGs2S5+cHfJKWIRv4gufuj09ulbl5oksVu620guCFEjW4wVmcAcr71gz366xZP8AZ53VolG5lbrnnHzck9gfQ1T8RyXAjtVRwSCAilyMMW65z97pjpVWNdloO0/4h3MTrDDbWiwB8GEQgxcDA+Vs7ScEZBrtRo9h4o8OXt/5cdleQL50sSPiLgHlccjnII9q41/CV1qhMptZ1uYWyXjiyJB1Jf8A2gRwR17+tdfH4g1TSNGuE0XRLe8vLmcQXa3DYQR47DoPQ1MvIwaai+5hW2n2tlPFFqFyybkVTH1MgPO4fSu+8UeCEu/D+mT6bqEGm24thGVkb5wx5BOO/J7c1xt5a2VpqtvfapdCBCUYRtyR3wMjuemateG7+W7gu4LqZpLO5mGJJiD5ZTLEntj1od3qmXO8tYu1jsJPClta+D7y+t74X+pW0YdltXKsiDBY44J7knA/SvIZNfV7gytbKEBVV2sGZgc9vat601O90nxNHe6PCwVpCAHZfLlXHKE56YNW9duNJs5Uvk0i2trORC8xtmHmEj+EbuARnr3oimt9QipxeruQfELTbfTdB0NbgSPe3sDXEoUZSNSeDx1YY7VxFnpM2raKtzGssEkWVy+NpUHIUE9OTn869B8W63b31hA1tbPJalAsTTtkwLjJzjvwMdq4C11iezkRInkew2lmgJ3FTjIPT9KqN7Al/Oek/DWGz8B+ENR8VvbPqF7eR/ZVVJAojBOcEDJ5IBJ9sCuJ0rXI9S0m600w29vJO5uYvKHluxGTsY8+vfoa6X4F65qOq+LE0XUYlvdH1BJI54JFBCEKWB9sYrh/FMdjonjzUbSwjIg+0uI2PJC7jgD24qY6SaMKTjGq13/pFu6sxPCEuHmiXKqMP/s9D6ng1ItvbwsykW6EjzHkZvmXBHZRyeQMVv6XbrJpquJYWgcBBgcu3Ujp24psWhWD3H2W4EtlG0oIkJJbOeDgdvpjNXc6peRi6vJa6h/ZSzSxLNaFhEUGZFGd2GHuTzXTSaxeaTYMl1GLeRMAhMOWB6dzkZ7fjWRqVvZaZeXKaZGtxJbofMnuT++kx2VFxhfTqa3PCUeg6np0B1S0Fg/3ZcMTnjhsN0x6e1J2tcnmsrtHM2muGYMwlkJwQI2YgjIJ5z/St3w1p58QX8FpeSOtv5ikuvDR45B/TrVXWfh/9miGraZ4j0q4soyWHmSESsPTbj9K3vheY7fV4pEnmEkv7pg0Q2sM9uMUOScW0V7Xmg7Ig8feGLPwzfWscGqT3Yni/d/aBllTOTgjg5PFeY32ka82q3Z06eO1tyNwLkLkHuBzX0n8TbKHVLe1tWt1F3bA7XRQZFGDgDtiuL0XwPZQpb3Oqyjz7lisfnNtRiMc7eMmohO8dTmhJTpLn3Ol+C2j+I4fBTS+J9aRpZ7jdAGuQ4Ee3A57c54ortvD+jpYwhb2CByoKqhTO0cdunbtRXNKepwSqOLsnofJjXc3nNGuZRvMpUsATgZIPsfbtVqTQYNd1q31G7QtbyQpElvHIU2KTz8wIPOSOegPesliHu5/JnlZ3AZcgKRnqPr1/CvU/A/gy28TaelzDewpqNiMzWzEYkTsR7jlfSuudre8epNxceapscbqvhU6lbx+Hb5ruy0bw3cTrbSvFtmuhKwb6FVxgMOoPau70GLSpdCtdFW38u0tI9kU0eRIz5+83bOeeK56PXtTGoxQ6nBcyH7QYbKz2HckXXYv0wMCvQR4U1e8VVsB5LbfMZCQssY9GXseOPWs7KG5NKFKlHs+5wl9plhp+uWsmp3amRXMiM33TkYXBHU4HTtWPcXsFzFMguUdLmZo2YkhSBy38639S0ebUoL4fZX32zNHAep3sTnr3yT+dbPiL4VSaf4X0WziSV7pIEN2Ex+7kOdzg98k4IzzxVcyTSZ0SqqFl1Zl+DdyaNqVobaZoEmJiEw4lHyhtw/unqCOlS6no0VrZvcWb3X+mL9xW3smTyqN/EQR1Iqt40CaBrOjWtnqoAitUdHXAPmDPU/UDiui0a/utd8JS6hESbvTbxAbiFBueNxksQvUj+VF+pk3Zcy6nJaXZXGo39tarZXbPPIIipTEm0Drg9cDJrT1ewsPOkltLeW5WCQFd52tGc4PYj6VF4ge8lsY5vtNr5saJdboAyvHKflVEOcn6ds8mr+r6zE94Ibe3tFjj2b2Rj+9I5OecEZ6073Ki5s6RLiwj8P+ZHcahYw7eFW2A3Ej+9n5h6kYqlofi7TIcWg0eezntD/rQ2TM3ckEd+OfSuK1XxjqesW91p7uZXYH7MuwKF2g4VQOAPSqHg+S5j8T2qXJaa0aQK8QfLqDjnJHqenv7UuTTUn2elpGrrdt9tvZTP8A6TM7+Y8bMcjjKn2xwQKnh0U6XJDb3avbvdfvyJV+VeMLu68nk/j7Vo/EJU0nxlqUVnDGYJkSRRIpK4KjOSO4x0+lYaeMWuprRboNL5YKxyuOV54H064zTWqTRpH34prqV7qRbl7i3RLVo/LVkXPyMwYhR3xzkZ/wp0MFxd232bVYoWhiYFlVdzYyP8TzXYXemaJYaDZajcG8gS5L7YbVVySp5YA9FOR+NZv2C21jR5/7AM8kWzDqy/vl9GIGcjHfsetNSQ1JNGZqj2NyyW2niJRIAhtbpN4fBwMH/wDVXCebo9rrq2sknnXPnbHjQEKT0Knkk/jWxqKpoUdpfamJrVy6pE0obdkHOQD9OTV/VYfCMotte0+ya7vbiYFHOdrSA5JwOvr0o22Im9Vy2N3UvFdj8OWg0/whp6RarMqme9uhvaNWAIRB0HGM/hXP+M4YL7WLLVbO0uFW7sYpbh4Ywds7ZLFc/UHFS2NvFrevFp9PGoTTuFwsjKz9sAYxx/SvSvBPwunW2u77xRPOlpEWENvbAqXTqSxbkd6luMNWYTUKPvSZwaaa9l4Ttbe52rPPPJMVfK5iKqNxI78c4rZ8IeIdGgef7fbSGBojGkkcm9IWU4yqkAk475/Out1nxPp97ZLo+k6EBp0TAtPPyRjngjkZ9c5rjb5vCNrHJLBpa21zlmAS7crnnkcc9aE3JWaNIqUlaUWjQuvAXga6EWp3PiyRWd2ZX4Y5GCVwRkH61S1uy8OaWJbixlvL+KKNipZdynjg5HC89q57UUkvrKSCxk8qJvmHknzCh245A5/SsrTLPWNNmie1vzcK0g2pE25iMY2lD1ye2Kai+41ScXu39xP4AudM1bX0sb/fZ2twSgkXlIpDja3PbPWvXvBngy88GXuqXusSQyyRlRAIpS4dm4BKkAgcA81xWh/DTV9S1SAPYhLCceY7tgGIjBAOO4PY163r9sbW+mmcObiUoGBbO0KoA/qfxqJyu7JmFaq3JQUhdIWPWZ5g7v8AaiMtIw646/8A6q474m+FbjXtVtS90U0+zi2lmJGw5y0gHc4xXQzSy6cqXFvHIvmZUAHH4mvPfGXi2W+1BNHtXlURpmeUEAFv7ufYfrShF3uhQg3O62E1zxrNNLDHqf8AaktlEnl29vaHDAD+N27nH86K5vUTIscYjuYYZB99plPzZ7huhorblR1csVpHQ5jVjZx3D21lbgSAqDIz8s3c/XmrXhCTV9H8c2EkUiSAEAbXOXXnLN6DIxS2g0ue9luGTzFfnGSCvf8A4FyD83pWX5uoandyW+lpHDavLhn3CMbfdj1ND1RMrPXp5HYHxT4rnvNW+x3gjlJk+e3VWKAcAK2MhuvIrP8AhNrGteGPFlvdam0qpeN9nlMrFjMW+6T3znnNdF4Y03SvAemza1r1/aapeqirFp9q5K7+zO/oPpUVh4h8L6tqcLsHs75pB5shGY4cnhlH1xUOz2WhnaEuh7f4SsbW5uRNFj7FCxmZn6lsnjPfnn6V5r8ZfE+uWWoXyC8kh024YeT5afMRjjtnA+taA8TXdn4cGmQIN5faJyMblH8Sjvz0NeceKtbkmv7Z9REk8aKDiZsjJ+9x6ewqIU3zXYqdJqbnL0RhWzXGrzNFqEZkQMp+1ZXIJ9Ox+leo+Ctbs9I8MvpNm08U8s+JncBDIegAxnAwK4HQ7T7VcXF1ZRPa6dD+9leUFoYwvIwx/i9vU1opc/adRu206GSVYUAViN23d1fg45Pp0rWSUtDd8s17xH8QXntNfvtNghkia0Yqjsow3HEjdzkZwR6+9UNKt31CKykms0jO1lIJ28gkkg8d62PDnjTV5Ge21i2tr9LF2LCSASSRxk8hWIOAByBVaO5E1/aziMcllfYCm1PmK/L0Gc9uKFdaBTk38R0NhqOhaQkCx6eLm9ZAZLhpyq47qOOOeCana4tNLvxf6ZbrLJM2IzKQDEcZIIzjjsR1/CsK5sJr77Qls0bCMABS2DzyefXkEfSl8J2MHmx6Vq8sslmnDTp/rIXH3SPbgZFKy3Ktu0dW3ie18YaDqq6jbJYa/YQbvOhQ+VcoeMYP8Q69/wDDyTUnllMEdpFtnXAEsZyGOQvTtXqy6ZpFrNPA017dO+Q0/wDE4zk/Kfpn8K5uTRFm/wBG02yKOzfI/OX56Y7d/wA6I2WwqULJpbE/jy0a4fQ7CyvbeRrTT1jkRWVmR8knbz3zjNYvh211PSdcg+23tvp7scSfaHIUIcYXGORiqGq24iu3guHgilDF1WX91wvRev3hjr70y4nuHuNtzLKvmwiTYWJDnIGQ3TI5qktLDVlpc9C8Wah4f1/TjZeMY7e+gRtttdWEux4z/Dz0OeayF0TRofDdjZ6LdNBBbszxz3X39zHnIHT61x+i+dcO0dpKRA4WbYVzscjC4J6HpzxWlHppkSNr+6kW6jJIhZSA5OMFgfSkopaomNKK95LU9u+DvhaPRpZr5pra8lZTIZlOQucnA7D69a53x38Tb/U9Mj0vTWhEszvFcMhILc8KvpkVZ8Iy3Nj8ONYsoYQ0k+d8ofY4DcZIzx+FeBajJLZ6kU8ySIh8AjcdmMcj/a9D2xWcYJycpHPGlF1JVKmtrWOp0q4vf7QnsLlr2GaSMlUCspDZznBIHQEY/Gqev2dzc6g5js5prYJF/AQGO3Pbvg8djXba14v1CHSLLTNTaz1a/it0KzSgeejMAxAfIJwrDNcVbeKNfvv9GkkMFoGdVt4k2J6bvUngdTmtU2zdOUtyPQIZvOUzztalAHhYfLkDtkHJPQdq9G8HXT6try2sE8C3UuDJsxuGOpVfXHJA+tcBr/hLxYrwz2ulXNxaSx70ntYCwOeegyR1NdB8Gvhrr0njK21vXoLrTNIsHN081yfK3uBwFBwQOmSRjAqZyja9zOpiIQjY+ltUkttE8NR2nmfejFtEZXOSxXGSx5981x93qn2i3Z55Q0mPmc+3f+tReI/EFl4gls73TJI7y0VmELrnHHDH8f5YrE+xnUZLdraRjFvzIG4CqvJH4+n1rnhCyuzkw1DljzT3e5a1GHUItFmmgOBKp3vIcbI1GS/PTPHPWvK9MSC80LUL97ZXMDLKN25S4yQc9/Q/gc17R4p1rS9G8Mi58QWQlsbxxAkQypdT1J7nt+lefjxN4WtkzokM9tZQL5aRNGzuSfUf45rWDdtjppVJO6SOMUpCIpRdLC86b5UU7xuPpkdKK3LiC0jR5p23x3UpmjRIPmAwBk7Rx9KK2udakralKbwNPrdnK3hS90u6vj80luJdsnsMNx29anh8B6Z4W0ZNT+Il5JFcuNltpVm4dg56k44z1PHArE8OeFdTsLiTXL8S2EMZMoeGTYXYn5VXHTPc9AK6W78Y2WsGBvFuk2eqW6HbHcxM0dxEB6OD8579qyfM9nocc1Uk7rY4m8ubW70WWw0vTFggmbzPtMrGSUqOgz0PbOB+dO0fwRqmooJrOOI2oHms4lXCBfmIIzk9DXUXWmaT4f1eMW9nc3UqYnijkn+9E7DuPvcDHI71lMALqW50eJ4bYubdLaMZOOchiO/fFXvsbR95aDtauri6ZpdZtZt8cURRVJCgMM+YORlegxWfok12+txafiz1WbKiGN4iFKdd2W5AHrxXTR/DrxZLo9kJrW0+zqMxNct8wyc8ADI+lWtasNWsNBkSbT9P01mIjub62ISSZPQ4JPPpU8y2RCqJ6RZPreqWusaJd6DY3ttYxMqBnlyIy4YHHA55/lXFalp2veHNIE+iziW6jKAzWbGQL8uOhGeT6jvV+xt9FMNvHrq3aMuHggiXaX69SemRjnHeu30S7sbS3ivo44bSKTBdTIScZORk/TrRtsW4pJ2MP4Vz3PjO6nTxLBLY6jACrXVvGLd5wBysgxgnH8WM4NS63eme6t7PTIIktU/0bcF+WADOAx689atXniyKPxIl9oiysIXK7WIAYkY+9zng/wA6xPFMuu6N4gjumW3azv4RcQTxRhVkYryoIGeOAaEnfUUI8rRq654htLKC00KO3jmhYlZb4qVZ5R1246ADIGfSqs+gXUF1cx6lNNFGTgNjIUDo3Hvg1gyLrVxrUSJD51vcuXKpFkAuRz7Eetdf4x0y80fVy1xK1us7HyVB3FjxjIPrz+FPbRFp8rUb6lXwzo0mrz5ml+zW8StJPdHtEp6g+tdX4d+IXh6G6SJrBV0jIAnf5p4wOPMkHp7jkZ71nardNZ6GVvmgkgliDNbHKiX0A29OeSB+deMy6wt/di3lstmm3jHzEjLb07M4ZjyR6Hr0qeXm3IqWqX5/ker+IfhJYeKdUk1jw14001tOlfzSsuGMQzkjg89+uKnSb4X+FrNNEvLm612RPmmuYz8sZLcsuCOM+menevMz4O1GG6nh0+A3UewSxTRkIk0TfdPJ4Prnpz1rNl064hkNpem03puMzR7ZMKSOAwJy2R245NCi3uznhSbesn+R6vqVv4DsbeWfw94gWVrhdwgmUsSPTOAevrVbw1rKajH/AGfeiSUQDdFcBeVAzuXnqP14rjrPTrDUbIRW0zW7gh4ZDk5wcFSD2q9HPJ4f1GKeWUNNbqVSNdpEnP3mHYYBFVy6WOtQtHlbudDonjfQteL+TpN1Fd3ReO35O2WJMgSMO/TJHtXHWtul1ql1LHaxTLaASTyuCYVA/jJ6AE9Aetes/wDCY6RD4Vttd0rw5Cssjtbht21kZRkgMP4SMkV5lqvjTU9aiudM1SIW9uZDItvbKEVn7Erj5se/fFKF+xlScu33lTWBayzyXVxfQWl0mN6OjbWDcjYcfL+dFlYXlxc/ZdPgXU76dQYYbTMhCnqSxIA7c549q4uW6nnnIuYEdRw6tkMW/wBo9c9K6zRZvHFz4jsf7AuY9OsYiscNtE4VIxwSCgyXzyTnOe9U20gnUa1gja1S91DwrO2l6XrLPexj/SUs3bbCf7m7+Mg9ccZroPBdrYeNoF0rxVq+qzG6RpVd7shBjsVAHTrzmsHxsY7vXJZbi2tbS6bCl408tCeueO/erGg2TWywNCm+4ljK7kQ5OR156Akmk1deZfJzw1er6nR+FPBuo+Ctb1jS/tf2zTHlSWwlD5+QjqQOmOAfpxXpeiafFb3V5d6hKqW1mgUleACf68/rUnw88L28VoZLnfKqYXBdtrtjkn1AzgfjWR8SPHOlafcvpMVhDfWisovcHABPGBj+Icc9qw5nJ8qPPc+eXsad33ZxHxG8nx9rzmx1m2SGNAtlb3TmNXdR8y5PHOSQ3fFcHd+D/EPh21S71e08u3uWSKO43hlB65JHtnk07XtNsLiykj0+28yDdiK6lVllAJ4D4P4DtzXQ/DjWhpOk32ka5Zy6jod2FaK0uDiON/VX7e4+lbq8VodfI6aXs1oun9dSTwlEdfJsPtmo6beWabjcW8SyrKjHowzwemCD0zmit3UdUMcUFpY6BHoyhd5NncHc46AHIzjHc0UnzPVaByOet7HJ+J9YutStzbMXkuTwykEKuOxA7DrWJpwtIvIsLxfNwfkSPgIT07ZPX3rrN+r+KNfVbjQbdJnYbb3To9hxnDLIgJXI9Tjr1NZ+o6f4X8K65I9xqOoanepJ/wAetuiBVb/ez1Bppq1jVVEumoz4oeIBb+J7azt45Hn02GO3kmDhQ+ACCARx1NWfhpDPrfioSoVtgCTIUUEhxk5YDr25rn5rlfFGuzXSxG1iKHHm4cPg984Bzj/CvU/hRoyaPpes61MsqtJDnzJRtZjzyPqaUmoxsS5OnTv/AFqcV8Uo9Um1P9x4kluWhOx4WymwdAOeCef84rndItJLbR9WN6ES3laI+dLMJA7A8LjqMDNZ+oQ3l9q94ZXkMLyMqckt97g5z/8ArNdV4mSPTLLTtO1gRrDKFuBJMNyhjkdup7VVrJI0jDlSMW5msbu9tJo0eZHHlKqSbmOOMHn37UjT2d64fzpESAbVtwhDFeR0PGeD1P51CmmadHqlpMG/0WRgZ0iJXA7On9116+h6GupbTtC0OQXdtPLrsF4PKbenky27LggsOhI7dsZp3G5yWljm7K4hFxLIkcqrKpARnABfGByPfA7dPeuwg8bXmhaLa6NqumW99HAiyGK6KtImeuFxxjPtUOgwaQLwXunXEs89sjzLaygIBtGThu4Xk445Oa5+2ifU9Zin1OUu1xKXaVWBIB/mPap0luRbn0aPWtI1nw1p+k3HiWxtxDd3LkpBJvcLKQM4xxggZGK8s+I/iy413xE13ZXjLI82VURlmSPA2hc8DvzV3xVfpNpH9i2yJAYQywOgxkE5G446nbj6E9K0tP0G38T+HNO0lW+w+KLGIm2mBCi8jGCY8jow7fWpSUdWRy+z99r59kch4i1WXULOI72NxGoDktjzMEnr09iKzf7JiS8W7uEd0nQSN5jAbj6Edh71raL4L1vVdWFoILu4eFts7yx+VHEA2SWJ6VuXvgbXr/xALjQ7aHUNLgmxstpkk4B4BOewzxWjlFaGkqsN2VoorvXYBZrukVcmKWNg0cQGMKW6AjHSsPVfDz+c1s3mTA7mBU7RHn1wehPrWpr2l63o1pImoJPDukO1NnlqR7KMdc9fasnRdLvR4e1HWbuWaOzttsbcfNJIxwo7D+HOc89KExuS67G5oHh/UpbbzYAYxAQg2H5Nx525Pc4NbcHw0bWLt7zVtTXRtDTrJcxbJZCSCwG4jPPfH0pPhlp82uag6WUspsLOFWmTOVVs9R6k1W8Z3utT6nq0Wo6mLvT4XLWzKCWVcZII9e3FQ227Jkzk6j9mnY7XT7n4XL4cXwRZa1cxwicTC5fdkS56l2XAHGMHjFY1p8IdIXV2uYPGNpLGk3mApGoOc9GO4jFcDoGkXOqSPHHFGk0keVdSMZznkY68kYP5mtptHktYpy8JVSQORndjqOvvS5LbMxjhuR+7N/gelXHw+8ISlZNR1+wAV8yFbmNd319DW9feG7ZfDdxF8O72zjMq7ZZYpFkcjHQNng18+vpkMEyC1k8iVDwkijLZ5ywAPf19K6LQVudM1CW6tr6OyLOS5t3IOSOQR/LOKTpvuJ4eo7Nz/wAireeFfEE1+YTYXKyOwgeWUk7+eD+uc4rrJkm0Jray1y9jkexw728AMjQg4HzPjqeuO3HrUsfxQ1VSJXshJ5Z6OAjSAe4Jx9arp8RNWuNSZ4bCxtop13OkcHmEg9CxPWq957o1Tq/aSNTxb8YYrK3/ALM8M2paOJVEspyCQeytjAOO/NcW01hr1lNc6DaTGYxMzW7guTxztPU85NWbu3s9QuDqFmsEdtdAu3lwKQSpGWRW4X8q7DwJrHgjwTeyw3uso0sioEd4G2LnqowDg5xmlpBaIzS9hByhE808N3M2l3rOFeWIDb86/O2Rzj6E4r0Lw98ONU1ixmk1BMW08IMQL7MHtwK9Qsfh/wCH7e/ur4W7TyXUvnZkfITPOFx0BNdWdsMJPRUX9BWU8R/KcVbMr6U1r5ngmsR6R4PNvY6lp11fXbpuGJ2TCA4G7IOTnIz6UV2fiTws/je6TUr0TaI0INui3ESSNIoJYNjOB1NFXGcbe89fmbQxNK37xvm66v8AQ+abWXVvDGtSQw3moWcrZMgEjJ8w5I9yR6jvVdIU1bVWuoxLBNLhyo+6f+A+v+Fer/ErwDf3/iOR7cXIsQglllJHGOpJPXpXJH4g+CPCc0dtpmgvrt3EQj3U8vlRZ77RySAe5ArRTTV0dHtYRipbjTZavpcXm+HrVxeyMFeSUiR1B7IuML054raTX9S0TQLTTtce91G6mYvqJllOfKZvkUBu/HH1x3qhH4hsfEVvb6hoynTDDOTcWbknB6h0YDnuMfSqeu69DeeE3MM0kOpJeZ2yEfMjKQPwzn6UWvuauKklMsXgi06NL3TYEaI4MEjKN+W6YHYjrVW/uvtFtb2883nKHO5ZUwwJweo464rl9Hu5fLSC9nl8tPuCIcIxyeOPXAp+pHbfJdXZldx5eFGT83O0jtjpmqsaJqyO4uPh/wCJpLSWW4TydgNwihMv5ajOMDqf5+lYtyRB9tTbNNJLAp/d43b9xxn8M/StSx8Va/p8kF5HfzJLIMrv6FemeeDxXb2Wr6T4zjtLfWLOC31kNsW7hwkbtnA3qOtTeUdyZqcFd6ry6Hn3h6IaTaTrPHH5k9u0YMuWKxnBLFvU4xjrj61b0qHS9PuYLm6vc2oYtucfvGGc7f5fgK3fGNpp2i6hLp2kzx6hqNuQLp5NuRkfdVawNW8O6rcaXLqcEMIgiJXZuCnJHTHoeOaaaepUJJx5lsyp8RbeHSLq0mtonaK9YzwMzfL5ZPOQOvcfnV3TrN7rSo9TRkit4nAaTzwCjgg4A6g+3rVfwzqen67oqeGfFUgtZIndtKvBl2tJOjxP32E9D2p2raG+geG7m2adnYXBeSViWRTwBzjp/jQm9jOE23ZnSfErXbjUI7rTE1BdjIoUIeX4BG4jucgc15SdQ1a1ntPsNxdCSJihYSbDF/ukd+DxnvXR219O+jTbUjmFwv7mV87fMVQGyRyflOBVu00xLjQ55VYG45IXbyqkdM/WhJRVh+zSWhma3431S50OK31PUru5h2uXeRy+4A4CsR+P41W8A6hLe3cmnROz2WrfuJIXO4HHzIcdAQcHj3qzpukLo3hzUb0Kl/fQ7YYrJ0DLArHDTOvRz0AxkDIzW7+zxDc6h4+tzIsT21sjM+UA2t0GMDg5pNpJmUpqN7rY9I1WWL4feHINOtjGupXY/f7Ryydz+NeLeK/EtpZafcTWitO5nVGjLKFIPJOOu3t9a7H4geJDe+OddmKpdW0cwtfKf7hRCOc/UZBB/nWFpvw9svE8sGZIre2uJRJ8xwSBlR0z2Pt0qYrljd7jipKnzdXr/XoY+heLItS1I2PhuxmSU7f3m3DDjlfw/WvWtYtJPD3h7yNQZb/xB9naUbVz5RI4+pC7jVyO3+HPwuWGG8vmkvnkXdHCgd1JOQzDHAHufzpNbTT7rUTqNl4hjuGkAkw0ZVwO2MADgfjUqV7Gca0qmnT0/rT8zyjRtOuLiwnvoLOSBZJf300z8OMcICcd/wAKimWTS1urq7aOWBR5kpjywVR0PT5jz9K7bxnqkSJCL6KG0g24UEnLdxtUd+5PvUFv9kgJvXhfyvlWF1O4ycclvXjHFaqWh0RlKxz1/Pa+RHJHMVFxCpEca4bAGRv7ZPX6VDo+oLJfWciTXrJIQB5eMjjse3+FSanaTIySSJiKWQyhZUPI5ORjsMj1qWOa0jMMVvgSISsrD5GGc54qjRao3/7U1PZePBYWc9pF+7GoXQEjFv8AnmgB49elW/CXw78Nazcw3Op3N/IJUMiW6OoAY/7QH5CsOWO6itQqXaTQECMbVOIuCOMAcn1Oe1P0W/1RFt7uyhls0QoCZl2pE28AZbOMAc1DTtozGVNSi1ex9F/DqGaDwlZw3DSu0W6JDKuG2KSFz+AFdEwEqqVc7c5OOQw9PpXmGkavqWiyado9w0Gq2epSMkdzC5U5KksF9uD34r0mdxYaa7wwMywRErCmMkKOFGTjPFcU4tO/c8DE0nGpfu9Dxf8AaI12Wy1HS7D7bLb25iMxELlWLZIGSO2M0Vk+OfDuoeP9XOtWenyTW8iKiRMfmj25GeDjnk9aK7KfLGKTPXoNUaag7XXc4DQ/F2v6b4hstQnvLm5875ruC4laRJYycEbTwM8/TFXPEvgLw6/i67udPicWJYzJAT+7IbnjKg4yemTTbyU23hWxmeJX1WViqHaDsVTjj3Jzz7Vd8K2+rpZfZ5zJc3csnmpCSWZM8fgOnH402ludEaUG+Z9CLxTbw6F4NlkEMcUI+UBFA28Zz7V53pWhanqmnz6tBD9vREC3KowZ48kckdeOxrufHOrXdprmoWECk2tsyW0sEuD55VeSM8g8nBHrWD4Y1ifwxqz3WkrIYb4eW8c0oYqNw498EHt/Omr20FNOaTOfs9Nu7e8FskzjLAY3YyM8A/Udq7DRrbToHX+1LgZO1SyncsXPT9emK6f4oaRY6ei6vfqtvcXyxPaww7Q24ctJg9vbjk1wvijULXUIrlYzmOSQyZX5XHP90dOtOLutCqcly3R1/jWzludUnktrmOaJ5kFtcR/c8vaoCEHp+PvW34bg0nR7gpdatFHfNgRxowYSHB6EZOPf61T+Hlr4evtEbTdX1yG1vr6HESSDCxsM7SXPQ+2ayviD4G1bw41reG4glhKqqTW+H2lcjB9MgjFRdP3RSqRT9lf/AIJzfxM8IarbeOv+Eh0ZlMF+4nb7RKERegwWJ5B/Otrxn4svNNSDT9LmWPKq0+wg+Ycc8YPHJFbsyat4l+F2l3WlQve3elXMtvLHbjdMYG2sjAHJIB4PHGenFczqfg+5W5j1XUlSBZJREYZfvj5c4wcA9Dn0NEUjOnGMbxjvf+n8zY8P2ehahYw3179oF9Ggn+zbhHFkkYLEDeckdOB6mr0OqXN/faha+RI8xcBraVAUmAbqB0IPAA61Rv4beDTDcWjXDywx7ZGkO0svTA29eta2hvceGfDD31sTJfPGzo23LdP4TjgDPJ/CnY3aSu+5sS3EGmtcWVzYWKW+BF9lQFMcdY2xweaw/FS31totuNLsbi0snVme6XkIei7mXvk965K81fU5Y/P1G6lkt3A4dt2M85A7Z9Kn0zUp9ShkiskaC9kBhCJKcMfXP0xkUKNg5Ettyv4Z+1Ra5aSxvHLNtIkRukuchlI/unvWx8OfFFvZ+J9Tg0e1zBK75MW5g5zgBTj7uTx69a5/w8Ft4brUNSgksdIsmV5ZlH3WDDEUX95iwHJzxk9ufSvD9ta6dous6paxJL4huLQzwpGP9V2B/wB4Kcke1E2jKcotaFqw8E2mparLcXN1ZqsLeYYAwdoyf746ZHoe4q/Zah4SsLlNNCXjSp+8Fxxhhz83HQZFcF4P8TQW3iRE1AyqlzGYSFxg5Py59ckA81eubS5unvbmzRi0RQvI42gHIAzxwvTNS4tvVjcLu0noY2r23hA67eas2nS3kksrHz7i6IiR+/yjp7AmrXhy8vb/AMZ2umwxW6WN0MmOI/MExnBOMk9vSiTSdX1jWAmn6ZJf2u9iYljGzcykZ6dAeeetegQwWvwj8G33iXWLdLzW/L2rGgAEYyAEXghSdwyf8KJSUVpuY1akKUdNzg/HHgHVkvzr2tR3MOkW6iMKxBY5OAAB90c9TVFL8W2mzTQMoaIbVX1xn3xgfrXrfwz+JVr8QYr238qWVNgjntpVHG4ckeo7VQl8PeF/h/BdXOvEavfS7kt7PHCRk8Aj9Nx/CpjU6Nak08Q43jJava3U8Yhk1PV0tHFhI14ZHlacLkAEbVyc5PHQDiu2074Xa0UFzchI2uCCzySDEa44+p47VJqXjrUpryBNJsLXTtO6CGOMAsucA56jH61W8U+LXtofsolmu2cmOSROQMdceg/rWnvHRepZPb8To/8AhIPDvhS0a2iM2sXESkyND8sWR/CG5yfYVh+MNbg1eCxvbuNre1miLxWyruCgDqc8Y461e0TwjHJYafd+TfTwPB9okhgTIkyflDHtkY4rm/GNnrlzduz2q2ySBUjgJAWOMdVXH4UopXJjGLlo7sw/CfiPUk8T209xcXMZgnSNfLIOxOgwp+6Ontya+mfix4ik0D4aanqkUJuJTAFVFP8AfwM5Hbmvj5bm6tvEkcuquttA8vlFuoyDwT9K+1PCOo2uq+ErLdPDdbrdVcuVZX479se1Z191I48fqoz7M+X/AITfFlvCWiS6TrQfLP56b3KFQeMDI6UVr/E+S5v/AB7qqQwQWwiZVUiIZZNoxyOceg96K0VOMldm8aEZpSkrv+vM2fg9rDXM19ZXOm2dxaWFhJMbp4gJFAHAB7An8eDXnd1qVxcvcz+a0YJDJ5SldoJ/vbu/pXb/ALP/AIiju/E19pEOjB7fVIHN3M8m51RARg8YA+bGPert1P8ACy11Kezt7e8m8olTLGu8KQeQCWGfQYFJStJ6DjVtUlZXv2PNfEWp6frN/ZnU/Ohv7VRBNOoDebg/K/XrtwCa6i40ay8K3cdvewHUbMbZohGCrNGwzuBzwOneo/E914Hs9SC6bp9zcBlDLPcSiPJwMAgDd3575qp4h12HVxCbiX7HFFGERYYzKvlg8LkntVL8DeOuttDe+N2l3Xi/w54f8VaBDdz28Mf2GaCOMu8WDwxA6dcE/SuR07QF07w9fT+InuLbUbjyzaQ+SSY1HUuDzgg+meK9BsPidF4O8OWg0qzivAflmUErhiPvED6VVto7D4lXU1rNeLpd8r+a4kb5XXJGQw69ehxUxvHfY54QlTbv8KPMrzQ5llH2mSN7fyifNLhfmPI4zmun8KeLdSgd7WF4pneIRCGcb1cAYHB74xVrxV4P06xsxpln4gtNQuk4VIGwSuOh6964TStKutP1ezW7V2ljuAzxglcKOSc+mBjPvWl00dPMrbXTPcPBviaTSIruWPSIYLqQbBJGNuDjklf89a4nxpqU+q2Pm6rcia4aRjHHk4Y45APb1/CotM8WXmqQ3EupyRmCV9kD20fltC/px95T938jmqGoC6W6kgMbtvIZmIwoB6bcd/X2zUxik7jjCN+a2pn2moyxTQJK0jxFvL3ucg/5xwa6DxbrNyIIrK1nmt7a4QKslvzu4HXnpnOR9fasK+XyrdZtQQrdQA8hWRFUZ5Yd+cYNZ9tZXU1/Ak7uxVtwUAFWVu4PY8d6t9zSTUtDtPBunw+JdM1HQpJ4VuJSJrG5cE7JkA+Vz12MM8dj0qnaafNperCxuozp5Xe8vlK26Q4x8pPXrn8q6G2sI/DXh0TWCRs003kG8lORt2htvpnP5dKo2d3darr1lHdwqrhf3iuSSgwTlM8jkdD61HVszj8TkTeI9AGpaJ4f03QLacWjTNeXMc5DOyxLkE+uTnj3p3hPUbh9TshYXskrwZjuvPGBtzkljgDocfiBXpeqa5pXgnQ9I0bWkZLu9hlkeSBcvGhIBCj+8xIHpx7VY0HQ9L8UQWl9pdnLHp6TjcJ2y77TyW9/xrPnsrs5FWirza93ueXWnhN9FjbxBdJFd+SwaL7Mm2NW5wWP64FVbbx9qujXnlpDukuiN4MQEbDtyfft+Ndd4o8bTXeoXMMLNHpSCWA20SfL7vjHPQ1zOo6xo0ugTQaGu+5ZP3t/cJ88eFyduOhI4yOetWrte8jaKbj7y3Onj8b6rJcpDpVzECULyeTERtwM8Z+mPxrf1jw3ceP/AIa2NpfSTYvkR7iXdsaORTuB5B6njH0rx3wvqcGmagmoWP2ogCOTrt80Y+ZQSc44I/GvStT8aHU9Lubq382K3eJSFDY2vnkYz29amcNrIirQ5klBFn4e+EtH+DGg315qWoyXerXYC8JgcDOyMd8dSa8/8Q31xruqJeTSb3nbMas5Y47dOhHTFZ0+sPrHiNLJTdyXkQEUTMdylRzgk9Oc10msRyrY35stLhj1OC12RTwRkFZTgHjseSeOeKqEOR3e5VKjGjeW7Oe01Gu/FMkK6jE4ZxFFGDtRWzhRn64616HpHgnRtL1e1tNVjOq6hu8yRNuI0JOTn16H64rl/B3w+1XV7C2ls/JQwJyZX2l37MAeQRk8/Su98a2t1punxldatn8TGEMksilYUIG0Zx7Z5PfmlOV3ZMKs02qaevbqatzrGoXeYSRa2ikMsNuMBVHQEjk9qi1nQjdaOJ7a1jJjBmk/vKD3xnnufzrh9L8TXy6dcPqFmbm7tihl+xtvQqerA455rvtX8VX09hDZ2ViFhnhAdpOqg844rNxcWrGUqUqbSgjhtQutBtoUN3DBMIWBHmwAMc9SvWmaXreira3A0+aCC3zuKJKVw2em3p2qLxr4Q+22cf2KLyjtYFQckf7R79a8+0j4X+Jb3KIkyWUTZMioQp9SPz7VqrWvc3fJuvzPVNa8NnxTa2l7pt1FdSoCkjJINyjqAfbFFYFr8PvGunXCDwvqN8kHlYZ48AOScnO7vRS5mtEzN1FHRSXzt/maXhbwwfA3wy1TUNJW4XV9Y2wo1yF3xQE43bR0zkn8vSvL7Swht7ibzYSkypskPTbxwc/rXY+G7XW9Z1XUHsri7vbw7VaQuxyuT8p7cVf1DwZqBiVbuNfLZSZP3gy3XORyf61UbRbuXShGne7V2eZXardCO1tBvkRtqO55HB+bHbNavhzwbqerxoJRK8BOx54eSrA9G7L7CtTUPDGm22pxPDrdhp+mtANyNIXmz3VgMY56YrpPBt/4f0DSrqw07W7i8v8AVHXzZxEURQmdqjJ6kknNOUtNCnNvZanJ+LpJtL0z+z7CWOS0T5p448AyP0wwxnA/+vU/wk1TTWZ9N1mFhFqZ+zJKFxJASeGX2z1+lZ934f1CTVCI7nfDK+GkGCACfvflmu21XXfCvgKCIeFdItL3W3h8ya9vGaSOLHXaM8tkdsClLshTk0tFv/VzI134Q+MNO1WSO1+z3sRlBiuI5VRwB0ypx+Of8KqeIdN8RaC4Gs2UlpwMT/LIjgjkbuh+hrlh4q1PxFqskt1dzJeXY3sY5GUMPYZ44/lXpmgv4r0vQ7xdUuIY9NyCkeoOuO+GUMfp0oTktxU5TUU3JMoeDbjwncqt3qWkus9qTt8qZlidemQMkA4PAzXQ3vhvw3q91bX9t4ihDoBHC97AVcYGME5Az2ziuK8T6rdXkVmkqxKy/MEii2xS4z83y8VU0LTLvUZ5rPU4XkuJm8yFg4IVMAduPwocet7Gjh1vZ/13PTtRtPh80QsNe8QiHUim6R4WLRlfQ5UqfpVePU/Avgaxe+0WYa/fSNhIy+0qDwCw7j3A4ry7xv4G1bTRLNNbSyxyKFzG33sA8D0PTiqT2dxLbWeyKFYvs+5wx/exOBxnnJBz3qeS/XQyVNyveTa/r+tz2H/hO/DHivSG03xJoz6eqTs1vLbtvUPjk8YIPUdDUvwb0zQ5PE1wbXVxeSxqQtuV+6gPcnr9TXiOnu1v51qUNy2dwDceWxA5B65xng9q97+A/wALpvDssviHVJWN9dxjy0YYKKRk5HrnH5VNRKEXYyxHLQpvldr+ZyXxSibxT8V9TuYLmBLfR4IbJVluFjV3yXbgnJALYJHpjrT4vGV/4Tit9L0O4tns1Y3F3KisC4cAkpkcAdBjrnNZ/jL4eeJYPEF29lZPcx3M5YXSSgR7DkdSePXB5z61JrOjpb3NjazG3m+y2qQo8Uu4vjPXscdKqKjZLc2w1KDgoJ3R1es6bF47+HGoXPhaxhGoyzLFcoDh/Lxk456nK/hmvOH8Ia34RWCPVowbrUIvkWBPMEWDgjA4L9D17j3ro/DGo6hodrd2dmyg3WHmCthuBgHOOOK6v4e+JY9T1DU9El0z7UbGCV4RcMS8jbchF7EkHkildw9Bzpzw7c1qv0t+h57Pb3B1GEazOtvHFgSIEBkXgAA88HGBjrmqT3rWks0csFvBDMSo7+UmcAnPU59PStzT9XaaeWS00KFYhKMW7RMJEYnk5boBn1rc1bwzpa2DanbT3V8Z5z50EcfywuV43EnhAQOnc1fNbc09pbc5WDwrqE/iCTy7a6W+hDP5cZGyQ7d28EdeOQPeuk8Hw634wFxNbTOLeRCFeRSpLYxlcjGevWu4+FljP4a8PXF1r96l5fS3A8tVk3+WNgJAPbqcjtW3qmlqmmzX2iH+zJbra82JeE2kkbE6fNnrWUqutjkliZc3KlptfzPN9PZNO0O50RLy+uNb+0CWe4lUoY0HROMc5HasvxSl5qtpvghnnuAQsrKM8evviut8QXd7dRIVliaZl2tIyqZW/wCBdcViCy1JIoWLukLsSqKSNoH88nPNXHudlK6V29TC8IWtxb6nHNCZ3jtoy0+5cK6k4IJ9eenvXot9bXF5EksEJW1K7vkPOR2ptgLFLZoZlWBXiyX343OD0561taHZy2dnLdXYWdmIaC2WTAY/3j7D+lTKXUxrVXfmsV9E1FbPVbC31CzmLXTrFbgLkM3JJJPsK3V1CS/8ULY2LR2ogDLOjKcug5QqOnXOa5aXxX4gfWbeK2ks/s65ZgQMADjHTjgnmqtx4yvrK7uL23tbQW+wr5zS5kZAx+bAHSocG+hzSoVJvmsr27nrTXdvbbUuJY4XYEgOQu7HU0V5mPD1/wCONKt7zV9fgSPJaD7OqMuD1/p+VFZ+zit2cLw1FaTlr5Io3Hw18UrpkWn2Gr2FtaKykxQNJEDz8xJCksT6k1naP8IvEOlecIb7TJt8pkVpJZd0fPAB2ZA/GvKl+Ofjufw/qlzb6qvn2/lMjG0h4Un5uNnNavwr+M3i7VLPxbe+Itda4Gm6c1xBbpaQIxYnAYEIM7SQcHj1raSqRdrof1yttdHceIvgzresalcXW7RYBIXIRLiYD58ZyNnscfWs+H4IeK44lRNR0WPbxkPI3GMA8x1y3g74z+KNY8Ma49/4la21aMCSxc2UBRsAlkI2dT+fTFa0/wARvHWseJL618MeIYjYQ6Y1xHK9tAcyouTzs6k8Y96pRq9GilicSo3Wx0WmfBnxJZnadT014s7tplkPOc/3OK1z8FYNXSSLxL9nKE7o3spmVkP4p0Pce1eU6X8bvHlrGo1C7gunZCHaS3jj8lg2CcBRk9OOmDmrM/xY+INx4S1PVNP1RdwkEkDPb242R7gNqqUy7c+nAGacqda2rQSxGIlGzaO7tv2fINLvpbrS9U8x3GwC5BBC9/mGefwrI8SfBHxjrWpG4fU9DEajy0QyTcoBgZ+TrXI6b8X/AImTpDYLdRS393NGYZTaxHCMvT5Vx15JI7V32ofFPUPDmleXquvJea9JEVe38iONIH3BcghPmIPUcil7OtHS6FGvXasmiLT/AIKeJYdMFlNqGjiMjlo3kJBxyRlOM1p+Evg7q2mxzR6rdaZLE27ZHA77VJOd3K9a871n4weMLPVIok8S+VbS3jxlprGA+VECMEkJyDnrjkYr3vw3f6w0dyt7rIuwH8qF2gRGZtgJJ2qBjPTjpSmqkVq0V9ZxN7XRzVt8Mda06REsbzTZLUcOtxvJkHuNpFZFz8LPGs9yJhqehxMrcCEMgK55yBHycfnXp+u6td2cEIgn+dhyxRTn3xjpSaBfaneuZJ7geRGcN8ijcfTpWSqTtzGnt8Ty87aOX0b4R6XHqVvrWsQwz6zFtfy4X22zSL0crtHXAyMY4zjmurvYfFd1ZXECS6XaSOw8ueGR2ZU7jBTAPvz9Ksa34jttMQqXD3GMiMc/njpXneu+JPF/lSTadepAhBK74Y8L9cqalKc9WYwhWq++7fP9DR/4V9qyWzJFc2mG5MbzyFN2eT93vXPX3wv8YXEqeXqOiwQp0CNICAevPl5/UVxOuePPin4f/wBI1XWbb7MCQCltARLnpt+TPvW/onjvxhax/b/EXiSA2bhTDDDaws8oIzxheMe5xXRyVUr3RvCvi27Jo6PT/hBe2esT6uL6B7+5iCTBpHKFh/EBt4zVuy8A+KRBHJPc6PBqC5Hn2skgwOcYygI4Iya5jUfizq1pbRSPeFFZCwJhjJfAyScD+VWdI+Kl5qV1a2ttr9lJdXTpFHH5S8FsfNnbzgHpU8lU0l9ah8Uo/wBfI6V/hxrMgtWuNZFxJH95p3Zz25B25z16+tdTP4aun0+KGKaCKWIMi4ztZWGCDxXzv8Ufij8RvCXi7V9Ni1yJo7OSJUUWMWGWRMg5Kk5H1rmrj4z/ABRs5rcXutxxiZI5lQWVuWaNiecbM9jS9lUdtUcE8XWlZNrQ+l/+EJ1CGFIrWWyVAdxUlsBj1I+Wnav4V1/UXLPe2QG0KFDMqgDtgLWz4QvdSj8LadN4puk/tN4A8+VVMMecYHGQCM9s5ras7lLmHzYbhZYicBlwR+dYuckyvrVZPm0+482T4ea2JA7XlhuyO78f+O1oL4K1mV4xdXlmY1GPlLZA9vlru7u6itot81wsaDq5IwK4zVPF17d3DWfhyCadwcG4ZBt/DIxj61SnORtDEYmtqrFDUvh9qN7rFtOtzZw2kUZXZGWDbvXGMGneMPBvii+EaeHdatrJVkRvMlzuCD7yABSMGtyG61e1tC1/qtu1xjJCxrtUntnHOK57xb4y1TQvA1/eWRur/U40ZvNa2VVhH97aByB15zTTm3ZMHUxDtqmkLD8PdRE5e4uLSROu3e3J9T8tYXiX4XeJr63lg0y90mGOR2yZHkBCZyBwh/GvB2/aE+IV1fpDp+ppsYqozZwsSfXGzvXU+E/iZ8UtZ1Zbe71K6trfBzMNNgKhgD1ygxk4rWKqPVNEfW8RKVotNnpfhv4Y+L9MheO51DRnVuiRPKoGOn8HpRWv4Z1jxoujWsOqX8N5qIUtNKIETcSeMAAAADHbJ5oqG59Wjf2mJ6yR5f4k1PTfDFrrHhy+0+xttehDrGygGJoJMAjI5BKnOMcEVXvPhg2hwq/hiTTID4k05LSG01W92ymQgZ8r5cHJ24yec15347FzdeJpvFaW01/pt68kEU6k5LL8uSpyVzkED2Ir1jwJ4um1LQPAWkafrdja6vpayHULS90qW4nwrggI20hDs/2l+8Oa3ndK63OGTWnkeJ+CNOMvi+bw9rUMdqkM8kcxkJjeJxlfmYdgetWtQW20XTTDotz5q3TCB3aXdiVSd+zGMqffsa674ufDu2sfEcZ8HreRW+puwkW4kztc8lMnnAB5JJ56muWuvBFzoXhyzOoqLktcO4EL7sPwMfkD1rSDbSKgpRV7HN6fe2zxC1vJFR5t4EjqSEcEDPtkDFTz61Pb+FdM0tI3hnNxLMzFsFlIChfbpXt/wu+CGj6tazXnjE3ZvGfcluj7AqbsjcQOc/yrq/GngjwLrviBdHmWSxu40jWFrRwj4XjbhgcgY61DrLm5X0IXO27I+c/AWuXXhfxfZXV9iS1t50aUH5sxE4LY7jvWr8fLrSL34iRah4ZumubCeNDvGcLJn5tp646H65r3tvgB4ZkEkt1eahcMchnZwrYwR2GPTtWtceD/AAh4W8Pf2bf6WmoL5zXUa3KqZJG4yA+AAOnHTAqHVg3o2LWfuo8b+EvgC/8AEUMUuqRiXT5JBJN57f60D7pAHbI/QivonRNHGm2Fpbs7SNZqwjfJyQRgAjvhcDmuY8M+M0ubC5m/sW5sY4+FEi7UZs4UIRwV9849K6Tw1eT6khkf5FOChPVj3PPoCP0qK0pS32R0cmlxk9tJf6hHGEZVUYOQOFrdu4/7M0stAMy7flXGFU461YtFjhMjKMEYBZj1ouNs8kaE7h2647Vzt30FKak0uiM7w/osTQfab4ebcyfOxYZPNcxpjXOraDJearEscDzSxwIq4LRByEJHbIGc16DLKtvEyblxjpnHJ4/GsVrK2lUKrghxnC4Cge1UpdWOFS8nKT0PPPGCaRNZC0nhluBFyN5CxqR3JHJxXnl5q2n6je2ump5ZiVgskkJwsKYOceleg/HeyisfCEbwSuJGkYKiELvO08E98Yr5ZltdU0C90q+sp5EinAkQ5y45KkMPwNddLWNzp+sxgrxXzPdPjPDo9rYaRBon2gSz2txDbmCMMrIoG9c56+p+teJ+HbaPTvE2mTSyPLJb3MYeBYyCu1lORg856fWu3+H/AMO/E/iLWrEvJNb6baztdrLcMWRTkZCr6n/9de++GPhX4c8O6tda1cSPd6gZ2lEkrALGxJJ2gD3xTlONNcstWcUpczvY8O+I2k+KPH3xH1u+0uymMUYWCIxxspYKOFZT/EOh7cV2vw8+Ek/h8rrfiptskLEwwEhmTsGPocdB2r2a6u4oLOVrQiNicltpywz3J/pWNe6nfDTXLmG3t3Urvchcn0yfWsvayatHRGtOl/TKs2pafeSQ6nrTSG0TIhsywZGOfvSEdTgdOgzWmdYudStUk0uRZYukaQACOMD1NeDa54q/slJbV1RpSxZUL5C8d65q213XdRuZ7Wwu8v5avDGvAIY84xxkCr9hfU65U6Uet3959LPpCXE8Ump3DXswJJihRmVePXOAPWs3UPiT4citktbXU5reMExtBbWmWOODhjwO/Nbfg+/Gi+EtN0ybzbu7hhUzzSAopZsnqevpVFobOxfUdTuY4vMZGuWiCqMIOM5PQdOKxVm/eOfm5tZfIoDx/pj2nmafYbrdRgSzqMk+wNUn8fRQ27efpkIRmIZnffnPqPz4rC8R/EfwVC1jFc+ZdGQP54tVU/ZQPUnqfYVh6ho3jLxELix0PVrFtIiWN4coIg6OMq5+U5ODjnuK1jTj1VvU0cqUFrG50ulTaJqup+RpdrZWtzIcnybcKfc57Vo6BNa3Wr3Gl6Xf2tzf2oLSqGLeVtOG46DkipPCxsfBfhv7Xq8thHOHO+4kYCONznADEcjjp65rx7wJ450nwb4pMd9Zw3c+sKEnuLViPJDMcnuGzwcDHSh6p26CdSztFWR9BjSp4ZWWS6WFB1dVyWY0Vq6DcpDpUf2tYWcEqJH+UyL2bHUUVzuTuZuo0z4x1zfZG6sIvNMdnqDxrGzMwXDc49gB+Oc10OqeKWspptd0uSOO8uD9mnt1XKmMRoofceWJKn6Yro9Iay8Y3GqxXYksNPutW+1xXcSfvPNdcBOeitkn2qLxz4Psta0+103wzbwWckEfmkzPiSXDFQGY8L0Jx7jmvQcls0ZpTWqOk8P/ABI8B+MNDi0vX0m03V1A8qaXOwzfdBVh0z3yK9E8Q+FLGPR2lWzaRy6PLhycOBjpn36jtXz58KPhDqWt+JFutZtgmkW6k5MgyX/hHHX3r6ugspYmeN2dy/AV+VC9MflXFOXI9GEKkk9dDktF8VPY6kIdQhjtLVl2RyBvMQtwMEjkVo2PhvSpvEU+vMjPPKylGAyAuc8Hr3NJqnge3e0K29x5NyhBDH7uOPlx6Y/XmrWi3Lxwx2ccSbo8Iwxn1yc+lS2rXgXJxkuaKOzheIqQdylueR16Vzmt6npWr2aJEDMokI3Mm3YQSD1H1qW7dUDFJWK4z5QGB0rgra1uvEetkW0RjtIXw7NkLnJ44PNRCHVsmnRj8T6G5r0ZmsUZUDwxAHYx+8Bn2/lVfwr4hN/YCG0sd0duWWS7k+VYyxBY89u34V1VrYW2m2LXk8q+TCCTLK2FAHfnpXz78cPGo1Twvqg8LavbR21xdxSSCObbJKm0q30BZRwcEgZ6VpH3lZIFNa6aI9W+IPxD8PeF4IoJbyO81GRcpbW7ByB2Y9gPrXzXB8WvH1/rN5c2OoyfMGEcKgFUPQADFY2meA9bvLvTZbiU29zdwlgz5+YcbQD7giqF7Yaj4MvLtiifaLa4QQzZyGPXdj3HPNdEKSitSLyWq0R6Ror634l1MW1/q96t5qkwtoneU7o/lGe/Qsp4H6Vxc/jvxL4dSXRrfU7pLiKTbcNFLnaQfug+nY16r8ToLH4f+DtG1jSI5ZNU1KFJIZi4Mdu5RSzIAOSdx/MmvGdM0G71y4ia3sWe5ux5qTbgiH5sEvk8DmtG1Ne7sDqSt7jdz0vxr8QrG++HMeka9fHUNYYpNFLDGAqZX5gx9QMgY/vZ4xVMaBeeJ9T0aysZ45PsFhCZLlY+SWAby1x3UHn8awdZ8M2WkeIdD0S8tJJdojWa8QEofMf7+PQE4GfSvqb4faC3hnR2tgsdxdtlTcIuDIM/L+AFZymqa0NG92y54P0Sz8M6LBp0E7eey+ZIZWBMj9yAeQK1hp0k7CefKo5wqev4Csfw34QGmPdXF1dy319PI0kkso55PRfQDA4rev5YrFPN8+QuDhRuzgewrjk7y0dyefX3dx1zpdnbw77p2HcKDkk/SuF8daDN4wS1js3mjigc5+T5cN6e49feovFvi7TvDVn/AGpq4und2IUSjHH6fh/WvL9e+P8Ad3WgrLolnHAplkh3P94Kqg5C+pzWsISTTRpFcusnr/XQ4j45WEdj4taGBfOvYkAnEWQitgBeemcDpXu/wR8L6OPBmnawY4Hv5I2V5dg3LhiCPwx1r521fxlrWtaldJbbfOn2sUjjErO5xxzn9K9h1PxufDegaHpcxsrNrWOOTUre2xvPy524HQknJrepFtJIFHnk+Vnruqx3Go6Nq8OgSwrqkdqy28k5wiNggHgHHfnFfJeofErxM2t3ll9rSaF5/szxtDuSUKMdDzgkZ7e9at38TvEF5Bq2oaRKltdQ3m2G3igJElsytjJPXaRz9ap/CTwNL4oW71291cWEFg/n3e0YlVQc5HYAjdz29KmEOTcxlPW0GX28S+DG0PTE1Lw9FLrun7hLFBujindhkpIBncM846ADHTitqx+Kz6H4F+06rKJNb1mR2hSAf8ekCEqoYdhnIA9K858falbxfEa61bwvaQSaPbTx3MLLuZJCoDMzE85JzkGt7QtFu/i14smuo9Lay0iKJxcXZBK5aQvnPZiTgAdqt2e/4kxny7JJ9jmIpNb8cyrZvfTXNxf3CrHC7HazrkLx0VQGNfRXwv8AhBYfD2KXVvFlxa6jq0qgQp5W9IMc/KWGc9OcDGKx/gr8N9V8LeKr7VLmxjtvLhMMTSESAndwyY6fKOvvXq76BealqN1eajP50skYiVQCqRp12gfzPesqkle1xpKTUps5PWfEP2u5eSO3G0twxOM/pRV/TfD+h6vqd3Z2+qpNc23MqLztz0/CilzQWh6SxWHgrcrPBdO8O6nH8Hb2e0XyvtTx3tuzPtcvFwwAPYq2R9KZdWHiCe2026vtRD/b7ZBGNwUo/AJb1Bweaz/GfjHVU1ewDSvc2lvZiGO1uYgiowAEke0dQCMZ71yF34kur6wt4rZHR7ZNoCtkKMnGAenWulOz1OKnOENHJ/I+sPAmsQaXp9r4asbiyuNUVGcfvgA7Hk49h+ddaNRWzvhZ6pdFtQkQSHYMBB6fSvkP4GaPF4m+Iukaff3M0HLylox8+UG4DPYE8V9Q678N5NV8RxXrarcQ+QuIzGq7ic/xE5yAO341yTUebV7jVSEvI7mL7Hje0eHPDFjyKpXMcdw8b2k3lSjowPX2oXQra3CyX11NLsB+aUgZPr+tYusamYmhtNKVpFBBebGeg6CsYq70FTi5P3GXpzbySie5lUJH8p+bv6+9cX49+J2l+FbJY4IVEa5JUcF2o1E3c837iJ2MgwERSTur5o+Kmn6vL4nvYbyFvMtSqiFSWPzVvClfzOicY0o80tX0RB4h8aa74nk1O71K+nS1lLyQ2YlYR7ieML3Cj8OK6vwn4RFr4I8Oa3eNBd22qXsge0kGdxiRmUsR2+Vsj0+tZng74c6tcwma70u8juQmxGulKJuPCgZ+vNeg+E/CuqWOk6VH4h1MWFit201jYsC00bnh2GONrAMMHsa6F7qTOOMZVJJs4PT9d17xZf6nr9xdSYtY1+SKPhYEcEgdgABnj0pl94MvPEvi+SaG5C6PLmSS+kwyiME4YDPLDpj1r03SbGHSbjVZdH037JZ6nbSW4nfeqICQCgH3RuAHPXJIrQmMNqzaWuj28jmLy54oI9kNnu+6DjknJJNNvS1jdUW1abOX+K50fW/DemaZb3N1I3h/TkEML8/aI8qu7gcMcA/SuH0u9a78OSw2l1NFe3N9DHFBEPmihRWz09yv5V7T4C0JtE0u5v7+2iVWVYWh2qXmkYAFT1+XGBjNO8KDSdG8d6jYLCr7rtkWOKNMxS8qQSDnZ26dqSko3S1sLlab5NDyiy8Q2mkNK+pR3FxrKGMbJmJTAYkM4+hGBXa6Z8dbiG8it57OEXEjCKMR5IyemPar3i3wz4b1zUbi706WSC9uWe3mKxhowwHXGeAD/WuC8VaOnhO68Karf21vejTLeSCdIsFZwCzRtz7Ng9wQOtEuWa1RcpVYpXWh7DY/FpLO4kTWd3mMwSGGONhI5IyDzj5SO/SoIfinDqHj7S9Cgt0V71fLFxJyI5WUlQB04OAfWvP/ABtouo63o+j+JoXj+361p895Lt4it7eMDEaf7RDcn24xXDJeR23gLU/trvFrtrq1vLppJxNnb+8X14G0/iKh04cvMkZe2TTstTY8T3viM6neaZ4yVNSjs7zfLHOSu7GeUxycrnjpx9K4SW1fUNbuoJZY7ZIopJoVlQH5ApKqAONxGPxNeg6nrDyWfhSRLZ73xNfpK17K77xIjnEZHX5snA6Y24r174S/Bmy0dYr3V4fNvGVWIkGSvHQg9DVznGMddDOV2tX/AF/X3Hifgb4ZeINX097/AEqzbTblMtBcTMVdxt6AZ45yM8Vdg+Cfje9SxuWMHm78vHK2JYznOG9fzr7LlsYoEYoRGp42ovX8KwtabVjBLBpAEEhBAmeHdt9OM81zKu29ERG8tFsfK6/BXxdFqWpR3CoiSKfs+ZgQ/wAwJGPpkV1dn8KtbsPh7qllFfPJ4gmysVvHKUj2PjchyoB4z/jXtGj6FrEd5HearqskskZyI0QKHPqT1A9hxXTSwPJFv39R0DcGnKu1oW4cvU+ePAnwh1HQtA1GTVDbTaleQ7Y4Ad/uRzxnt6c13fhzRNfSCztdS1COy0u1jEg0/TrbYrOCTgtnLAccnqe1eilJUV3jEAkA+UsCQPTpXFf2P4ov9RQXXiKO1sg+8RWdqdz89CzGkqjlo7FRujoNK8Si8jUrpt+of7u5ACOO4PSrGu/b7+weytXbT0chJJGO6RlPUIB39zVfVNfis5lthLbwuCdzuRk4qva69FeBmlmHy8J5fLH/AAFRbqkUqc371jU8N6Dp/hyF4dFt1QuAXZjknHv1680VTj1VInzHOIzjB3ICP1oqWpN3YvYTPIPFHwj1LW9Vli1mOG5uHYvHqcKMm89CHUHAOAPqea85vPgX4ntZ7qO2hjlgQM4nEgAZR2HPXGK+1J7y3QEbsMDn7pqkFjliKRJtjfglhkEH2q/rMuqOfmc9Wj5D+BfgjxLY/EXQtUhtZbezjZpJp2TrEcgg57nOMfjX1q0nku8sjsqv82HH0qM2trYw/u1jgWNcBxxgDgD6VWSWSfbLJNDLFF83X371FSfO7pGkYJrRkN9qsQuIkuIJZElJEQYZyc9SOw4pb1C5TFqZZT/yzBCoBV2O6hu5yyRKWB4kUggDHTNQahqVlYBnvb21tnP3TPIFH69ahFxutEVGiZbKTf5cPlgyu6rkIACePwriPCPi7Q/Ed/Ndw2EEwtnCtdTxqrE/wlQea6q58X6IupXGkC8ju79EJaFGDcY5PXsO1col1pMmhtD4asYER2JaacbQobowz7jGM8VtBaO6NYwk1qtDttQuDfNbqkZmY5K/NiMAkcn1rz7xo0OpvbaZDPFKliguLq4MihYsMRyT24II9cUzw9f3mkeBNb1rxXdm2js5WSIjkvgDCr6qSQF+tfNd74hNzNfSRNKIJ0JaEHO1d3T3OTn61tSp2b12IvGGiPqdtc0K4s9F0jSbiOa2hMd4sq8oSrAhCPVmJHtXgDeINdTxFq0VmXbU75nt3gKlnLswDgD1znHp+FN8D32nx/DbXprOe4tb2K4jjMpILKZA2wr9Cre+cYpnhvxKnhXxRZ+I7uNZsTOjK3zMdw9exOTz/jW1OKUW1qQ5XScXY3bfQr3UtLtNMW6vdIvLm5aVbTcOVG4K0nGRzkDPbn0riLTV9a0nVtRh1CC6N4FZH8xCJQ5BycnB4PP4V9MJ4QsNf+Ff9qaLKl1qN6GvjcuxVndjkx7h0UD5cdOK8w+KenC9n0k34LX4083HmQybcxhepfByeMZ/WiE1N6Du2rxex1vw30+w8U+E7PWLedLBrSWSC7hmBIeXaPm5OQSCD/8AqrhvHy2TrqOl29zDc3sLCabYRhEPy4574IOK2/g14og8OXNt4Y1S2Ftp+oxy3EBLeYTIyYDkkc5AIFeaeMdHuNV8Z+INS0yDybIXQtvMJ2oCVOFLHjcQm78amKkpNM1VaUY2etzZt9T13UvhJb7Unj0zw2XHnthFlWYjbGRwSvB5HrXL6V4jivtfsr/V7GI2cEQjkhGf9I2527j3PIH4V6xavYx+EL7Q9Fj+1a9qmn28cVjdMpQSRHJcDpkAsQp4P6V5l470K18O6VoVhBdG88S7muL+KI5SMnHlog9Rgk/WqvbQwfPF6rQ94+GfhCwPiGwvNYNqhZBc2Nqp2/N1wueTtzzXquq+K7HSd8UKG5uwAWjiBJH1PavOdZMPin4b+DNe0i7EV5byIs0q/fUlSJEx2YMB/Out8LeHHWX7Veb1gJyY2zmZvVj3rmqNT96TNowpuLnUenbuTtbeJtYk8+6vBY274IhhOGCn1PrV620OC2lEKajdC4xvO6fJx64/GrPizVryPSZLfRIkN/MPLi3fwk9/TivPLGwv/Dd5cvBeS634vnhSOeYtmKzQnjIz8x749u3eIpyXYlTnJWWnkv1PRbkXdnIFN0Zwo3YyAQPU1VhuhNKS5CAnPlg7iT6sew9q4iUXeiILnxJq0kZv7lLcHbueVnY7UVR2GfYV3McNjFZbYCrBl2mSRSSe1S4qJo4RS3u/Ig1TxVo+nOI76+tUkbaNjSqpHXtVS68TRPaM1innn7qqOn1PqBWRb+Gbu0ut9rovh64jJzHcXCkyqMk85BNW9b8JXOpiKa5WNpIidrWjmPGcZHbI+tUowT1ZKjTW7/r7kTab4ZSSUXupxiaRjlE3ZVOgzj8a3mt47ZALe3QueBjHr1+lZuk6HdWtqkBubyNFA2r5nQZqr4outW0y1K6WZbuZmH71h9xfoKTvJ2uHLzSspFu+8PC5kJ+1eXNnLoACBkUVwll4r8RWEbQvKHJbcWliBbPue9Facs0dawtfpJf18j07QtX8+3ikJ+02UvMM44z7EHvUsmox3T3ENhODOnRfxrP8G2OkWfgiw0y1mlurZEwrOdzO3X8PwrlPBl7Lc6hqskcUQuY7hoJ4T/rl29mwSPxrHkTbfY4VGMm3azRoePvEtpot7pFjqcwja93jBztOOevY8/rWGtxo6QR3MeqqplHl+XNJ973I6ZwQMn2robzRrfXNXe+HlTxYTdFI2dkkbbgcdjwOnauevvBGlahY3Pl2tzYnVWU3EmwEo6gqDg/d61rBxSSLjJRVmjgvFHxUk0eS7sNEvIYbWMvukQ5Zeww3pn0ryW7/ALc8X6w2owXYv5bONblpJ5MRxoG4wW45PY9areLfDFzo19rVs1reCwikaKO6miIDYb5eenOM1Wg1NfDulJb2rlbieP8AemI7t/8AsOD0Izn8a6lFLZaGbnz6bIzYJ10+7ivBLMt66l2OcNHJuOSCO39a9D13XtUtPBFpdKLgBDsS8QFRNKSTgEcHaBgj1zWZ8QtDtvCOjeDr2TMuo6zZm9ukIGIkONoX8CevcUs00LeDdH0R5ppNKvJzfJK2Ayscx7V44KsMHHUHp6NNP4SYVGk1FkEfiObxFolw3ia5lljRVFvEZNqySk4JI9lya1/hT4HtvFl7e+ZZ3jR6dAzqkRC+acnA8zoCTj8M1iTeFNYuNJ0awazS21C1mlEjXI8pYwCCC5PBAweec+9SDWdV0jUbux8L6lew6ZMCFuIiE+1SE4Z9p6AncB6CjW1luPm5/j/r8iv4p8Ca14XCo97bD7SEkazSQjzJOeFT+LBzg1Lf+GL64vfDvhmSa1t5NTEUqNknDSMQN/cY/lXpPxgij8P+KbMa2zxXNzDaXFvcOm6IPHhZFOOccfgWrz34hatbReMNH1DT4hbW1pBCUkjk3rKysW3A/wDAvwxUqzjp1JcYpXWx6rbR618OvglqXhjUW2apLcSBCjjbEhYDhv8AaAJB96j+KTaPqUWi2UMpnuIrOONVgY7dqoN4DYwy5A5HGazvjXrsNxPp8dvOkklzYLdXFs0uApYgrHn1C7uDzXGfDLXZ7PxHpMlzayX1tZCZIElOQEKMAjHoAN2feinGyUkWnFWibXxBiivPD9l4k0i8xe2t1HDF5bAiCDYAVI68MOv+NHxQ1C5v/hrodjcRR2LXTf2g0kakfanXMTM/rkBDx7muP0zUF0TWkv3SEXMQ8+OKVCyvnIKEEYI+Y8H0r0LUNVPjTQrDQdSnt7e7gcG2Pl4Ee9Rzuxjbg9M9vpVuHR7CaUruO/Y5r4Kazb6fc6jrl7Z7ho+mym0hVsmRg24gk8jgsM1i6fFpsd5o99fS3ia22po7+a25ZoHwwkB9RyOTzkV12i+HwJf7FlRY9StL4o0mwRk24jxg84wTnv1NYVxoOta0/h62vNPaKW43W1o32cphNwCuSByM9/QE0KC7kfDZs+k9Z0eOHXpjp8wENw9ur26jCiQKcNj1IPXviu6unj0/Sp7u+nEdtbRtLK4H3VUZbHrwK49pBZ6/ZW0jNd3mVlk2jjzNiqB/uqB9as+MPGVvpul38Fs0dxqlvayzraEZLgKSdw9MZ4rgknKyNakW4RS9S7Z67D4i020l8OK80V5H5puGXCxqe59+OlF7Jp/he2a4vGZY9wViF+eaRjx9Sa8q8L/Fqw1DwZJcK76Tc27rHiCPcjcYG1QOBweOOlZtnqNxdJaadcXF1d6TZyPLaz3oJnlLMTvY9D1IHoPetFSfyNKdLndoml/wnkXj/wAe2OlW2kt9nsrgXMV4kxQgL/ET6Hpj+VemLeXEmviwRUnuwvm/O/yhc9QBXmui6RoOjwk6VD/Z94CSLjezk5/hYZ5X+VdzpOqFBDcRCK7ug2HW3OGweTjd2pzivs7F+zlBaxOiEmoRyeXd2zbemU6elWprO7kjaW0n2ydlfgHgdfyoGuXk20raBEJBJkbH9KZDrEE6IJ1ZWxnPQGufXsc7v2KAXxJ5wj2WpPdlBwcn1NaktheXlmbWQwxMQA8iZJxntTkklnDC3uPkA6bs4HuaZqVxqUdu6WLwRsCFGRkk+1F3fQmU7uySRz2r/wDCP6NOsNytvLNg5Qr93nuaKvaP4asrEy3eoPDd6hcEGaWXBGfQA9KK054ruzX2yXRs2Zpb6CeFYtMjVUYsREV54IAzjiufi0uaym1K50/SYLa7vm8yWQyEEsMjP61o3ba9LOgttwXuwXgfWsTV7zXdLcm/utsI+fzRHvC9vm9BUxT2CEOitf5i6VbalZXG9oY2mkbMqxn5ZPcH1rea+RraMxwHys4YcKyn3rzTUfG9wmubEUnywCTtIjcn/H613eg6tp2taW+JkgnKnekrcL7+4zTnFrVo1rU6nKpuP3Fa+thrUdxZ3llDPp7IY5IZhkNnI/AjPWvinxV4eNr4ovrBZnm8m9+yopGXY5xz74r13xt4n1SLUJbGw8RTmKCUq0ltIUxyRjPfBHWuRvpE/sXTfGljdbdS89rK7iLB5BKF4nOR/F0PHB7811U6XKrS2ZhVgnudf8Z107xfqml6RZJcifwza7L2Tyx8kAC8deo4/M10mj+H/Dtj4D0y/vrIsmnq8tms8hDhXbLYHAYknOK8v0WzvykiT3UX2rWXaSVW5mKhM5aTsjHrXa6pZJ4x8DWEaanEYNIieKVzk+XuAK7gP4lK/kc1ThypJDjFJc3Kct4s8Yw6tqHiHzIrmSG7eKys/MACwBWUnaOx74681zM2kXs/iyy07RJIJrgRlkEeGAOCSGJwM8/5NVNUskstRNtaXCTwwz4kuSuGk3EgOAT2IHrXon7PEem+IfEOs22rWweW6hZJpYidqhyFOB2JxnI6GtJNQiZSblvuN+JOoXXjrwS91rTCzvvDVlH5UXlEve72CO5z93aVGcZHNc98BvD0fi3xLdRTJbyR2dmZCZxwzHgD2yT1+td9ovjGe8ml0PXreGeW2nmgt5Y12iSINtIYZ6YAPPrXGaZ49Hhzx4t9pOn21vY29y8TRxjYsiL8uWx1zng1moySajoOUIq077mda+FHvL/ULXWrpbK5ijPlxT8LIFyM7z2+XjHWovDd47+EmXS4Jku7ffG5iyzTlxkE9htAPucnFfQfirwxH4shstf01IleXT/OAYhVCvyd3Hpn8q8L8N6LpDeIpLe51UJoYaUTXEEnysAnyj1zk9e9XGopq4Ri07owL7UFlt5jceTPcRxxFVYczENgKT6gHtXs974Q09PCOi+Odcl+x3g09THZpETFI3liNBtBGDg5z715fpGh2eueJItGR3USXjQQ3bMEO1SAXwfRe1a/ibUdXsLaXwjMZvLsriK0WcfMoSJ2Ysh/vEMhz6DFOablZMV29ZGJD4ySfWLe5uonKyottJO7HOF4yD3+XAz1IFfTuk67a6b4a02SbU4HsbZHzMwG0gEBQp7/AHsADrXgHwj8FQeJ7q7sRqEcd7Y3/mW02zzA8YyrErnkE45r2K0+Gsnhvw9ax3k7X9rZ3n2mRAxVScqQwX1GM4z3rCq4uybNFNtcsvU0oNRSz07VNeuYXaRWkljTb824dB+R5rzn4U+I18T+NNX8W3enTKNOtm81hIvkkkEc59s57Ac1z3xo8aX66DJptg/l2rXDpcSEf65u+0jpWT4T1X+y/glc2lkkT3mrXsguFVssIowhAYdcHpj0zRGD+Hq/yKrVLycUcJDd3kd1e6oLUPp8l00ksEfyxJ82RjHQc4+lfQPh7xdb6yunwSWNtp9ulo0s00x2x7s8LGx4Py44968G8a2draWmlR2V3LeG4tDNO4UoBNuJYY6HAAr3TWdCs7D4C+HdI1CSb7T5LXltJE/ytMyb1Occj5+ntVytdRMqdWdPSx0WoadbO7C2vrKUoMuBKq7c9M1ha+zaNpb3rT26HIWNhMMFuwyK+driC9tvEISe8UrO6hpgTtZfUj1x2Ne0alFpn/CQa1oGrstxpFvb24tbe05llIRXDhxkBiDyRSUWd0MdK1rHQ+C/i5pkF5dQX9+ZEClopVkypwoJBB5znoe9LrPxpt5Jp7dLdHt41DhklG6QMeMHHTGSfpXz1qujy3evyr4esLi4tbpf3MMKF3jGeVPXLA8E967rwh8GdT1/w9JdX92+jTxz7EW5ibdJHj5sjIwAcY/GpcIp3kjkeJlOV+XU7Xwf8ZUiu7xNTiuGt4ommQQMNuM8A/pXfeDfiNpPi2/K+Xe6bFKnyPdLjzMdQp+nP0rzmz+EPhmS6v4LXxBPFZqvEpjy5YgZVuMEZB6dq7LwnoWi+GpLOR9WvNUWziIWIx7UVj/ECeg46UpxpvVblx9tJ+9D8P6R6/DptpHErS4nDDKmXnA9hRXM2uraprw8y3jW2gTIUyZYtz6D+dFc3K+rIcJ/aep6Ct2strKWjdGXIKHg/Wucn0a6u78XL6rKbAg5tBEhVxjHJIya5/WfibYi4aOLTpJUGQHY7WP0FO8MeLtQ1q4ktoNMURsDh8n5frUqEkrlrBVqcXNqxm3/AIG8N2k4igurw3csuRbLLvQHjIx/CPxFbX/CF6PJpt1bW5mV5oiocPyvvjjNdRp2j6dpNqUigjMsh3TSkfM7nqSarTmxSdWSQ+b0wvoKbqyezIVWclyxk7Hw18UbLUPC/iq60y7iVJEIaOVOFlT+FgPf+dYcbuNAS5gnCsl1+9t2/i2jIYjv6V9dfFj4dweONIudQjtx/bUEAS1y+C2Gzya+W9Y8JeJdPv44fEthJbG4ZokeUYUnGQwI4IJ/PFdkKjn11MZLXVmp4V1fVNI8VaVrot3uo74kMixbl2dJFTHooxjriu18SuPCHjKc2ysfDHiSyeVfKXaHXggY6bl5XPoRWT4R1K+0B59Ghn2jTrOebYhUo0hDHJB65U4zweMVgaX8QNdm0/RtHkW0eHSmcxyyxmRkB/hBznoMVpZ3Lfu2bf8AXUq6paSW/g7TLu9iZGkfyrZSVPmRh/nEnfOWGBxwfeuj+EGs2eleNTfaSt1ZW7KbacAB1JPTscZI4qxrfiSw1TUmXUNGE+lR38jxSwsV2fL821uRg4Bx7Un9r+FNMsFs9LW8sTffKt/IBtgckYYgc5wCM/w5zTlqtUNLW900dh8SfC9n4e0iC/sHuLcsjL5jvuYySMi4b6ryT615lAqXurSXuqxKImXzn2qIwH8sgjGOAWwfwrt/ihpepz+E/D11papcwpZ9LJzKjYIzIT16rz6Uzwnc/wDCSeBLptZWxsn0+4htJJrjCGQcgbm7nk/lRCVoq+oNJy5To/AusS6n4avYrXW7SwkmsDaraTsTsVQVGw/w5X65rkfh74SS6v5LHVbZori5ixFF5RTdHkZcE9HHBGeOtSxadDoDX39s2lrcAzKUunJcG3LFPOGODtPGO+DW38VPEmu6Tc+HNN0SDOlyQrb2l0g8yaZAVXdv6k9OlJuztHqPrzSPMLPxKdE8aQzxWcc10kkiHd9xg/AXHbHPI611eheNdPk8Q67oviXSfOlN201rFMMkSDhkJ64IUY7cCtT4hX2laJ8Zbf7DpccdnbxxQzZXbsmxlpQvqMg/UVU8JeI7DxZ8Xre08Qadp02+Wa3t9Qjj2zbsN5buQcHOOPrUzk2uYmDstdr7FLwvenQviyltYzyafc3MrKEjjOQrnOzb2/h4z2r6pmlu5tPvLa5QqGGDuGACDgn6d68Qjs7SP41WVxDaLe6va2IZBOwCnbkhgT/Hzj8qb4m+MHifQ5tfsNd0+zEzForNolICE4HOTkqPXuayqRlUaaRTXK+VtHK+Jb7RLjVLXRdRSGGzsZLw+awDPJJIrZkbPGBkbV7cVz/wuH2vxbBObUXVtDIrSsibERVGzew+hz7muWnjluLi7ub6BpJrqCR53VtzO7OAG/2eefpxW7YeIdS8JQrpOgkQafeohuLm4iBkkRuCfRQMngc9zXQ00hKScr2Oo+JvgLQ7O6drbW4oEbMUNq75KcZ3H0zXrw0Yah8DrbTNFuGvLm2tYxC8xyROig7QT0HOAPTA6V4t8b2SPx9b6cl7G9jOYZILoKDGkOwKSSOpD78+1d14a1U+AbTWtH1CW41HSFnikF9bjcsKyR53HPbaQcf7NZSTklJPULRlpHQ8n8EWum6x40utD8VRMgmWQzXjT7fs8iAtvz0xkYP1rb8FaTqMXiq4msfLvLa1STz9ULHylQj/AFueOgwAOtcZ8S9LXT/FV9p9tIXeAHzJCuzzOdwYDPIwRivWPhULO5/Z58YXBneJ7WSSH92v31KLgEdyxbr24q5Ts/Uy5krvt/X9Mb4R+zWPh211Lwg5j8R28ZN67lsTpvy6rnjJbnPoK9q1bWLaO1sm1GymkeVQGK8AD1I/pXy98K7uU+IrCytr25itlYzXMjYUYHJGM9MD86+sNNS08Q28kkUSlAisJGO7KsOPocc4rGvZNNnTT5UlLocNHq2i2mrSOum3DWk8YVlDAbCM9B781qwjTb+OQWFiIt69ZckL6Zx1FO/4RI6hNN/Z91bOkbbcZOc1Z0/wrcWrb7652wxkgKmWzj07VLcd7na5UuWylr8zQs9NubW0iMFwLpmX5ndNoJ9gOg9qKsWz3tom21sWuIxwMN/Ois9Tm97uvwM+8+Glq9yzpI4UtnygchRnoM84rrNGttM0O3MFvbfZWxg7vmLHHWtadpEsybhdxxtJ7/XisuRJlwbciUDqWj3Y465rJzclZmLrSqq1SQ261J5GENqUPq2OCPrXHX2ja7b69NqcTJL8q+THC20DsyuCcMMcgiu8gfzrcCRgzYydvA/KrTJuXCqqhcde9KM+XZEqahpEwYZvtaxmUSQ7vvRyDYRx1FYfxE8MyaxZYj2yWzJ5Min5iFPIYehB5zXM/FT4xJ4T1GXTIdBmu7uOETbj/qwmeSSOaofDH4iv8ULfxDY2csuj30MKtbY2yImcjdtPLc9c+tWoyjaWxUZKPvbeR4jrekjwd4xgtL2Jbkm5j+1XEr7vOgI+eNv94dux71qfEn4W6r4b8ST6p4ctJJfD0ii5EsRx5UJwSpJOcgHHPWub+Mmm+J9F16KTxDcJc+cgKSxr+6kwMHaCB+Ir0LxT4vvPFlv4Z01JJ7W0ks4I5jF8rSsVJkHXoFU13XbkrfMyajJ6dDktGEtwLbSmkkm0VdTWS2tSwTdGW+bDdQfu+3HtUereEZr+AW2nz/aYr+eVYikYaQTLIcK2Ox5xjitPw7e+E9ViuNPto76zvIYN8N7c3HyRRpyWI7dMH68V7n4H0S00bSNIRDau8UfmR3ij5iGyd2emCWp1KiijVQi1qeDeEfEl98KNVsIPEttLNBA8sQWFycKSN4IPHBwcV2/x1vNDuNB0y98LpGP7RlFzcxJ8m1ihCllHQnnPsK2/ixomm+JtQ03RrwpI005L3kA+eAE4BAxhuSSQa5SX4W6rpfiNk1TUv7UisPJcgRsqm1VGjU4H3mDbRj0yc1nBrmUtiJxaaX3HN+Ef7X8WaTa6RDAlwNLimAkViJS2WZI2P93dkgd6m+KevzpaeHIrD/QLawtisdtEfniuflL5U8jnNXNH+Idn8Nb7VNKsrKK7vWneSSbeQqHsD68Y+lcTreuReLPGclxZWrEX+JPsy5Z3kbkhSOSM5A71qmnK33BJ8q31NnUZz448VWcw1WC3kugGuppsqNwHKj14HGMVqaTb6doFwYba3t5dS0+7YRXJjJaYScxsD2AUNkHpWfc+GtPstBtpLi4jgkuIZI1RwWe2uY3JKMo5+ZcAHtSeCtWkuUMVpaR3OrxOCvmAqqhATk92Py4HYZPWrsrFRtzXloxbqQ33juR7G6ktr2dZPJ/gMUrE4Xd3G7ArnfEWtzeIb241G5UGdkNtMDgFmAwH+vynNWdeabW7az1aZRZz3Ek585RtQqWLFAfXk49aydXubRfIuLFVuIrhgs64wUlwQAMHpwCT3Jp7aky69jsPhPoNp4h8aWkOk3d8zPp7zXTbQCHBGV56rnjn8KwvGNldWrTWYuYJ4jcSOskByEUkgD2HHT2Ir0n9mu1k0m18V67e7Ibb7Ilm6kfvIWI3Bj6L0+v4Vy/h2K21LW9N0mVne3niMM0gABjZcsr7hx9/+VRCV277IIxck0Y+peGdf8WeKY9CaKM3dpYxqLlWLRvGqbvMJ5xkHHHoB1r034ua3p/hXwPDpcFk0sl9HAhZ3xuZIwCzfQHAH19K7fRvGmn6XqsGnSafDB5sRRJwyiOVFHUHrt4+maxvit4e1fxPHawaXpelXFoP3sjSvtK4I49RnHUDtWPNeSvoU6bhd9z5j8R+JZ9c1G2v7sAT20aRqM9VXhVHsB/Ouh8L6/rum6R4h0vTHiktdUx5ls6j7w2sGXOOoOPwr0e9+Hug2dqpu4GGptxkSHYpH8C56jtnqa6tfhjfahGdY1KLz754wBHCu0rsQKmAO2AB+tVeKfvMc8POK55vc4j4G+DbvWfM1Ce2S3hiJkadiQZBt4jx2GeST6CvoDTNLNv4Wj0o3lxbJI22R48Ca4x1Ck/dGOM+nSsu18R6To+npokVslpf+WFaFeisf4WPUtn866e104ForvUJTuReAzBAn4npWFSbk9di1BQjrsWNH0a20m1ddMsBAsmCY1c5OOmSSe1XIrfUp1VdlvEp7Nzgd81x2ofFDw3pGpS6dLeJ9oiyCVcypn+5vHBb1FdZI1zq2iyTabfNHLcQsIJlAKKx6NjuKycZbsyndK7GWOu2NtJLY6xcQ291BwckKrjJwQf6UV4de/DPx5OC0klvcXm9t85vQ4dcnHykcf8A66K3+r03rzohyovds+hodXi1AMbB4Zo16sG6HPII6iq51iGCR1kdQ/BAT5j+QrwK50D4py+LtVh8jVoNCmLqtzbNbiV1A+Q4L8Z4BrW0jwj4sv7az0bVvD8qWinb9ukuFWWNeSSWR8nnjBz2rL2Md+Y1UaOqudp4xs9dvNQS40WVkjQHaQ21skYPXjGK4Oa98Sx3EsNxqV2ZEBLDzMhQB6jgVL488OfENp44fDGktDaRYEbLOhbjjJ3NwK5TV/BnxOn0VLe00a8S7njkgvnEsIEiHpj585POfwrWEYpatHZDF06UbaO3keK+NvE+p6zrlxPPcvISPJZ927zFB457ivV/2PdCnm8Va3q8khS2tLYW7x9C7OQfyG39azNP+DXjOHS5o/8AhEbgXa4aOWW5hZi3THDcAAnivRPgx4X8feD9cZdT0CZ9Ov4fKudjwjymTJRuG5yDtoqRTjdPU8yb55czZhftQx3vibVNB/se2mu7SJXUtEM/NvwRx9DzVKPwg3h74cz3esPby69a4ntre3kxPaxSfu38zHY5z7En1r13xJpPijUPB2vvb+H2h1V1MVrDHLHllJGcHdgZ554rzX4SfDzxzZ+PTdeKfD062F7DLDdyyXMbAKwDDo5J+ZQPxohNQjvsVNwT0Z4WLK8t1kZLMFUwJHkO0ck8Eehr6S+G2vSX3gnVIILgW+u7Ue2sGY7mthGoOxT97ox49q5P4y/DLx3qnja7m8MaBK+lSW0cG2OWJUIXI4BYfX8a6Hwb8KvGVxrXhzxDrEMNnc6cojntmcCVwo4AIJUDAUce+aqVWM1ZihOMNEzTi8RabqdrHNIl5p17buYw91GyiVlGcq2OuOcdaunxs+paC9uLpkuGItHvIxueKCRgHcDHJA5H51RtfAPinxRLql54l0250iaKZ76CK2likE8pjCqi5bjhec45brXNeBvCPxGs4tTj1Xws6rIElRvPh3Eq33VG/AOCfb9KT9n31OuGIpSXJU+8x9K+FsOt+I7HVNVXdpUX7iYKT/pixoQsgI+7kBB7n611H7PXwku7DxM3ijUIpLSzhUiwjcgtIGzy3fgd++a9L8N+HdZ3PbajpYhs5bWJ9u5fllzkoSG4x7d+/FekrbuoVVGFAx1rKrV3S6nHWUYP3Xc+U/2ivAOpaTrt/wCJNGspJbSY/aJJIzkxPnJOOvXv/KvOvAXj1dM8S3mtJp6Nq13bmByvCZONzj0LY5/H1r7j1rSTqVjcW8qBxKm3Bxzngj8q+SPGfwK8V2V9NbeGNDmurO4bzWd54gIuThF+YHpjmrpVVNWn0JjKyucwbm6a+0mfWb2O8sPluXhSTcbdD8pBUcepHpmqHxB8Mah4P1C2ZBDLp91GLq1lB+WaIY27l7OO4PrXpumfBjxH4VuopP7DfXYp0jkeBJI0WMkHdGxLAnaR24OR716h8TfhrdeKfBEVtZWPlX0KB4Yi6jb8mCmc+w9sgVtKrG6V9zSUlKN76nl3wQ1eHxNY+NNC1CF7ZNTs3vlki+UbxGEbp78gdOTXmHws0m8v/iBpGlWUqTR3UpEg3lV2Dljn2GSPwr0bwb8OvHvg/wATafrukeFbxmiUx3Vs91CBMhXDKDu4GR/KneEfhH45TxhHrDaKNHZL37QNkyEKGbOBhjwBkVN0m2miYyvNO+pxnj7Srv8A4SfUbOz1KW4bTYz/AKPu5jhQ54yc4zzjrg1f+Hfj7V9P/tC9Hn38dlatJ5cjt0yMZJ7dT+FdDrfwh8aa14u1vU7jRbvbcLO0LtcRAllGIs4bocDiuh+Dvwm8TQ6nrb+K9JazsbqxNmiNLGzHLA7uG+v51UqkbasqFa0tGbuqaXpPxg8I6f4o8O3TaPJaO0Ui3CZDPgZXj3PX3ru7TxMnh/w7p9jM4u9V8gKNgOMgY3H2rP8ADfgG88F+D00TSrdr8vM8zZdRGpJGM5OTjFXdD8FX7SveatEPPZuEypx7nn9K5m01aT0RvT9ny81R6drmLD4ATxBcWetanO8d2kvmEnjzBnPPvkce1eU/tK+JdT1XUodItluYoLCQl9rH94SF5I9Bxj6mvpdNPv5L6dJISlrEo8pty/vDz27AVRtvBlpb3011LZteTTyidmncEI4PBFEaqTvL5EVaqnd3PKPhv8KPDqfDfT5PEljcSavej7SWV9rwgklcdhxjOfWvRNPvLaz0y2gl1WO00+ACNS0oZ3Ucct+ldNc6Xf6gsqXUvkQ5IVISMkVyV78LtEvbmJxoj2xhbeJEuMM59xux1o51L42KEqcV5nQtrgt4U+w2TyxEDa5kUBhzz3oqzYaM2nWcNrZ2MQSNAgywxx6c5orO8ewuan2X3nLWvxcstV8aDQfD9it7bozC41GS5EUMYXGWHyncMnAPAJqb4i/FjTfB9+NPgthqWoAZkiS4EYj74Y4ODjBxjoa8l8NaXoFr8MbzUfENiViubkx2TW7N9qj+Xq+CCyh+gxxWz8Mvh6msXV7qXjaI3KXEfkrDeFVed+CsgOdwbA9j164rR04K76I0lh6UPea2/E6rTPjda6pFqQsfD+oSXNlbfaPL3DDjIU/MAcAE9cdBnFbvgj4kN4jt9SuLvRm0+1sSsTXH2kSxvMTzEp2rlhkZPQZqjdeFtZ0zwbqtj4PXTbXUXkaC0Aj8to7fABAZi25hnO48H9a4D4z2Fn4R8D+GvCaahdSNJMZ7iERr/pOT87vJ2wW4A69+BUqMZaIhRozlyxW77s9Cl+LEcWrGzbRpNsswgtJPtKbpju2s7JjciBjwcEkc4xWbrnxqTS/EGpaSNBkmlspmhLi5wJMd1GwnOcjHtXDR2dpp/wAb9GFvYzamktrbSQ3VzCd7yiDG8sRgcAZ47Y4PNaPxJ8Gzp4vHi3SYJ9TsHKSXdlaZEqOoyzEHkKwHHUjNNQjezRapUlJKS3Rty/HgQSBbnw3JErxF4na8wsjchVyYxjJBGe2OlW/E/wAal0HXp9Kl0SKSaNInDnUAitvQMBynB+YU/T/E/hP+wZW+1RKLOJZYomjzKM87Rv4PLEY6ivHNZvLmXxHqmrCb7RLIUuh567gInydozwSuUXGOBn0qlTi3saQw1OTd4WS9T3rwX8UYNeGonVdOGkJaQC5DPdLLvjzjOMArzwMjk1n2XxavtS+ztpPg++uo5ZAhl8/agBJAbOzpgZOcYzXm9qkcvhq8i0WLT92tRQwGG3t2WS22SsWJZuqcqAM9STWhpfiHWPhtYyaNeaJJqUayyC3jl/dsUJ6rwSVLDOOuTkUvZrogeGpq9o69Fdnt/h7xdpuvRs+n+cdtw1sQ6bSWXqwyeV9xWRpfja81HXLnTItHiV7NnW8ma7YRwFc9SY+QccH6+lcJqvjrxzaxW7y+H7TQ4LxjDBJcQM4hkJwCzLnbuPOWAGOT3Ncra3mrLf3A8PXZuNavZp96wyGaKRDgmTaR1PzcYIxyOtEaS1M4YWMr6fjc9aHxS0668F3viLSLOe7is7lbaeGRvKIJKjKkggj5gR0yPSutk1aT7HqE0VsC1rG0ih5QquRu4JAO3p1weDXzWbq4ttA1bRXvpraJVkmubeO2JxIwG1GOQqKSE9SOmBX0X4VWRdMtYb2Vbi8FuhmlVSI5GZFyUz1HH1qakFEivQhSV0r/ANL+vmc34B+Is/jCa4S30N7dEi3RTG4LxvJg/Ix2ZUf7WD9PUh+Id552zUNCTSoxJ5Bn1C88mMyg4KKTHlzgEjA5x2zmvL73RvHHhjxbqJ0Cy1C1s5LlbeOW0Tz0aJmyGCtuxhRg56e2a1brS/G/jQ3l9qdtfW+kpIESxkRPOm/hLRq52ryN3zY4z16U3CF79CnSo35tOX11Ov1j4qm116HSdL0b+1rqVwsa21198cZZTsxgcnJIGBmvRJrxbd7RbhoomuG8sBpOS+M7V4+bofTpWT4T8L2vh2wht7c5ZFAdwoBc+59OuB0HpXQ1lJxv7py1pU27U1oFFV7q9tbV0S5uIYnkDFFdwGfaMnA6nA9KxdC8Y6Nr1tfXWkzyXFnZqGe4WJtjAgn5TjLYxzgVNmzJQk1dI6KiuB0/4j26/a7bWrGW21KzeKOeC2PnDfI2FCnjPGCe31rJ0v416FLY3k+sWl7pc0MjpFavE0kswXjgBflYnI2k54zVezl2NXh6nY9UqpeXMlsdwiR48f8APTDk+gGMenek0fU7TWNNgv8ATplmtp1Doy/yI7EdweRVp0R8b1VsdMjOKnbcyS5XaSOU/wCEy23Pky6PqEebh4BKYz5fygEsXxjbzjPqCBnFRS+MrmK8aN9Av/s48sicZYMrMFZgAD90svHUgkjgGuukhjlx5iK2DkZGakOcHHX3qrx7GrqU7aQ/FmXpGu2OqyTx2so82GV4WRiM7kOGxgnOMj6Z5rSLqHVCyh26KTycVRfRtOaZZls4EnVndZEjCsGf7xyB1Pc965+bwcp13+0pb2eTCgKpRfkO7JbIG7O35cg9+lKyYlGnJ72/E3X1q0F5eWokQS2hRZTI2xQXUsACepxg/iKK838T3XiODSxp+hNe6leW126z3kmnhyVIJVfmZAwAYDcM/dwfWitFTR0ww9NrV/ieDTX1m2ppNpqala2cjMLaJZEkkQhNu0McZ+bBz6e9cdq5XUNXubfVboG20lI1gh88jyotu5inTcxYkk+vtXoVno1zqeotYWkVpY6gIFtmllbYkaKcM3Qjd1ByRuHTmt3wp8PNB8U+P7a1t7C31DRNF3xaheSKUW6nIzgLuyDnHHTaPeuio1b0Oyu0km9Uj2v4X39r/wAK38PajfXM3krZqsV5qTKszJ2Zj23AKevIAzmvGfHXimTxH4yk13wrJf6lFYOtqbOa2XELNhFkiOTuRmyDkcEjsRWp+0jqc974h0Hwtozq+FDtZIQAztwgx0ztBx6Z6Vd+F/g3RtH8Tm4TUvtWq2ESiaxtnAhjDqeZH6P/ALo6MO/SsYLkXMzmoQUI+2vr2KHgxdR0rxHceIfHUqWKNDJLLavdYmTcSmfLBOFJyAO5HTvVDx58S/7YLDwhNc2VkGEd1L5Sq8sZGBuYnO3k8e5Oa9X8a6n4XtoBZ+Kru2FtqKtCiOCjuhOSSQCRsPRjjmvOda8GaZrGhM/g/QZL9tMVIIZEvwVvEIHMvKuGUA5XAB3cGqjJN80kawqczU5r/Ipaf4Fn1jRdEvYVh/sy7XFzGxV3jG5tx45YcHGDuXPPIrc8UaXF8NNJmPhzSlvRc27G61C4l3NFEcAIFIxjp+PJrsPBep6XqvhGzOjWFpZWVjJJaXNqnSCXGSUxw4LEc98k5NdW0WnX91Y3NxFLFdW+5I4wWVHBUrhwOGGDwDnHapdR31JqVpXvJaK+n5HzdqOpJeaRp94ut3IupmHnWMcpRLaPf0DLkZIGQCMD8K0tX8T6PqGttreoaG1u1tLE1tdR3ZMtwEcbSwIIAIABwPbPWuo1Hx1F4d+IGr6GfCdjNZ9oYbfM9y+Bhi3IYnnjGazdT1TSNN8T6Nqtx4Ob7Lfwj7VDfDc0QdsZVCAuRnPQ5Hoa1vfdHQpOVm4+mpv+OPilouvaO+h6YLidL+No55xEQIgOoIyD9cevGay/DniPU/CkMWj2Wh2dtJOXjF88RSRgPuYHWQ98nj68mu68UeBPCQZb2RbPRLkFreN4pFijkZzlQ44yfbj8eK5LShpvh7V/EXh/XQt5pCJFLC6RyTTJIyFAw6hRtIA9ycVCcXGyRhSdJ07Rjfy/4JiW1ibzwrbaBYTQ6n4l1u5824jn3KlvD8zB3XoGxkhsZ547V7yPL0vTodN05oXu7e2H2eCV8FkQBc4HOOgyO5rifhV4RbwfHqt7qAlsbZB5UMc1ysi+SoDGVyBwx9zwF963fA7afrKprkCvNN5bRRzTtvkRS3zJk4OPkU8gHpWdSV2YV5KbbvdL8WdNYSTzWkb3kAt5yPnjV94B9jxn8hVhVCqFUAKBgADgUpzg4614p8YviTqGn6kfD/h9rcEwk3l1HLuki7FFGMAjI55POOCKzjFzdkclOm6suWJ3Hjr4gab4WMVog+36xOwSGzicAgnoXP8ACPwJPYVwp1r4n+JYbm70yKx0q22qI4GdM4IIyXPzDPBBwK5D4bf2X4Z1u0n1jT7tYL2ESR3Vyu/ZglRIFYfL67hXRatrE/jXxofDmmlLbS7h0E8scAR7gxpnLnHzKMDHP9K6FTUenzPRjh1Tdkk+t3t9xix2nifTviPpF34luTO1oETzNynzQuM/MO+M5PB459+p0Pxpret6i+gQeHNPutOu0KSrbgrDBE2QS/cdehC7h05rztrG9t/E91pWxhLFN5cxWURDJODh3JUbgPevZ/Fdjp/gDwZqt54b0zOoXUaW4ALMSMkAseyoGY9gPUCqnbRdWXiHFKKtdvbsVLe3v9W1/VLLTLCTw9ZvMZrjUJPmkuZY2VRsB+6uMEHP6GuZ1jS/CkXi+9m06eS7urh7m4vL2W5QwWTYI3FDguEYZ2qec456CDQPGWs6n4WsdL0KS4l1eWP7PPJJgNGBk+aDnqVx9ACSc1F498F2XhfS9IWKe0mup0k80XNxsy+Ad0YA9SBk9OOtJKzs2EabhJRk7Ppb831/E63wV4z8FeF/Dq6Xp+pG6miLSSmK2dTNIQWZgpGF4XpnjgVlr8VPE2sS3cnhnw8klvGVREmDOw/2nKkY+8pI7epp/hXwVBZabdXvj23tbO0hKy+Y7hWkYDq7g5YDHAOCTXo4vbPQrW1j03SpG0eVDIJ7JFaNM5bJUHcQRzkA/mah8qeiuYVPZQk7Lmb+7/hzg/DnxcnGsw6V4r0trS6lm+ziS2RtkbZ2/PvxgZVjkZGMda9T0vUrPVbRLrTrmO4gbo6HI/8ArVy3jbwrZ+JNLTUILGRtTiC3UEYkFs00gX5FlbaemSOQcVydv8P/ABLpOogaJqC28FwY2uJon2HIZjkjBLkdxwGz9am0JK+zMuWjVV78r/A9goryLXZPiN4fszA2rWl7bsm46iLMB4SHyQRnHK8ZIxUmkeOr/wAM2MKeLPMvIZdrw3KMhlZXbqQCBtGfyHel7J2uncSwc5R5oNM6C2+H5stRvZ9O8Q6vbW9xIZFtxNvWLOMgF88ZBI9M0V28UiTRJJEwaN1DKw6EHoaKhybMvrFVaXPnazt5/F8Vt4S8B2xi8MWbK17ql0nMr5JYnPVvReMZzwMY9g8FafpdrYovhyCKLRYvktxGp+dsne5J5JzxnnpXI69HpVj4et/CXhaC1a3llJuRMWIlSPaZGJUgljx82eo7iu28MS36aXpKXFpDGDAWuDG21UcgEbVx0yTx2rWd2jau24Xeif8AV/U8F+MHhrUX+L0t1bx/ZbO7gg8zUZZBsg4KO/zEcgDgDP61D4ZvPD/ws8cuy+If7UtZo9l0YrYvnnKhWBK5BK5+rCvY/if8M9E8exrLeq1vqsMRjt71OSozkBlzhhk9Pevnnxb4Q1TRo5bfVNL1DbaOzPc2tspgngBAD7h905zx2q4SUlZs2w1WFSHJJ7aWPVvippeieK7Wxmi1OA6laW/mPEH3HymUkDBAOM4564xkc15XbQwE6ckWp31nCkTS3EwmCyxkgbQ0YIJAHAGCeccVZtovh9MQ8La7BcToqCzkw6RuAMszAhiD+npjitvQvCdlq9kGk8SWNpKSLlEnVXCICfkaYlW3AEkkDGMfQWvdR1U0qcLO9v67HYfDJvCfh3wo8cXiaPybi5Bu/PQoA4TIRAw44Gd3tXoGjazoWpQ2w0jU4vte90gSeT5mbBPKk5PHI9q8H1TS9O0vxJqaeLtaS7tynnQW9hmRnkcffLEYVQR1B71zOmyXnkXE9hJPHeQXST2t0HRF4VlGB/e5x6dOvaXT5tbkvDxqJyTd39x6D8MLTU0+KN3HFKl0bVp/tV3cghg5yCIxnuQCN3YetZ/xKuZ9X+J9wl3PdWlvaqsFlPLACivEqv8APyu4MxYYHdh2zW94W+Htk2h6Ff6lFqlxqlxcIbmNWMYjUtl3cdduFIJJ78Vk/FHwbd+Fk0qW2cz6JbeZdO0uCI5S38WMbsBlCnrx9aE05bgpU5Vd9diWx8NXnjewbVNYvtQitbaWQBLiUl5g75CO2MEbjgYA2g49DW1Jox174l/ZNBZ7P7NFFJeyhEc2Ugbf5eQcMc/L374OBXEWev6po2q2l9p9y7L5RS3jP+tUOQRFJHjoW746Yr3/AOHeg/2Jo0t/qUEcet6k5u9QkAH+sbnaD/dHYfWlOTgGJm6K5k/JIf4u1RJb6Dw9HbyS3F0EkJeAvCEy2AT0zlD19vWtXw5o9n4b0KGwtFSK3hDO7dAWJLMxJ9SSeasWNy11czN5UqRqqhWdMBs5PB/nXA/H+/e18ByW7I32a+njt5XRd5Ccsfl752BQO+awiuZqJ5qvPlorQtfEzQfFuvXtjbaBqUVppLKwuNrtG4bsWIOWXH8Ixz1rzS63SpJ4f8PuVs4oma9S6ii3XKhvmkZQu7aeoAbPIPBrodL8Rajf+JrTwtY39zbaNFYRIs5XbLKfLBLB85HJwMHqpHrWJp3jHVPC06XOu3FjfIt59na6WBDO9uPvLvDZboCSeQSBW8E0rHfRpyguXR9lt95s+G9O1/X/AAZptxp0ty1rIjQrE9yFSFYgwjbGCXDEAEcHoe1XtKm0rwJq8N74s1GRtZuy6/Z4zG0drGW5lO1RtT6knB+uMebxj4ei8WwWiy6x/ZsUiXUV3BdeWkKyLvVfKVRmIBv4iT1qfx9pnhO+sZPEkFyzT6w4hhCsHTzQG3FyCcDaOmePSjV6PZifvO1S6T8vwNvxX4msJPE1n4f1zS2utEmuEU3FxCrRzNIA8bRt02rkqcAnB9ue4u11IazDa2kFudJW32yRspHXIAz0429Md+a8+8U2kV98N9F099Xgs9Ut40azaZwEndFIwGwSSFz06GuOvfGWp6n4Nli1m83yRFRatGxSQyoQGU9Cx2kk7h+ZOKShzWsRGgppcvS6f+Z6n4W+HHh3RNVe+t0lu7+OdnWeeTJj3KRtAAC4wSOleU6nNrd94v1K91jwreyagZS1tby7pLePys+WxUD5wOG4IBJ70nwdh1ODx9GNLZ4dOjWWS7jaRmUxHIG7P8ZbGM9CD717xY6i19LOCjxlMbGMYBYc5wc/4UNuDd9Qk3Qm3J82h89eKNF8UHSn1nXbq+dWYCWC7k2iSXkFUQdtvHbG016h8N/iNa6xPY6E9pPFqiRbZEjG6JCFBPzdhgHA9sc1v+KNKTX7C7t9XDvpb2o3eUZDKsytuBCLxgDBz1OcdK8V8NeL9U8EzGS1soV065UtDDf745rmFRhWTrt5z8pH8waf8SNupXPHEU3FrVbHqepeJitzd6d4x+06TZ3LMIXRghVRKQh3oSRkLknpgj3rO8feLr2/u7LRvA2tWwmELzXUoKszRhSAFdvlyT1Ocjj1rnbjRtd8dWF54tMQtr5YzHaW7xFmCFMEKo9z3HXJrkNAvb7TX1MRQ2NrqUCrZtb3IOWJ5YhTkbztxzgDtTjBblU6EH6rp0v/AFuaF34i8TyaIbTxDf3S+YRbxhiRIs//ADzfaMuGBBBAPTOfWz4o8I6/pf8AZ0mtiKeGbFvF5Um+SN8/KnPGMZwQc5J6V2nw+0jw94p0TUrV7G5srhLpTco19JLIx2/K4fIKE89OmDVH4xaVc6Ja6fdC7udQ0dTHb/YbklxGwGPM8z7wJA69QcnvTU1zcqLVe1VUkrd9D2XT7WKxsLa0gUrDBGsSKTnCqMAZ/CiltEEdpCiqFVUUBQSQOOmT1orjPGe55N8N9H+2aje2WqafO5sLlpJb2Vf3V6zEMHXBwMkBio4HAr13AVecAD9K5nxf4m0fwHoAvNRbyoAdscMQBklbqQo7nAJ/Cvmbx78WNa8Xm+tNPmNto11LEqW7KFuEAA3IWU5Ksc/nit1CVTXodLjLEyvbRHtvif43+FND1xtLQXuozRtsmeyjDohxnAORuOcDio4/jj4Ie2gkeS9RJss4a1b93yR83ryO2a+f5PClta+IrTSE1ePR1YCYvchi0MvH7vcq8MuSPQnHNbdv8L9c1bT7ibw7LpmrQ5+zzFJ9jxOvzEZJ29+oPftV+zgtzo+rUoxvI938Qal8Omj0i/1aHTX/ALYOLa5FuCxyOrMBlcZwScYP41z938LPhxqEkZh1bZGwOyKLUlZGBwO+SenrXkeseD/Fmn6TB/aWjXb/AGKOXEluBMI0ZvnygyuSwPPXBzVSx8J3c1nbSXmkX6Q3So0U0kbCFYwCSeF3ZOP/AKxoUEtpF06CXwTPdLT4IaBb/aJTcT3kkkTosdyFMOTjaSoAJxgd/evM4fDFm3xHtPDkrTQXCSBDJcIAtwEJJCAD7g/h5z8pPFc9pHivXfCd0n9j6pdNYrI0kVrI5YshzhipHPXJ/A/TvLP4zeI3u7O7m0C3ewjiKyeYjJKZMdQ+MDoeg/ixRyzXW5pGNeD0fNf5HqPia+8W2v2230Lw7aXsMUa/ZZri6GXKjLFl9/uqOuQSeK4nUbbx343hfQ7rw/Z6JpglSaWWWUyFN3O1TyCwBz8owDxXo3gLxnpnjKwludOWSCWJykkE+BIoHQkA9DziupFY8zjpY8/2sqLs4q5xvhr4c+H9EtpFa2OoXUriSW6vT5sjsORyegzzgfrVnxfb3WurJounzz2b4jlkuhGdgG/OAc/McKfl/wBpc+laniHUv7NsWkEkER7vM+xUHGW564pnh5Vnie8bJkYlRnqB7+570rv4mJOdvay+XqQeN9SutG8MXNzpz2cd2Gjhie7kCRqzuqAnOMn5uB3OBVPWbK01rRotM8QxtdWjhVa62mP95tOJABwMnJ9BxnrXNfErxU48R2fhWJprGOfypJdQ2f6sl/k2Ag78sADjkZ6ior74X6RfxSi51nVhOyMj733YY4JbBB9Mdf6VUUkk2aUoJRTnpf7zz210LUJtdh0jwxdz3NvHIxtL+OfcIwSd5k4BVRgHoAx+7nPPReKfD/h3whFNf3E6aprw8vdYRhNm8gbnMfUL1bHuPY1l+MtDtfB3iK1bQDcy3MtqYUSNv3sEbEguXyGGfmAAXAzwRWpoPhG31DxFa6dqmp6j/af2NLm5eUeVMznONx5DtgDOewOec1tzdb6Hc5tpTb09NTI0ptE1KJI7zUmvr+aSRDpVsrxrcFmwp3tuChRk4HAAGAO8njPSNI8BeKYlnmu10K5tjHK0kRZLc7TtZeMOwI3cfN2rNtYrHw/4qUWd1Pevp7y5JUMUlAPz4wOQSGwBtOMZ4NUzr3iTUI7qK51G4vLNH8yRpIElVTjPmKuMjPPAGRn2q7O+mxfLJvmjt/X5HU3/AIEv7yz0+70m5tvEWiiNTAdpJ8tgd5XJx1HTPHHeuJt7uRro6bPMkCwMYWhiy6xKnO7IGFbIwOp4r0j4ZeKrl9VTQ9cubaG22BrNYEFv5UgOdjAAcsCSQeM+uap69oC6l8UZ7Oyt7yyM6Qz3V1CyCOZ1G7eF/wBroMnGR09ZUmm1ImNWcZctT1uZ/gzxjB4BMttqej3Aspmwk5L/AGkR/wC2rfePfjHWvbtBuTfM9xbNMunhQsSSxAeYfveaGzkqQQAPaqHiHw5YeLLCWHUUtyp2+RPBhpI2XOct0OMnjpya8o+Ff2rRPifJpU5nlkMM0MnnXGGG0gqRGSCRgZz0weKzlaabW5yy5K8ZSWkkdh4q8TXE3jNvCF/FBb2NzCALne370yKVUYBBHzHGAe3Xnjz3U2g8YfESxji1CAR2F1HbpALdmEUSceWrtjexOT78HnGK3/j4dNGp6NcTT6jb3vls6bYd0eAy9QxHIweFHue1Lqvw51PXtL0e4spoFkKLMbi4LCQHHykhcZ4IPIJHHpVRskm9Dai4Qpxk9P8APueu2sbR6i9pb2iW+nwRLtdcAMxz8oA5GBj/AL6rF8QfD3Qddu5rm7hnjuJnDySQylGfAAwT6cD8q8e8QeE9R8MeI9NsPDniDV7jxLc7XJjQiNVzgGRjkEZ9ew57Z64eMfiB4e0Ke68TaFYtFbx7BMZgrySYULlVJBySeg7Go5GrOLOV05KzpS3+TOQ+I/g+Lwjrunf2Ze31pYSMjQneWCup+6XOAp5zkkkjNdf8W7i58U69pHhHR7iNxMFubnABDR55O7BAAXJ465rAsdS1f4marYWmptNYKxlhvLaGB3tzCpyDknCSZ+XPPbpzXovg/wABPoPim71u41M3LyQtbRQCFVEcW4FQW6kgACrlLltzbo2nU9nGPtPiVzuYkWKJI0GFQBQPQCinUVynmHyv4vW8+IPxI8SQ21rLI1nE0VtayzYGUG1nUYwNwzjuDjrmuGFpdy3kWlaiVtr22ljtkM6KvkMOhZlGRgY69vpRCL3TtWsbw3GzUH/0hJ7CdW82VWJy3vkHjj73ccV6h8Q7O1l1YW9v4bm1XTtSiTUnk0lQjNKzAOzsA24n5gRnHIIA5Ndz93Q9uP7uytoeWaze6nqeom0unfUL5p827RRFvOfGMBgASGGML7DjtWz4Q1658Nazd3NpYzTW6W4g1G0up1SLHYFxj5shsAjOSRzWlqEXhrw+t7rnh7VtT0nXLCVhFpOoxLI0cuSduc8pjOD2xyRxXqfhKw8JeJ9C0y+n0LTU1TVomubjT3k2mZ1Yszoudp+Ybs+hx60pTstiKlXlV2tDo/AnjjRfEOkre6ZFdLPOCxtpc7BLknYHI27u/Hbmta71nVBqsFra2qTR/aUN0+7AgiZT0OMMwIBx6GvLvEnxAsvAE914a0zT31a7djNJJfSqsEQdQQgX+6Bt445qlo+peKfG3iaG4u9YbwzYz25sUijkEYZjg7YUblpMgHPYDGR3ycOvQ5VRvedtPM9Z1u88LaHc2T6/e2NvqLMy29xdMvmgYG7a3UAj8OaPGnh298VaJ9gg1K3gtZcMZVhDO8fXAOcDnacjFePa14e0/wACvLf3d/Dr3jBlWeHT79tyQbvvSEDO9x2BPv71zenzat4u8QyTaprVzpmoy2ztazSzmODzY2UBc5AVWAJGB6ZzzRGn1TNI0X8cZbdbfkbnxEtNO8Aa5p+u+Eri4s9Qhuha3UJm3idV2FmZe2QRkZ78Cvo7Ur77Jo91fxQyXHkwNMsUSlnkwuQoABOT06V4BZfDDxFrfimy1bVNNsLa3a6ilvXW6EpuwDueULyo3dwOPSvoyoqNaGOLlFqKTu0eQ+F9O1/V7a31PxDBNd3N3IbqKGSU+TbRuSVVcjAwr7emeK72Ix+EfAzv5EjxaXZu4hDbmYIpIXPqcda33O1GIUtgZwOp9qjuniS1le5x5IQlwwyMY5471LlczqV3USjbRHj2rfE/QtW8JzXyefaa3OhtoEgK/abYOAN4f+7nnsfbvXPWev8Ai/wnd2iz6jPqtlc28dwq3/zLNnOVjlzlSFIHTrW7L8FtCvtMuNQ0fVL0pcwNNab8bRuAZd2QCV9uDzXMfDzTJdR8dafFdz3GyCIrKs7BTIgjA27Mnb05xjH610R5LOx6FKNGUW47Le52PhOCy8U+MtT8SATeYIYzHaXS5xMiAbQM4cKQDng5I6d+Y17xFqWk+PkvfEYZb2ytPs8KJD5a3DuhBkLZJVcliACSMY9a1dd8CeEY7+XytXv9ClmujZwrd58p5HCyMsOcHHzbS2SOSM1W8QaTqXge/gbT/wDie6bGNt2k0RdkOcgyg5+U5wMeg9KSauEHGUko9rWf+ZZ07xT4Wth4Xub/AE2+mv7hGga+uZVknt2bgbyAC7fNhSRnHvXQ6x4Q8J6JA1xqcl3GI3jma5mvXQgLtUfdHcqDjHJY+uKwfiVoFrNoMOq6ddafpljJcoY2jyzyh48ENwdrKQ3TJxnocCp/CnjOfTvh/LeeKrLOlRSC3szGv72UrjPytwFBBwSQe1Ta+qJcXJKVO+9mr/1sJ8ZktdU17w3BAiR3d0NyzomXbDjAzkYAyT37Vs/EHwG3imNf7O1H+z9QePyJlkzGtxtO5W2A+pJ/GofiH40tdL025TS0judWh8l4xdR7ltRKuRL04OOOO5Ga5230D4oxWMN7p+tfahqKQF4WmXMIOCxJPAHX7h5pq6Sd7CjzRhHXlttfrc2PB2g/8K/0qzh8V6k7T3WoxvClvE0kEMpDIvOOCwbrgAHHWuv06zsNS8Svc6zbadH4j0+5k8p7V/nMBB8sMTgt8hUkdM1w3hPX/FeneIrzSfF8N5dKbN7q2/cBzH5YYl9w98DPJzjjmj4Z+Ib6bQtb08rJda1Zac8lvdM4PnAbtuXJLBskDnsKUot6kVKc2pSbu11X9eWogsIfil4/kmnBfS9AuNq3EY2LIRJkQkZ3EnBJYYGMcc1teKfita6fqZ03QbJNQvBujWV38qGMgdS2OVyOcY6fQ15n4b1i61LSdOs7S7XS7CDzIbyUt5cVxJP94PtHQKoAY89eeldx4a+FVhaahG+s61DcWMpVrC2gk2CVRhs5PLeny9QeT2puMU/eNJUoQt7XZbL9TW+FkEuuaxqPi3Vb2K4vJM20EEDkpBHwSMYBPOMHnj61Q+K9z/wk/ivQvCNi1xkz+bdMq/u1ULnJ9SBk9sZ71xkt1cfDvxh4ngjhE80ttI8L+YwXy3YMCFB6gZHBHIOK6L4Z+HZtD8Mz+MVge6vGg3WdrcyBAAQAz7mPBIzjOOPrTaSfNf0CUFCXt09NOVev+Rq+FNYFr8YtZ0ae7WzsYIBBZWXmbY3Y7TkL03dTn7xJNet189weD/E/9kLr0Uy2Pia2muLmWKa6SZ3STG11bkDowAYgY/Cug8E/FTVL6O00+70K8v7qNljuryJgFj+fBaQYATC89ecHpUVIc2sTKth3VSnTd7aP/M7Px74807wisEU0tpLfykH7LJceWwj5+fhWOMgDp39qK87+M+naToccGt6dZQ3LancMZZ3/AHyg7cgJ1ABO4/UUVUKcWr2N8NgKVamptnlsmm6DZaHYX+mz30GsONps5k/cJKD8xMhXcRjP9a6T4VfEa40O4e01dop7TzBDBbpGiGEkn5lkzwv1rd8GeMpk+FV7N4tsGYQMLayWWAZvzICERcj5sZ+8MjHbiuIsvAOoT6pp0Wo2UWj2ofy7uSS9DnyyQOh/iHOMADpn1rTRpqRV4zvGa0Pede8JeDr28i8VeJrOxaa2jLF5Z90JB4UlfusT245J715z4cOj6r8X9M1PRdaaL/QJYbbTbnO6NCrKgjYcKDkttPI/WvVPEmgHWtFbR3EF5pbxpCok+Z1wMGRmJwzA4I46ivm7/hFvFOhm80aLwz5VzahpRqkSHzRDyWxKDjBGcDGQDjrWULNPU5KCjJNOR634i+Gmt6t4xvNTgv7a3W4iQTTTwq5hZEUDYSMkHaCTx1PoDXkuq+GjPd6jcaLqEmtWumr9on1GPhYXzk7c89enPPPpmtGbUYfEVrZ6LrOr6xp2qoYrbNyZJYpR5h2+YF+ZD8+MsMdPWvRvBXhLXdC8TroGrWOnTeFZC08NxZsI3SbaRhhnewYFhhs/Xiru4HRGo6OkmeeavqGn6/8AE6G8tTHdWWoiG3vSpMW93REdkYjIIOMe/HTOe9vfBfw98TyLoWg6wYtViLJt8xpRKBtLkhuGwOhB7elVNZ8P+A/D+l/8JHYtqdzOZRLDbeYyGSQEgIykAqpwcjjIFcjoHhy68T3NzfacLSztXuAixwyIjWsRJyTk7sgdOueR3FG+qbRatON4txSO2gtPEfwu8aeHLabXjqHhvVbw2QtpRgRAgbcehHHTjGRxXvFfLni/T7qLxfYaXZaxqes6xby2r6db3e+KIuAGyS3G3AB+XoM5NfThlMNl512VUpHvlK5IGBk47461jUWxwYlaRk3dsfOZFiYwqrP2DNgfnWTdzu/lypsn3xBkjU8Ow/unp6c5rGn1S3+IPgrVIvCerSWxmBtvtwgYeU3BbAbBJAOOO5ryXQPizLoGnw6dp2iJBoFhHFHDukLzhN+0tIcbQW5PTgnvRGDewUKM5NpLVHT/ABTutas/BGn291f2l1DdO/2uORzHNKd4KwptXkL0LcE7R60fDTwdd6Lrmp32oaKlqsAktoZvOZmnJ6uqZwARjk8n86474u+M7bxxr+l6L4bZJYkPy3SA+YZWO0xgensRyQCK9Y8TeJbLwho9pe6673coEcW1ch5JAAryBD0T5c8Dv3zWnvKKj1Z1JThTUbWbvocP8X91x4jsLb7LLeyRadvUJEx+zO7kl2weDgdxgYH1rGvfEXiC88LL4cgCXESxAm+aVjI0e75V3ZAbuuDnp+NUPE914i1DXZdYmsokuHQyJGkpDXEMfaAbv3gZQp49ffFa3izw5qFhPb63YW63GnzxyXgjkCxS6dJINyRuFf5hyQPcY6VasrJnRFwjGMJ7/qYWrv4p1DQl8Pvbzt9gkaTFmpxtKnIkYDGQFY9zzWp4t8Rrrfw80LTdNS+jmYixu7V1adnEKhjhj97JYc9T+GDrfDW+ueNI0Kwkt7u8jlSe6Mm4QkIMSOMjncTjH49a5O4vfEWj+LrdpWuINT0w78N/y2hQncW7BG56Y6+vV9fQp2lLl6rX1NLxF4um1Xw9p2maraJYLaIplu5FIeUIu1Rt455JxnGe46V6JC2o+M9CtNTe/wD+Ee0qXT5vMhhLLcFlJAfjHyKBuwPXHvXD/EbX7XxzcWsuiXLXKwW8kd3ZeUdqlSrlw54YY7AZ4rGjv7W4TTJJ9CWeBMWckunCSOWFGJUtGCxAx15HIyDS5braxLp80E0uV6+dvvOp+Beo3EOratod3cSSJqG+6gu0mMjE4w3JyVOCrc9x0qp4QmTwd4z1+5luLuaDToGR4m2hpSWUKzdM8fN0J/QVJpPwm1SO6jk8O+IrWWzcO66hCTlG5AGFJycEcgjp2qj4m8L6xYXsEXiW4tbbSVhZTNBLmWbYAA8hI4A+8SxwoJ9qXutuz3EnRnN2fxboteIra11D4QaK2nQ3tzd3F25t41jbfN87AkjHQHGPw9zVfx/oMlh4X8BWt7Dc3HihYTbIsDlSE67cYOWUlenofatrVdM1CLVvAnhnRrySJrUJeO/nlUuBnc5yD8w2qfzrT8LrH4o+MWra7bqs9jYRmKCU4KiQAR8d+f3hBHb60r21I5+X3r6K8v0S+ZQv9I15fGfgdbpLXVL61tobfUjxN5eCS0jA/dBBOHxyR9Km+L3ji3vlfw5o1nDf3ryiJWkUSRs/Qqq925xnnBB+tcppPi/WI/CuqRW007+JdYvFjMsUTMYkJKHDHlWDE4U4xmm+CYrPTdX1qO50/Ul8W28ZSGO3kHmlcAyNGGBXzsA46ZBIHNPltq+hUaaT55a8u3z1v6I3finfDwt4R0fQGhgfVNRt0S/mjjCb4olwA3rgnAOeMds1D4d11/Dfh86LpXhWS+1RVYagRCVV2yeWVAd42gYOecnHvg/EW6vtQ8cajHd3ZlX5I7eKZVCwApuYc59MFeu7Ppiup+F3jO20/wAU6laa7qCPcanJCsRiixGrcqN2BwSNvt06UONoLS/UfI1Ru1d7/MZYRfEPxLM0d7ptva6QF3xW91arGkbrgAKPvY2sevoaKn8Xa5cJ4nvdB8J6omnQ2uJbs21u5la4YktubaRjDKcDvmii0ns0hQhOa5oqKT7o6LSY9O0rRbWy1ExS6ZaW6pGXTebLaCFKE5JIzjd1/lXE+O9Y0Q3V7pV9e30z2bqLr+zoRlc9FLyYXB74zx+dZXjHxdrFl4t1DTtIt57uLTbgIUNnlZ3/ALhIJO0Eg5HJx0A68vpNkPGfxAaC8P2KG7vTe3dpKSwDEBWHIUgnJAXPGaIxtqyIxt78dj0R/FPirxY9rpnhGE+FdEtoYxPqVwUkZOcBA3K9ug545IrufCd9rNprN3pHiC7i1G3toSf7RaDymnfOSpUccKV55zz+Hifh7w5qVr401WDw7qkmk6Rpt89pPqDSRxKsQYOVZ3HznOQAB0HXHXttW+Jstr43uNK1TQ7Oa3t7+NLXUJJQiQwMoLSF/mGQOcgjOcHFTKN9EclSmnpBX6+Zwut+JtW8ReO9a8QeHI49Nn0xD88chf7TGsgRQwJCknjK9OO/WvXNA8SXLfChvFyW0NvrH2eRmV5GeJirYLkDoDtJx0BasbXvANv4s8ZRTLbW1t4fEAaSWywjXpbBw57jByCP61U1G/1/wla3nhrSvCb3mnAiDTpVR7hGjIyfMDHHykn0Bz2xmh2lZIpzjOKjHfT7jzSOeW9kvtUhvo5JNQkWWaE3JWYMDjJLdRnBHXAH1rqdG8e2nhrQLuGztbGO48hxJOijzRd/8szg/IygFiSeSRwD3ozaJaeKrLSofDvh+6mvbeBxd3GmTrHZxPv3FVZwVdj0xnjOAeM12fg34PedqFlrPiiOG2u0l89rG0lZ1LDoGcn7oOPlUD3JqpTjbU6auIpuPLLQ1vgj4LlEcHjPxFey32r30ZkhWZg6wq38a+hbk4GAA2K9iLKFJJAAHJqiv2exs8nbFbxL90AAKOwArzRdd1y+me416JrGxW8FvDCtu4WZWdcLg4ZhtB+bgZPTA5w1m7s8+0q877L+tD0HwxomnaHpj2mlBxbyyvcFXlMnzOctgknAz2HFfPXw/wBe8LeG9Qu4tbsI3mhaa0kuyWkWVNxGAuSAMdc8+4r0Ia1J4W+IOn2uoxyizuC1kk7uVQ72ymFx8xyAMnoM4rgPjX4fh8O+MLu6Ml1FpOuASPFAnyvLuG9S+MLng468mtILVp9Tqox5JOLd1JHrOjeEfC2iXkV1omhadaXJIMNx5bSYDfdZSc4PzdfcVxItofGXxRu/7SlmSx08SvJZzjy5cxlUBGD0Y4bIOD3rpPDOpau/w1h1KK0hlvrG0zFEuWBRTwOMkvsB49cVy/wdvbFk8VeJLnT/ALMkcMk7OY2Eki8tJhyTkZXp1B70oq1y4p0+eXVaeZn/ABT0CG/8Q2mr6feRvYX2nIsBjC4gRAOETO4gjnA9T7Vd+CdlHJoPiF9ZVE0VfLVJnXaJGVTnax5IXI49T7muXuIdd8ZWD+Jb/wDtGe+RWWxtLSEtDCeCpVRngADP9ah8SeI7nxjeaXoMVjBawwRsY7eCPDNKIy0hABC/MVOF/rWtm48ps1L2apvpv5dT0b4P3GkSazrNtpMNxaiHyTNHcQqpVi/yhZATuGVbj6Vi3uqv4puvGVvb+G1/4SVEVf3bO0nlq4QoctjODn5eDnBBqh8E/EKtPc6Kum3Ud25E5mD7sMmSFcHGVwRg9efTFbPimw1DwX8RrnxnZ7LvTtQIV0TCgAqAyuxPXK5XHcVL0m+5Mly1Wur2MeHwJ4k8O6Dp+vaM8kN3saWe1Ef71ctj7mPmG3GR79PSnZyjW/Gun7bOHSxqUrWskcLeSVYj55MHq2ccDAPpnmurh+KGsvb3d1p2hymwRWMlxMXkxgDkgYC4HXn0ri7PxQ/iL4jaJrt/psa3MRiLmNiFABxliflzg+3bpVLm1uaR9q2+eK/roW9X0XxJ8MdWX+yr1mGoSDyVsx8spD/KrqRxkkDjscdjXeeLPiHoenalqlrrMrX8EdsttPpK2gaIzZzITIclgRhduMfKc5zXXeL7+fw94P1S7jhMzWERkhd03YJJA4zztB55FeB6Db2vjbXE02WIWWqX0Ju/tsauVHRmbG75DjHOcdvSoXv6yMINV1z1Ft1/ryNhp7z4neKLv+yIJdNvYoGFsWdhCsQGAr7c7SdxB28c967jSdJT4ZeBr20/t3SrLXroCaOScEoFQKCqx5y2MsAQOSwzWL4d8e+EvDmp31vptjDb2HlxxPqkTbpJ2A/1jRn+Ak5BzT/2gHjRPD2pfZ4LyB1KLcqw3nIDDbg5Knjpx9eKbu5KL2HNylKNK1oP9CX4CaMt2L/xNq05u7uOaSOC5mch9rYZy/OCD8uMjIwa4/SfE0el/EPU9VnCtFdak8E0qIu+NWDAMGwSMfKRj0+tV/DPjHxFoYl0/RNPS8gMZlns5lMkkrPgE7OpQAY46Z561f8ACes+FtDg1jVtdsWt0v7g20GnQYliZkXc+GKgquWUYJ4z3qrat73NZU3GcpSV07IwYLDRrnTbm90nUfOvLQu81vqjYeY5zuEq/eJz04OT9a6HWJFMegpc+H7q31Gy8ghXnAgkO48yLyyKAM5zyB9K0vC+nWd5puseMfFNrJ/ZdumbS3kCgHLAgKdqggNtA7Nnmjwj4Lv/ABvbSeJ5r1LXUJrokyg585AMEMi/Kpz6f4U3JdS5VVF++9I2+/t/mVPHniiLWvE/neGnMdylsiXEmWRJeTyoHPGRyfbpRXSaf8OfFiadGlnqmn6Ju5mt4kabLjI3eZwzZBzgk46CipU4LQmGLo04qC2X9djstX0Lw/480tZp490gWWFbiBirwuRhiuOMjHfNeQaj8Nx4VJi03XnjvLmR0a7kJjdLba2FwFO4lwCW46elev297Y2+r6rPc69pJSzjIaCBvKeDbkv5g3nPPsMe9R6VdaF4l1X+0NO1C11CS3BUmOUt5e4DOF6YIPofr2qItx9Dy41XTej90+StQ0XVLyabSdLe71IwESXPmJ5ESFvuPtbnB/vHr6CtZ/A/iPS4yU0lp0ePEUeBKXZxt2sBkbvfoMZzX2Fa2cKyO+1N7Y3MQMnHr9KmdQHOGwTT9tK5f17TY8w8EaB4j8LeBbS0tktW1KSbzrpJdzCJSuCkYBwWGFHOFPJ9K6PRW8TBLZtUeOWfy9s3loER2xjcRn5R3wK6l1wR346iiCNmRlkZSSTyAVGOw6+lZuV9Wc3tm220rs5TUvENzpl1DaHTkjhkBIud2IQQfukDkHn05q9d+J4tOtoTcRO07syjyY2KFgOBkjvWpa6Vp9vCYo7dWUkk7st1OT1zUl9pOm39rJBeWME8LsHZJEBDMvRj7jFK67D56Vtjz3T5dZ8Y+Gv7QvLz+zomk/c3Cjytiq+fMKP9zIyACCSOeM1c0rWLXxTNYRpcXF4bG6VDKsDokhMbDeTjDAg8jgA1ua34SttQ1CWeENC11HtuJRO4Ix0Kp0yRkEjBq34R8MW3hqG5gsHIglbfgjkserMe7H1puSsdEqtNwv16I57xRoOvpdaPPCbbV9MsJfNmSeLfeMQchkPC8ccdePwrp7o2PijRrrSrqVFknhZXRSpkjz8ocA55B6HHBrdVQDwc1y3iDQEsp7rX9JtfM1OOJm2K+xpQCHMYbsrMoJH19TU3vuZKftFaWjWx4/8AELwZffDa3sdb8M+ItQWdrpLZIZDkMCv8RHB+6SQRg9ua1PhroN/4mXxDq+rTSW+n6natYx2sQEccrMc7gvYA9DwfmOff0nVY9G8d+ApP7VEcFlcA/NOQrW0wYqDyfldW469eO9eR+FL3U/hJqOo6N4xaWTR5y93a3cMXmNJIMDOemSoGVPcZFaxk2rdTrhVlUi4P4jjvDPiXXfBupxXhtr1RaiSG5s5VaOF2BwNzkHkHJ4/ujsa9V8OeJfh14g1DTNfvo9P0jXo5mAjkcx5lJ2gg8K55HzY4zXN6/wDFSXWo/t2gwPDq9uGe2tZf30UgJ2MTgDPGeM44/PzTW7y113V57zTtPhgup7lZVjjkYqjlS0oVSBwzgkdMe/WtHHm1asdEqUqrvNWdt0z0jR73w18P/HM0WnazdarZgtbyxiAMbcuRuJlzh8YAwoz1z0rsLfxnoHjLw5qunamZ9JuUhe6a3dg5WNTuV0OcFmXB2/7VYfgjwH4P8ReFtM12S3v7Xycia2aQsfMz827HPXuMdea6QfCbwpeQ/boLe+t55rc7I5GJZAQOq+uB0PrWcnG+t7mU501ZSb5l19DjPgl4nNlc3unXBzYzvHObh5QggQjBMu8YGcoNvvWX8YNI07QvEWo2tla6gkt/ieKSRUS1Xd99ItuC2OpyeMgYr0C/0/RPhd4Nv9Q0SBze6vJFDFHdnftc8AY/urlm+v4VzmmaR438U+AtQh1GecSxXS3FpdXrbHdQSJEwBuxjkcDoKpS97nK9opVPbbLZ+f8Awx6d4Psfs3gKDTvEssd7CtuI555yfKkj2DGQ3AAUgccEqT1Ncbd6j8M5dX/tGy1VLS5urBtNSa3V1j8psDsOCAAuew964GLxPqGp+CNT0a8luZ2ivA1u7SeYXi67c4+7xkZ45x2rqtH+HHhrxV4Uu9W0KW4e8aGSOKDIQW90o+aPtkbvXI54NLkUdZMiVFU71Kjau+hPrPwe0u18J6lPDcteOlgxt8fKBgmQvlfvfLkD2PX0zPh5Y6X8Q9PtodUW9stQ0i3htre6hmEe+LJYKowcMo4PfBGeah8P+OdSsPAa6EtveN4hR5IoI1UMbZFUcsD95RkgDHbpxUeieD/HFja3Wo2U0MOozkJJFAy5RCg5I4COQRz1HPIzVWdmpMv37SU5a9HsdtZ/adN8eao9loWn38ekW0UNtNbR7LiOJj88WScuR97PTn61l+O/GOhRNDZeG/D2m6pcW00sjNLbhoYXI+YrgbWY55IP8PrWBpt/FaeDdU03UPEcFtqFxqJRntJWaQgJ8+9xklc4+Yfmay/Dvhy0uvFVhosl6tssoKLLp7q8M8IUnBGQVJGcn3oUFuxxpR5uaeqXrqdLH4/vde0Ww0TW7LTktJyFvZXLRhoFOd0ajgMNvT1xgU/4eeNPDngzRtWkGpXdzpVxe77KxFuWuIlPBLfMcjp1x06c1n+KLTRfCfgzXdMvNRNzPfTN9h8mJfNhVSrBd3Py/d+boe1Yvw7+GN94pge8vp7zRrYNHgJGUeYck4J7cjDY+lNqHK76IqaouEntE+jPDmtf25bT3KWF7aQLKUia6j8szrgHzFXOQpzxnB46UVesbdbW1jiTO1FCDPoBgfyorjZ48rX93Y+YfEXhHxD4V0ue3u/Dlnrd7q0/2WK/Mhkl3OQSJMYwD0znsSTjius17wRL4R8I6NrfhuF7DxLpyRrcG1V5o5E+9Kjgk5QHcfyHpXeTeKpbO4hF9KkqTzpAqJG27LHAYAZG3GTk9AOcVY+IeuS6J4faa2ubCC6lfyoxfByj/KSy4Qbs7QT7AE10c0m1c6KlWpzJNb/ianhXVhr/AIb0zWI4Ht0vrZLgROclNwzgmp9V1Gz0jTrm/wBSuEt7S2UySyv0Ufh1rkvBviDwx4e+HujTvqkVppk8aCN7glCXf/YOSoJ5A6AV4jqniXxH4mv7vWp5be40+2nnjtLIzAQkn93gIcMRt+bnqTx6Uow5n5GdLCurNqOyO0j+N08mpa1/Z+g32p2ayr9mIIjWJdoBBIUnJPPPPNRf8Ln8S38EjaN4VhtkRgWvLyYmIL2yMLgn1zXX6fp3h3UvDehveaRco8SpeiyQtlncbSZSOH467uQOvNcjD8J/D0lwt5oXiW+s0mnGIpFBYIWZSgyMkZBxuGMdc9ad4djqjChfWNrf10NHR/jallNHY+NtFuNPvETfJc22HhYdmCZyufTJrpLb4seG7/xDpFrp+t6abC8R1ZZg6TLMcFOoChcbhzyTgCvHPizp3h7wlqlrpOgXd5FfLMty8gj80QfLtwRwWJIz1wBWZ4a8Oadrd54i0rQkhutWntEltpL0EbWSVTMQ6ErnGSDjnOKpwjbmLnhaMo86ukfYSrx82CcdcUjZU/SvJf2dfEsmoeG5/DupPKdW0FxDIZFILxEnYfm5yMEHPpXrJk/eK3OOlc7VnY86pB05OLHDdt6c09gdo7n2pHJz7d8UqhThu9Ig8xjt7nRfEmt2mqx2974evbhJba1eJcK5wzFsjBO4Ag+or0JLjTdWSe2D212qgCaE7XwGHG5fcetcf8V/DJ8TQabBFKILuCUz284TLxyLggrzg5GQQeoPtWb4amEGqwk6ha3E1jblr1IAolmkA6Mo6Y4I/EVdrq53Kmq0Oa9mYPx5tIfD0nhvVdNg/s60WR7K7urOD5oYW5CjHCgkv6ZJFeR67o0mkaiZrfzV09wz2EmDPHcAkFnXy+hPdSeOlfYV/Z2upWM1pfQR3FpOhSSORcqynsa8X8c/DCbw/af2n4IN46wEs9iHMkgDN1iJBJxk8H657HSlUS0ZphMSlaEmcroXjeb4feH1trS1s7+e8YzXeZW8u1c8eWx53fLtxj1PWvZPC2r6N450eLULENa3EW1HQMPNhGThfYHnmvJvhDq+jL4l13SPFCqtzqgjiktL5QVDqT8hBHBO7gc1Zsru3+FXxBurG408Pomq+XGl0koIFvkje5JPKltpXgbRnninJXdlv+ZriIRlJqK97dPuVviWt1I+leDNDutT1i7sHmupWkl8+UjJwm4Dkhc9RxkCvQvhXo+seHvBWot4p84lleQQvKZZEjVTwcE8nk8HPPrXM/B7SvM8eeMvEMNrJBbQzSW8MTR/fcty4Y8nhQTj+/Xb+Kkt7H4Ya8dVup1jlt5mklVl8wM+cbTwCckY79O9TKX2EZVp2gqS8r+r1PHfg9opu7LxDMlvafaJYGjsTcKCWIDElUbG4DHIJB759dj4DeIJtH1+80LV7opbyIhVbhsPHcE8J1IGRnj1AzycVyV5rt/Po2l6BdrcW9tKkccc6ENc3UTYBSMk4CngEDr3rb8JeCba0+LcOhX06f8AEu2XIjJ2mX5Q4Xcv3sE98ZAxWsldO51VIL3lN6Nfl1K3xIiTTfHGsQ3Nta2Ewm+2ae6q6tK25csx6FOTnGMEGui8XS/FSS1P2aMz2BhUE2CJicleWGDuxz09q734xaG3ifwHcvpLRPdwETxyKwG9UbLJu6gcE/UCue8B/E2WD4W3+r+IY2nk0uVbVWiI3XAIUISTxnnBPQ4qFJtJpHPGs5U1JJNrT/gmR4I+ClvLpFvP4lMgldNwhjJR0RgCY2IPY59wa4fX9Jk07xhqNpbTz2+nQzPbx3Ai5iUrlVU/3R93cK7cfHC4bSZl/seddZkG2GBfnjzuxkfxEnI455Fbfwq+H1xDdv4m8VRrPq07NLbxSxhWtww5LDoHOSOOMe9VzShdzK9rUpOU6v3FP4SfDY2M0Wr6xaGMQx+XbxSyJceYhAw/AGPYHPrXq+r6hFpBst6AxTSiAKqklTgngAEAAKxOcdK5S013xRP8W73REsoR4btLaKQ3DoQxLJn5W6EluMdgtZPx7uZG07SdMtPtj3dzdCREtz024XJxzj5jx69egrJ3nPU5m54ipFSe5na9dePfH0aHw9HN4d02Ni8cnneXPPyQCcjhcfw4696KbqXirxB4e020h8QeGJFtECwwSQ3m2V9oxlmye2Tj3FFbJS+zax0KnJK0IJr7/wBTuNRi0XSbWeVreKKKxj853IO2PHIzz1PUA14f458faX4w0GGGS7msJHkMlrBHCZywGeZOcoSOw4ABHOa80vvFGuak1p9t1S6lEt1E7jfgMemSB7E0j3k64tlcLCNMXAVQD8ztk5655PPUU1T5XZ7hSoKn70ndmjY6VDLY3Wqa/Zy3HngpFJCSmJyxwXxwFIG7kc5FXL7QZNP0Wzl1KKZrh2LLIjkh4Qf4j03YPGOnesdCYoNT8tmAiWBEGeACxzx+A5rSmUWepahDbZihWXiNSdvQduhqzvj2Rd0DX/F1rJb6d4c1cmWWdnj0+1O+SPIO3jadw2g5JPUc+talz4t+IGnatpOoeI7u8tIIpsGO6tlghnCnLb1C8sQcZ7V337MkMc3hyfUpI0N9NuWSYDBYCV8dOK9C8eaTYa1oU1vqltHcxKVYBuoO7sRzWDqLmtY4KteEaii438+up4/418OeF/FU134rstT1FL2bynutNtkjlmiJwu4ruBAxjv7+1cf4W8JeNH13Ph+y1HTCY3AvSptvLUcHc/TJ4Pvisu4iSx8SXmnWg8mzcyxtGpI3Kr8AnrxgV6V8FdQvB8VV0b7VOdLt9MeaK1MhKK52ZbB7/Mfzq3eEdDeSdKleLuvM8+1K88Q+G9ZW9s2udL1/TsJNu3MLzewxlsYck5J3cele5/D74w6Zqpg0nxUyaTryHy5PNO2KVvVT0Gc9D3ziuT8Uu2rftCafZ6ifPtbd4kiibhVGQccdeSTzXpOueCfDc+s3WoT6NaS3f7u43yLuHmbgN2Dx0HpWc2na5hXcJxi6i1avodPoviHRdfkuYdI1S0vXtnKTRwyBmQg4OR16961zxgDgGvnn4y39x4PgOs+GXXTtUuryRJriGNd0ioi7VOQRj52OOhJyckCvXvhnqt5rXhC1vNTm8+5ckM+xVz07AAVEqdoqXQ4alHljzJ6HTSRrKu18+xBwQfrXn3ibw9oeh6te+ILLQ7z+0DG15c3NjEWZgpAO3n754O0Y3YJPNeikD0oB6VmnYzhUcHdGN4V16017TIp7aRvN2/vYpYzFJGfRkPINbRrxXxpr2p6d8RPEVtZXTQwwaUl1Gqqvyy5+909/pXr8LGbToXl+ZniBbjqSuaqUbamlWmopTWzPLPjP4VvfEkbLpGk2rXiAPHc7CkxkBxgSDjBGBg46elcP4G+Gb6lqEieJbxw6xqGSJmK/eyoVsYJG0jHv04r0XxRe3Wl6v4d07T7iW3s31ORGjjcgFVQFVz125J46HvXQ+EtJsbLVdRltYBHJJL5rEMT8xVc4GcAew4HatOZxjY6oVpU6Vkec/DvxpBoEms+HvGd7cWd2LsxIbhy8cRI+VQ/uNp9OtRfHrWrzR9H0vR7e4UW+oh3uxEjO5KgYVT0AYnnvxVT4/WVt/wAJnZXPlKZWhUknkEg8EjoT74rkGkfVfFvh6x1B2ntbiWKGSNyfmUnkZ6jOTyOa1jFP3zeFFVEqz+Z6L8Hrd7z4d6fNc2cd3Pa6pILSVbVZimf4sn7uD1b6fWt34leDNY8Qy3GsWENrb6tYRxnS5EmIkZv4xJn5RjJ2kc+tWPiyo8HfCO+i8MD+zI7RUWAW/GwGRc4+uTn61w/wN17VHks4Jb2aWO5tZZpfNO8s6XAjU5bJGE4wOKzSbXOjn5nO9WOh0vwKktU8Maj4P1JMalYTSx3do7eYoSTnG7pjkjFc38RPATeFfDmr3enXjt4feSN5LAjCom7CovP8ORgnHBrmvF7vo/xJ0zU9NdoL2e63ySKxIYswB+U8cgntXtPxluZrfwc4gkaMSXCI+043LzwfamrxkmupraVKtFxfxb/gZnwK8OpZeGYdXuLiO5uL8eciqd626kY2qSMgkYyPX1616guOorB8G/8AInaIQAM2cROBjkqK3h0FYSd22cFeblVlcQ4zjkY5zXhWoQi++K97dXvi6zgS2njnt4jcryqcCIIcKvJILZzk9DXTftA6zqGieG9Ik0u6e2e41KOCUqAd8ZV8qcjoa8f8E6XY6zfXkOpW0cyRxXEiHG1gwR/4hg9uma2pwtHmOvB0vclVv3Pf59H03VPCdhF4pVfLEhlVZC0BVjuwDk5zgnNFea/s+6hda7aXOnaxO97ZWsKNDFOd4jPTjPPSik/cdmzKtz0puPN56eZ//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-power photomicrographs of hematoxylin and eosin-stained sections of a skin biopsy showing three different histologic variants of skin Merkel cell cancer (MCC). Top panel: intermediate variant of MCC with vesicular, basophilic nuclei containing prominent nucleoli and multiple mitoses. Middle panel: small-cell variant, histologically indistinguishable from bronchial small-cell carcinoma. Lower panel: trabecular variant, which is rare and normally only seen as a small component of a mixed type of MCC.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mosby-Wolfe, Times Mirror International Medical Publishers, from: McKee, PH, Pathology of the skin, 2nd edition, 1996. Copyright &copy; 1996 Harcourt Publishers Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19863=[""].join("\n");
var outline_f19_25_19863=null;
var title_f19_25_19864="Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis";
var content_f19_25_19864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19864/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19864/contributors\">",
"     Imran Chaudhary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19864/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19864/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19864/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19864/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/25/19864/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac syndrome X is a clinical entity that needs to be distinguished from angina pectoris due to typical obstructive coronary heart disease. It has three characteristic features, each of which can be seen in other disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angina or angina-like chest pain with exertion",
"     </li>",
"     <li>",
"      ST segment depression on treadmill exercise testing",
"     </li>",
"     <li>",
"      Normal coronary arteriography, with no spontaneous or inducible epicardial coronary artery spasm on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"       ergonovine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      provocation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Noncardiac causes of chest pain must be excluded before the diagnosis of cardiac syndrome X can be made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=see_link\">",
"     \"Chest pain of esophageal origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of cardiac syndrome X remains uncertain. Two mechanisms that are not mutually exclusive have been proposed: myocardial ischemia that might be caused by coronary microvascular dysfunction (ie, abnormal dilatory responses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased vasoconstriction); and enhanced sensitivity to intracardiac pain or the so-called \"sensitive heart\" syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. It is possible that the syndrome may result from a variable combination of coronary microvascular dysfunction and increased sensitivity to painful stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence supporting myocardial ischemia and enhanced pain sensitivity in the pathogenesis of cardiac syndrome X will be reviewed here. The clinical features, diagnosis, and management of this condition are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5802?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac syndrome X should not be confused with the metabolic syndrome, which is also called syndrome X but refers to the constellation of insulin resistance, obesity, hypertension, diabetes, and dyslipidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYOCARDIAL ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several possible mechanisms have been proposed, data supporting the significance of myocardial ischemia remains inconclusive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data concerning the possible role of myocardial ischemia in cardiac syndrome X. Exercise-induced perfusion defects have been noted in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, in other series neither perfusion defects nor regional wall motion abnormalities were seen in response to stress with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    or transesophageal atrial pacing, despite the provocation of chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Similarly, exercise-induced left ventricular (LV) dysfunction, suggestive of ischemia, was noted in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/10\">",
"     10",
"    </a>",
"    ], but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/7-9,11\">",
"     7-9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that ischemia in cardiac syndrome X is limited to the subendocardium, which might explain the inconsistent evidence of perfusion defects and LV dysfunction. Support for this hypothesis was provided in a study of 20 patients with well-defined cardiac syndrome X and 10 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/3\">",
"     3",
"    </a>",
"    ]. Perfusion of the subendocardium and subepicardium was assessed with cardiac magnetic resonance imaging (CMR) at baseline and during adenosine infusion. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At baseline, regional perfusion was similar in the two groups.",
"     </li>",
"     <li>",
"      During adenosine infusion, control subjects had a homogeneous increase in perfusion of the subendocardium and subepicardium. In contrast, patients with cardiac syndrome X had increased subepicardial, but not subendocardial perfusion, suggesting abnormalities in vasodilator response and subendocardial ischemia. All but one of the patients with cardiac syndrome X had intense chest pain during adenosine infusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that chest pain in patients with cardiac syndrome X may be due to subendocardial ischemia. However, an accompanying editorial suggested caution in interpreting these findings, based upon the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Earlier studies that reported evidence of ischemia with radionuclide myocardial perfusion imaging have not proven to be reproducible.",
"     </li>",
"     <li>",
"      The findings suggest heterogeneity in the increase of myocardial perfusion in response to adenosine. Because this occurs in response to a stimulus that does not significantly increase myocardial oxygen demand (adenosine), it is not clear that the impaired increase in perfusion should produce myocardial ischemia and ischemic chest pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further evidence supporting the presence of subendocardial ischemia in cardiac syndrome X was provided in a study of 18 affected patients and 10 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/12\">",
"     12",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress test induced myocardial perfusion defects (in the distribution of the left anterior descending coronary artery) were seen on cardiovascular magnetic resonance imaging in 10 of the patients and none of the controls. In addition there was a significant correlation between the perfusion defect score and a lower coronary flow reserve after adenosine infusion.",
"   </p>",
"   <p>",
"    More direct evidence of ischemia has been provided by measurement of myocardial high-energy phosphates after hand-grip exercise, using nuclear magnetic resonance spectroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/13\">",
"     13",
"    </a>",
"    ]. In this study, however, only 7 of 35 women with chest pain and normal coronary angiograms had this abnormality, suggesting that the disease is heterogeneous. It is also possible that reduced perfusion limited to the subendocardium might not be detected with this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Possible mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;If ischemia is an important cause of chest pain in cardiac syndrome X, at least three mechanisms may contribute: endothelial cell dysfunction; abnormal cardiac adrenergic tone; and, in some cases, occult coronary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Endothelial cell dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac microvasculature in patients with cardiac syndrome X may have a reduced vasodilator, or even a paradoxical vasoconstrictor, response to several pharmacologic agents and exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/5,14-16\">",
"     5,14-16",
"    </a>",
"    ]. This coronary microvascular dysfunction may be part of a more generalized vascular disorder, since it is often associated with endothelial dysfunction of the peripheral conduit arteries and smooth muscle cell dysfunction in other organs such as the bronchi and the cerebral microcirculation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. Because of these abnormalities, cardiac syndrome X has also been called",
"    <strong>",
"     microvascular angina",
"    </strong>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11785?source=see_link\">",
"     \"The coronary microcirculation in disease states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations are compatible with microvascular dysfunction in patients with cardiac syndrome X:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue level perfusion, as determined by the myocardial blush grade on coronary arteriography, was evaluated in a series of 55 patients with cardiac syndrome X and 44 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/21\">",
"       21",
"      </a>",
"      ]. An abnormal blush grade was significantly more common in patients with cardiac syndrome X (58 versus 20 percent in controls). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H4#H4\">",
"       \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'Myocardial tissue perfusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       Dipyridamole",
"      </a>",
"      SPECT imaging was performed in a series of 41 patients with cardiac syndrome X: 18 had transient perfusion defects and 5 had reverse redistribution [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/18\">",
"       18",
"      </a>",
"      ]. These patients had significantly lower values of brachial artery flow-mediated vasodilation than those with normal SPECT studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35192?source=see_link&amp;anchor=H4#H4\">",
"       \"Basic properties of myocardial perfusion agents\", section on 'Redistribution'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with cardiac syndrome X also have higher plasma concentrations of the soluble adhesion molecules, E-selectin and P-selectin, compared to control subjects without anginal pain, exercise-induced ischemia, or coronary artery disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/22\">",
"       22",
"      </a>",
"      ]. This observation suggests ongoing chronic inflammation associated with enhanced platelet activation.",
"     </li>",
"     <li>",
"      Nitric oxide and endothelin &mdash; The abnormal vasoconstrictive response of the microvasculature has been attributed, at least in part, to abnormalities in nitric oxide and endothelin-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/23-30\">",
"       23-30",
"      </a>",
"      ]. The possibility that endothelium-dependent vasodilatation, mediated in part by nitric oxide, is suboptimal and defective in patients with cardiac syndrome X is supported by the following observations:",
"     </li>",
"     <li>",
"      In one series of nine patients with cardiac syndrome X, intracoronary infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      , which acts via the release of nitric oxide, produced a lesser increase in coronary blood flow than in controls [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The intracoronary or intravenous administration of L-arginine (the precursor to nitric oxide) augments the coronary blood flow response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      in patients with cardiac syndrome X but not in controls [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/24,31\">",
"       24,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, are elevated in patients with cardiac syndrome X [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       Acetylcholine",
"      </a>",
"      -induced myocardial ischemia that is presumably due to microvascular spasm can be ameliorated by fasudil, an inhibitor of Rho-kinase, an enzyme thought to be involved in pathogenesis of coronary artery spasm [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormalities are also seen with endothelin-1. These include increased plasma levels and downregulation of endothelin-1 receptors (a possible reflection of increased endothelin-1 availability), possibly leading to reduced responsiveness to exogenous endothelin-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/26-29,31\">",
"       26-29,31",
"      </a>",
"      ]. The elevation in plasma endothelin-1 correlates with the elevation plasma ADMA [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relation to serum CRP &mdash; A relationship between increased serum C-reactive protein (CRP), a marker of inflammation, and endothelial dysfunction has been reported in patients with coronary artery disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/32,33\">",
"       32,33",
"      </a>",
"      ] and in apparently healthy individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/34\">",
"       34",
"      </a>",
"      ]. There may also be an association between serum CRP and cardiac syndrome X as illustrated by the observations that elevated serum CRP correlates with coronary microvascular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/35\">",
"       35",
"      </a>",
"      ], prolonged and frequent chest pains during daily life and increased ischemic activity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/36\">",
"       36",
"      </a>",
"      ], and reduced carotid artery distensibility and increased intima media thickness [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adenosine &mdash; It has been suggested that angina-like chest pain in cardiac syndrome X may be secondary to compensatory release of adenosine, even in the absence of myocardial ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/38\">",
"       38",
"      </a>",
"      ]. Adenosine can directly stimulate pain receptors and, in one report, provoked intense chest pain in 19 of 20 patients with cardiac syndrome X [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/3\">",
"       3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Adenosine can also contribute to scintigraphic perfusion abnormalities and myocardial ischemia during exercise in these patients. This was illustrated in a study of 26 patients with the diagnosis of cardiac syndrome X and 10 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/39\">",
"       39",
"      </a>",
"      ]. All patients underwent adenosine thallium testing and exercise thallium testing after they were given intravenous saline or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"       aminophylline",
"      </a>",
"      , an adenosine receptor antagonist, on different days. Cardiac catheterization was also performed to assess the effects of intravenous adenosine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      . The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Perfusion abnormalities on exercise thallium testing occurred in 14 (54 percent) of the patients with cardiac syndrome X. In seven of these patients, adenosine thallium testing induced a perfusion defect in the same area, while intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"       aminophylline",
"      </a>",
"      reduced the exercise-induced myocardial perfusion defect and prolonged the time to 1 mm ST depression.",
"     </li>",
"     <li>",
"      At cardiac catheterization, the patients with cardiac syndrome X and abnormal perfusion studies demonstrated impairment of coronary flow reserve after adenosine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      infusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was concluded that some patients with cardiac syndrome X may develop coronary ischemia, manifested as a perfusion defect, due to failure of the coronary arteries to dilate appropriately during exercise. Adenosine may expose this defect by increasing flow in normally responsive arteries, leading to the detection of a relative decrease in flow in the abnormal vessels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predictor of subsequent coronary disease &mdash; The presence of coronary endothelial dysfunction, as detected by a vasoconstrictor rather than a vasodilator response to intracoronary",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      , may identify patients with cardiac syndrome X at risk for the development of coronary heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This relationship was suggested in a study of 42 women (age range 38 to 66 years) who had angina, reversible myocardial perfusion defects on stress SPECT imaging, and normal coronary arteries on angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/40\">",
"     40",
"    </a>",
"    ]. The following findings were noted at follow-up of more than ten years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 20 patients with normal endothelial function (coronary vasodilation after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      ), all had complete resolution of chest pain after six to 36 months. At the end of follow-up both stress SPECT imaging and repeat angiography were normal.",
"     </li>",
"     <li>",
"      Among the 22 patients with coronary endothelial dysfunction, eight had complete resolution of symptoms, 13 had persistent episodes of angina, and there was one cardiac death. At the end of follow-up, all of the patients with persistent symptoms had developed mild angiographic coronary disease (mean 32 percent diameter stenosis), while the angiogram remained normal in the four asymptomatic patients who were tested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Autonomic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supporting the potential contribution of autonomic system abnormalities to cardiac syndrome X includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased cardiac sympathetic tone &mdash; A predominance of sympathetic activity could contribute to cardiac syndrome X by increasing microvascular tone and sensitizing small vessels to vasoconstrictor stimuli [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/41-44\">",
"       41-44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myocardial imaging with I-123 metaiodobenzylguanidine (MIBG) is a method for assessing cardiac sympathetic tone. MIBG shares the same",
"    <span class=\"nowrap\">",
"     uptake/retention",
"    </span>",
"    mechanisms as norepinephrine at sympathetic nerve terminals. Increased cardiac spillover of norepinephrine would competitively inhibit MIBG update. In one study using this technique, defects in global",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regional cardiac MIBG uptake were detected in 9 of 12 of patients with syndrome X compared to only 1 of 10 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased response to beta-adrenergic stimulation &mdash; The possible role of increased sensitivity to beta-adrenergic stimulation was assessed in a study of 58 patients with angina-like pain and a normal coronary arteriogram and 22 matched controls free of angina and known coronary heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/45\">",
"       45",
"      </a>",
"      ]. Increased sensitivity, defined as intraventricular flow velocities (&ge;3",
"      <span class=\"nowrap\">",
"       m/sec)",
"      </span>",
"      during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress, was significantly more common in the patients with angina-like pain (48 versus 18 percent). Six weeks of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      resulted in a 74 percent reduction in angina score associated with a decreased in intraventricular flow velocities (2.5 versus 3.4",
"      <span class=\"nowrap\">",
"       m/sec).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Occult coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, patients with cardiac syndrome X have normal epicardial coronary arteries at the time of cardiac catheterization. However, use of intravascular ultrasound (IVUS), a more sensitive method for detecting early coronary artery disease, suggests that this may not necessarily be true. In a review 30 patients with apparent cardiac syndrome X, three morphologic groups were found on IVUS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal coronary arteries &mdash;12 patients",
"     </li>",
"     <li>",
"      Atheromatous disease (mean area stenosis 38 percent) &mdash; 10 patients",
"     </li>",
"     <li>",
"      Marked intimal thickening &mdash; eight patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patients with abnormal coronary arteries (atheromatous disease or marked intimal thickening) displayed a vasoconstrictive response to exercise that was attenuated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    . The group with normal coronary arteries showed a vasodilator response to exercise. It is not clear from this study whether the observed lesions were sufficient to account for the symptoms.",
"   </p>",
"   <p>",
"    Another method to detect occult coronary disease is the use of double-helical or electron beam computed tomography to identify coronary artery calcification, which is associated with atherosclerotic disease. In one report, coronary calcification was detected in 10 of 16 (63 percent) women with cardiac syndrome X compared to only four of 18 (22 percent) with a normal exercise test and angiographically normal coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/46\">",
"     46",
"    </a>",
"    ]. However, this observation does not mean that coronary atherosclerosis was responsible for the clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Antiphospholipid syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid (Hughes) syndrome has been associated with a number of cardiac manifestations, including an increased prevalence of myocardial ischemia. An association between this syndrome and cardiac syndrome X has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Ischemic heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENHANCED PAIN SENSITIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second possible mechanism of pain in patients with cardiac syndrome X is enhanced pain sensitivity (hyperalgesia) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothesis that enhanced pain sensitivity might be important is indirectly supported by studies that could not demonstrate evidence of ischemia in patients with cardiac syndrome X after stresses such as exercise,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , or transesophageal atrial pacing. Despite the frequent provocation of chest pain with these stresses, some patients do not have perfusion defects, regional wall motion abnormalities, or a decline in left ventricular function or myocardial blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/7,8,11,48\">",
"     7,8,11,48",
"    </a>",
"    ]. In addition, chest pain can be provoked in some patients by movement of a catheter within the right atrium or right ventricle, which should not cause myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations provide support for enhanced pain perception in patients with cardiac syndrome X. If present, hyperalgesia may result from abnormalities such as sympathovagal imbalance with sympathetic predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/4\">",
"     4",
"    </a>",
"    ] or reduced activity of the endogenous opioid system [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report compared 25 postmenopausal women with angina and normal coronary arteries to 22 healthy postmenopausal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/51\">",
"       51",
"      </a>",
"      ]. The women with apparent cardiac syndrome X had increased sensitivity to systemic painful stimuli, as demonstrated by an approximately 50 percent reduction in the time to forearm ischemic pain provoked by a blood pressure cuff. In contrast, these women had no apparent abnormalities in cardiac autonomic function, as determined by measurement of heart rate variability and 24 hour QT intervals.",
"     </li>",
"     <li>",
"      A second study of 16 patients with cardiac syndrome X and 15 controls assessed cardiac sensitivity to pain during right atrial and ventricular pacing, using increasing stimulus intensity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/52\">",
"       52",
"      </a>",
"      ]. Fifty percent of those with cardiac syndrome X, but no controls, experienced pain during atrial pacing and 94 percent during ventricular pacing. Some patients with cardiac syndrome X experienced chest pain in the absence of cardiac stimulation (63 percent with false atrial pacing and 50 percent with false ventricular pacing).",
"     </li>",
"     <li>",
"      Regional cerebral cortex activation may be increased in patients with cardiac syndrome X. This was suggested in a study of eight patients with cardiac syndrome X and eight controls [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/53\">",
"       53",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       Dobutamine",
"      </a>",
"      stress echocardiography was performed in all subjects, with positron emission tomography to measure changes in regional cerebral blood flow as an index of cortical activation. During dobutamine stimulation, cardiac syndrome X patients (but not controls) had chest pain, ischemic ECG changes, and increased blood flow in the right insula, suggesting cortical activation consistent with pain perception.",
"     </li>",
"     <li>",
"      A similar phenomenon of esophageal hyperalgesia may be responsible for some cases of chest pain of esophageal origin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=see_link\">",
"       \"Chest pain of esophageal origin\"",
"      </a>",
"      .) Whether this might contribute to the chest pain in cardiac syndrome X was evaluated in 20 patients with this diagnosis who were evaluated by esophageal manometry and 24-hour pH monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19864/abstract/54\">",
"       54",
"      </a>",
"      ]. Fourteen of the patients had esophageal hypersensitivity to acid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distention, twelve had an abnormality on 24-hour pH monitoring, and seven had symptoms temporally related with episodes of a pH less than 4.0. Although uncontrolled, 8 of 11 patients treated with acid suppressive therapy reported an improvement in chest pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24746504\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac syndrome X is a clinical entity characterized by angina-like chest pain with exertion, ST segment depression on treadmill stress testing, and normal results on coronary angiography, including no evidence of spontaneous or induced coronary artery spasm. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of this syndrome is not well elucidated, but two proposed mechanisms include myocardial ischemia probably from coronary microvascular dysfunction and enhanced sensitivity of an individual to intracardiac pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Evidence regarding the role of myocardial ischemia in cardiac syndrome X is not conclusive. Three mechanisms are proposed for myocardial ischemia: endothelial cell dysfunction causing decreased vasodilator response or paradoxical vasoconstrictor response to exercise; abnormal cardiac adrenergic tone due to both increased sympathetic activity and enhanced cardiac response to sympathetic stimulation; and occult coronary artery disease, discovered with the use of technologies such as intravascular ultrasound and electron-beam computed tomography in patients with cardiac syndrome X and apparently normal coronary angiograms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Myocardial ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence regarding enhanced pain sensitivity of the heart comes from studies that show provocation of typical anginal chest pain with exercise or pharmacological stress but no definite evidence of myocardial ischemia, as well as from the presence of chest pain during diagnostic right- or left-heart catheterizations or during right heart pacing. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Enhanced pain sensitivity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/1\">",
"      Panza JA. Myocardial ischemia and the pains of the heart. N Engl J Med 2002; 346:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/2\">",
"      Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). Circulation 2004; 109:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/3\">",
"      Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002; 346:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/4\">",
"      Cannon RO 3rd. The sensitive heart. A syndrome of abnormal cardiac pain perception. JAMA 1995; 273:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/5\">",
"      Cannon RO 3rd, Camici PG, Epstein SE. Pathophysiological dilemma of syndrome X. Circulation 1992; 85:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/6\">",
"      Fragasso G, Rossetti E, Dosio F, et al. High prevalence of the thallium-201 reverse redistribution phenomenon in patients with syndrome X. Eur Heart J 1996; 17:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/7\">",
"      Panza JA, Laurienzo JM, Curiel RV, et al. Investigation of the mechanism of chest pain in patients with angiographically normal coronary arteries using transesophageal dobutamine stress echocardiography. J Am Coll Cardiol 1997; 29:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/8\">",
"      Anselmi M, Golia G, Marino P, et al. Comparison of left ventricular function and volumes during transesophageal atrial pacing combined with two-dimensional echocardiography in patients with syndrome X, atherosclerotic coronary artery disease, and normal subjects. Am J Cardiol 1997; 80:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/9\">",
"      Cannon RO 3rd, Curiel RV, Prasad A, et al. Comparison of coronary endothelial dynamics with electrocardiographic and left ventricular contractile responses to stress in the absence of coronary artery disease. Am J Cardiol 1998; 82:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/10\">",
"      Cannon RO 3rd, Bonow RO, Bacharach SL, et al. Left ventricular dysfunction in patients with angina pectoris, normal epicardial coronary arteries, and abnormal vasodilator reserve. Circulation 1985; 71:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/11\">",
"      Nihoyannopoulos P, Kaski JC, Crake T, Maseri A. Absence of myocardial dysfunction during stress in patients with syndrome X. J Am Coll Cardiol 1991; 18:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/12\">",
"      Lanza GA, Buffon A, Sestito A, et al. Relation between stress-induced myocardial perfusion defects on cardiovascular magnetic resonance and coronary microvascular dysfunction in patients with cardiac syndrome X. J Am Coll Cardiol 2008; 51:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/13\">",
"      Buchthal SD, den Hollander JA, Merz CN, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000; 342:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/14\">",
"      Wiedermann JG, Schwartz A, Apfelbaum M. Anatomic and physiologic heterogeneity in patients with syndrome X: an intravascular ultrasound study. J Am Coll Cardiol 1995; 25:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/15\">",
"      Mohri M, Koyanagi M, Egashira K, et al. Angina pectoris caused by coronary microvascular spasm. Lancet 1998; 351:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/16\">",
"      Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001; 141:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/17\">",
"      Lekakis JP, Papamichael CM, Vemmos CN, et al. Peripheral vascular endothelial dysfunction in patients with angina pectoris and normal coronary arteriograms. J Am Coll Cardiol 1998; 31:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/18\">",
"      Masci PG, Laclaustra M, Lara JG, Kaski JC. Brachial artery flow-mediated dilation and myocardial perfusion in patients with cardiac syndrome X. Am J Cardiol 2005; 95:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/19\">",
"      Cannon RO 3rd, Peden DB, Berkebile C, et al. Airway hyperresponsiveness in patients with microvascular angina. Evidence for a diffuse disorder of smooth muscle responsiveness. Circulation 1990; 82:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/20\">",
"      Weidmann B, Jansen WC, Bock A, et al. Technetium-99m-HMPAO brain SPECT in patients with syndrome X. Am J Cardiol 1997; 79:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/21\">",
"      Atmaca Y, Ozdemir AO, Ozdol C, et al. Angiographic evaluation of myocardial perfusion in patients with syndrome X. Am J Cardiol 2005; 96:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/22\">",
"      Senen K, Ileri M, Alper A, et al. Increased levels of soluble adhesion molecules E-selectin and P-selectin in patients with cardiac syndrome X. Angiology 2005; 56:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/23\">",
"      Egashira K, Inou T, Hirooka Y, et al. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993; 328:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/24\">",
"      Egashira K, Hirooka Y, Kuga T, et al. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996; 94:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/25\">",
"      Piatti P, Fragasso G, Monti LD, et al. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries: comparison with subjects with insulin resistance syndrome and normal controls. J Am Coll Cardiol 1999; 34:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/26\">",
"      Kaski JC, Elliott PM, Salomone O, et al. Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J 1995; 74:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/27\">",
"      Newby DE, Flint LL, Fox KA, et al. Reduced responsiveness to endothelin-1 in peripheral resistance vessels of patients with syndrome X. J Am Coll Cardiol 1998; 31:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/28\">",
"      Desideri G, Gaspardone A, Gentile M, et al. Endothelial activation in patients with cardiac syndrome X. Circulation 2000; 102:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/29\">",
"      Cox ID, B&oslash;tker HE, Bagger JP, et al. Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. J Am Coll Cardiol 1999; 34:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/30\">",
"      Mohri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 2003; 41:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/31\">",
"      Piatti P, Fragasso G, Monti LD, et al. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation 2003; 107:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/32\">",
"      Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/33\">",
"      Sinisalo J, Paronen J, Mattila KJ, et al. Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis 2000; 149:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/34\">",
"      Cleland SJ, Sattar N, Petrie JR, et al. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000; 98:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/35\">",
"      Teragawa H, Fukuda Y, Matsuda K, et al. Relation between C reactive protein concentrations and coronary microvascular endothelial function. Heart 2004; 90:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/36\">",
"      Cos&iacute;n-Sales J, Pizzi C, Brown S, Kaski JC. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol 2003; 41:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/37\">",
"      Arroyo-Espliguero R, Mollichelli N, Avanzas P, et al. Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur Heart J 2003; 24:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/38\">",
"      Meeder JG, Blanksma PK, Crijns HJ, et al. Mechanisms of angina pectoris in syndrome X assessed by myocardial perfusion dynamics and heart rate variability. Eur Heart J 1995; 16:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/39\">",
"      Inobe Y, Kugiyama K, Morita E, et al. Role of adenosine in pathogenesis of syndrome X: assessment with coronary hemodynamic measurements and thallium-201 myocardial single-photon emission computed tomography. J Am Coll Cardiol 1996; 28:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/40\">",
"      Bugiardini R, Manfrini O, Pizzi C, et al. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 2004; 109:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/41\">",
"      Rosano GM, Ponikowski P, Adamopoulos S, et al. Abnormal autonomic control of the cardiovascular system in syndrome X. Am J Cardiol 1994; 73:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/42\">",
"      Montorsi P, Fabbiocchi F, Loaldi A, et al. Coronary adrenergic hyperreactivity in patients with syndrome X and abnormal electrocardiogram at rest. Am J Cardiol 1991; 68:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/43\">",
"      Cordero DL, Cagin NA, Natelson BH. Neurocardiology update: role of the nervous system in coronary vasomotion. Cardiovasc Res 1995; 29:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/44\">",
"      Lanza GA, Giordano A, Pristipino C, et al. Abnormal cardiac adrenergic nerve function in patients with syndrome X detected by [123I]metaiodobenzylguanidine myocardial scintigraphy. Circulation 1997; 96:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/45\">",
"      Madaric J, Bartunek J, Verhamme K, et al. Hyperdynamic myocardial response to beta-adrenergic stimulation in patients with chest pain and normal coronary arteries. J Am Coll Cardiol 2005; 46:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/46\">",
"      Shemesh J, Fisman EZ, Tenenbaum A, et al. Coronary artery calcification in women with syndrome X: usefulness of double-helical CT for detection. Radiology 1997; 205:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/47\">",
"      Sangle SR, D'Cruz DP. Syndrome X (angina pectoris with normal coronary arteries) and myocardial infarction in patients with anti-phospholipid (Hughes) syndrome. Lupus 2008; 17:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/48\">",
"      Rosen SD, Uren NG, Kaski JC, et al. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation 1994; 90:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/49\">",
"      Shapiro LM, Crake T, Poole-Wilson PA. Is altered cardiac sensation responsible for chest pain in patients with normal coronary arteries? Clinical observation during cardiac catheterisation. Br Med J (Clin Res Ed) 1988; 296:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/50\">",
"      Fedele F, Agati L, Pugliese M, et al. Role of the central endogenous opiate system in patients with syndrome X. Am Heart J 1998; 136:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/51\">",
"      Lanza GA, Pasceri V, Colonna G, et al. Cardiac autonomic function and sensitivity to pain in postmenopausal women with angina and normal coronary arteries. Am J Cardiol 1997; 79:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/52\">",
"      Pasceri V, Lanza GA, Buffon A, et al. Role of abnormal pain sensitivity and behavioral factors in determining chest pain in syndrome X. J Am Coll Cardiol 1998; 31:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/53\">",
"      Rosen SD, Paulesu E, Wise RJ, Camici PG. Central neural contribution to the perception of chest pain in cardiac syndrome X. Heart 2002; 87:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19864/abstract/54\">",
"      B&ouml;rjesson M, Albertsson P, Dellborg M, et al. Esophageal dysfunction in syndrome X. Am J Cardiol 1998; 82:1187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1501 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19864=[""].join("\n");
var outline_f19_25_19864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24746504\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYOCARDIAL ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Possible mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Endothelial cell dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Autonomic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Occult coronary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENHANCED PAIN SENSITIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24746504\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35192?source=related_link\">",
"      Basic properties of myocardial perfusion agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5802?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=related_link\">",
"      Chest pain of esophageal origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11785?source=related_link\">",
"      The coronary microcirculation in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_25_19865="Cardiac remodeling: Basic aspects";
var content_f19_25_19865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac remodeling: Basic aspects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19865/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19865/contributors\">",
"     Jay N Cohn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19865/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19865/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19865/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/25/19865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is associated with significant morbidity and mortality attributable largely to cardiac structural changes with associated cardiac dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac dysfunction is defined as an alteration in the relationship between preload (often defined by left ventricular filling pressure) and stroke volume. This relationship is depicted by Frank-Starling curves, which identify a shift downward and to the right as cardiac dysfunction (",
"    <a class=\"graphic graphic_figure graphicRef58693 \" href=\"UTD.htm?32/56/33677\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remodeling is defined as alteration in the structure (dimensions, mass, shape) of the heart (called cardiac or ventricular remodeling) in response to hemodynamic load",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac injury in association with neurohormonal activation. Remodeling may be described as physiologic or pathologic [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/1\">",
"       1",
"      </a>",
"      ]; alternatively, remodeling may be classified as adaptive or maladaptive [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remodeling process frequently includes increases in myocardial mass. The heart can respond to environmental stimuli by growth (increased myocardial mass) or shrinkage (atrophy) with a dynamic range of at least 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/3\">",
"     3",
"    </a>",
"    ]. Myocardial hypertrophy is most properly defined as increased cardiomyocyte size which may occur with or without an increase in overall myocardial mass; however, the term \"hypertrophy\" has also been used to denote increased myocardial mass",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wall thickness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic remodeling is a compensatory change in the dimensions and function of the heart in response to physiologic stimuli such as exercise and pregnancy. This type of remodeling is seen in athletes and has been called \"athlete's heart.\" (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H1613344#H1613344\">",
"       \"Definition and classification of the cardiomyopathies\", section on 'Athlete's heart'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pathologic remodeling may occur with pressure overload (eg, aortic stenosis, hypertension), volume overload (eg, valvular regurgitation), or following cardiac injury (eg, myocardial infarction, myocarditis, or idiopathic dilated cardiomyopathy). In each of these settings, remodeling may transition from an apparently compensatory process to a maladaptive one [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three general patterns of remodeling have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pressure overload leads to concentric left ventricular remodeling with or without an overall increase in myocardial mass [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/5\">",
"       5",
"      </a>",
"      ]. Concentric remodeling is characterized by increased relative wall thickness (ventricular wall thickness as compared to cavity size). With concentric hypertrophy, sarcomeres are added in parallel and individual cardiomyocytes grow thicker.",
"     </li>",
"     <li>",
"      Volume overload or isotonic exercise leads to eccentric left ventricular hypertrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/5\">",
"       5",
"      </a>",
"      ]. Eccentric left ventricular hypertrophy is characterized by increased cardiac mass and chamber volume. Relative wall thickness may be normal, increased or decreased. With eccentric hypertrophy, sarcomeres are added in series and individual cardiomyocytes grow longer.",
"     </li>",
"     <li>",
"      Following myocardial infarction, stretched infarcted tissue increases left ventricular volume leading to combined volume and pressure load on noninfarcted zones and mixed",
"      <span class=\"nowrap\">",
"       concentric/eccentric",
"      </span>",
"      hypertrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of remodeling as a pathogenic mechanism has been controversial, since factors leading to remodeling as well as the remodeling itself may be major determinants of HF prognosis. Consistent with the hypothesis that remodeling is pathogenically important in HF is the observation that angiotensin converting enzyme (ACE) inhibitors and some beta blockers, which improve survival in patients with HF, can slow and in some cases even reverse, certain parameters of cardiac remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/6-10\">",
"     6-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, an initial report indicated that reversal of remodeling with both medical therapy and a left ventricular assist device is associated with marked improvements in left ventricular function in patients with advanced heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .) Recent analysis of clinical trial data confirms the importance of remodeling in determining prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The basic aspects of cardiac remodeling, such as the mechanisms involved, the factors influencing remodeling, its role in heart failure progression, and measurement of remodeling, will be reviewed here. The clinical assessment and treatment of remodeling are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/842?source=see_link\">",
"     \"Cardiac remodeling: Clinical assessment and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIC CONCEPTS OF CARDIAC REMODELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different causes of cardiac remodeling share common molecular, biochemical, and mechanical pathways. The myocyte is the major cardiac cell involved in the remodeling process. Other components include the interstitium, fibroblasts, collagen, and coronary vasculature. The process of cardiac remodeling is influenced by hemodynamic load, neurohumoral activation, and other factors.",
"   </p>",
"   <p>",
"    A common setting in which remodeling occurs is after myocardial infarction. In animal models and humans, left ventricular (LV) remodeling usually begins within the first few hours after the infarct and progresses over time [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. The entire heart may be involved as disproportionate thinning and dilation in the infarct region (ie, infarct expansion) is accompanied by a distortion in shape of the entire heart with volume-overload hypertrophy of noninfarcted myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]. Patients with no or limited dilation at four weeks tend to remain stable, while those with progressive dilation over this period tend to deteriorate over time with loss of function in initially normally contracting myocardium (ie, pathologic remodeling) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the GISSI-3 trial suggest that serial electrocardiographic changes, particular involving negative T waves, can predict postinfarction remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/19\">",
"     19",
"    </a>",
"    ]. Lack of negative T wave resolution or the late appearance of new negative T waves are associated with less recovery of wall motion abnormalities, more pronounced left ventricular enlargement, and progressive deterioration of ventricular function; in contrast, normalization of negative T waves is related to functional recovery of viable myocardium and is more useful than QRS changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Functional changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial remodeling phase after a myocardial infarction results in repair of the necrotic area and scar formation that may, to some extent, be considered beneficial since there is an improvement in or maintenance of LV function and cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This cellular rearrangement of the ventricular wall is associated with a significant increase in LV volume. Some studies have shown that this volume increase is not a prerequisite to maintaining LV function.",
"   </p>",
"   <p>",
"    As the heart undergoes remodeling, it becomes less elliptical and more spherical (",
"    <a class=\"graphic graphic_figure graphicRef69944 \" href=\"UTD.htm?38/34/39458\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. There are also changes in ventricular mass, composition, and volume, all of which may adversely affect cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/17,18,24-26\">",
"     17,18,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time course and extent of remodeling are influenced by a variety of factors including the severity of the underlying disease, secondary events (such as recurrent ischemia), neuroendocrine activation, genotype, and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/14,24,27\">",
"     14,24,27",
"    </a>",
"    ]. Following myocardial infarction, for example, the magnitude of remodeling changes is roughly related to infarct size [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a human study, left ventricular end-diastolic and end-systolic volumes increased progressively from hospital discharge to one year after an initial, moderately large anterior wall Q wave infarction, but remained stable in patients with an initial small inferior wall infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with progressive postinfarction dilation, the end-systolic volume index increases progressively and LV ejection fraction (LVEF) declines due in part to the chamber enlargement itself and in part to loss of function in initially normally contracting myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These changes are important predictors of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cellular and molecular changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remodeling is associated with a number of cellular changes including myocyte hypertrophy, loss of myocytes due to apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/29-31\">",
"     29-31",
"    </a>",
"    ] or necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/32\">",
"     32",
"    </a>",
"    ], and fibroblast proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/33\">",
"     33",
"    </a>",
"    ] and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the pathways and cells involved in LV remodeling are incompletely understood, mechanisms at the molecular level have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As myocytes stretch, there is an increase in the local production or release of angiotensin II, norepinephrine, and endothelin. Locally generated angiotensin II is thought to play a role in these processes, in part via alterations in gene expression (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Role of angiotensin II'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/20,36-38\">",
"       20,36-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These neurohormonal changes stimulate expression of proteins and myocyte hypertrophy.",
"     </li>",
"     <li>",
"      Increases in angiotensin II, aldosterone, and cytokines stimulate collagen synthesis, leading to fibrosis and remodeling of the extracellular matrix.",
"     </li>",
"     <li>",
"      Reduced nitric oxide bioactivity contributes to the cellular and interstitial growth since nitric oxide normally serves as an inhibitor of remodeling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The end result of pathologic remodeling is further deterioration in cardiac performance and increased neurohormonal activation. In addition, it has been suggested that remodeling and the myocardial changes that accompany it contribute to the pathogenesis of ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=see_link\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cardiac myocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocytes and other cardiac cell types are thought to be fundamentally involved in the remodeling process. After an insult of sufficient magnitude, myocyte numbers decrease and surviving myocytes become elongated or hypertrophied as part of a compensatory process to maintain stroke volume [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]; the thickness of the ventricular wall also may increase due to myocyte hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/17,25,26\">",
"     17,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Altered loading conditions (eg, increased preload) stretch cell membranes and increase wall stress, which may play a role in inducing the expression of hypertrophy associated genes. In cardiac myocytes, this may lead to the synthesis of new contractile proteins and the assembly of new sarcomeres. It is thought that the pattern in which these proteins are laid down determines whether the cardiac myocytes elongate or increase their diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/39\">",
"     39",
"    </a>",
"    ]. The increase in wall stress [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/25,37\">",
"     25,37",
"    </a>",
"    ] may precipitate energy imbalance and ischemia, leading to a vicious cycle of increased wall stress and wall thickness with further energy imbalance and ischemia.",
"   </p>",
"   <p>",
"    Cardiac troponin I and T, which are released during myocyte injury, are elevated in some patients with HF, even in the absence of coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Using a high-sensitivity assay, the level of troponin is an independent predictor of mortality that supplements the prognostic value of B-type natriuretic peptide levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/43\">",
"     43",
"    </a>",
"    ]. These data suggest that troponin release may be a marker for ongoing myocyte damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Collagen synthesis and degradation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myocardium consists of myocytes tethered and supported by a connective tissue network composed largely of fibrillar collagen. Collagen is synthesized by interstitial fibroblasts and degraded by locally produced enzymes called collagenases, such as matrix metalloproteinases (MMPs).",
"   </p>",
"   <p>",
"    The significance of collagen synthesis and degradation in cardiac remodeling and HF is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In human and animal models of remodeling after myocardial infarction, fibroblast stimulation increases collagen synthesis and causes fibrosis of both the infarcted and noninfarcted regions of the ventricle [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/34,35,44,45\">",
"       34,35,44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Myocardial collagenase is present in the inactive form in the ventricle and is activated after myocardial injury [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/46\">",
"       46",
"      </a>",
"      ]. This may contribute to an increase in chamber dimension and is a possible cause of myocyte slippage, a contributor to chamber remodeling [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an animal model of hypertension and HF, increased expression of MMPs coincided with the transition from hypertrophy to HF [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of hypertensive patients with HF, those with systolic dysfunction had a lower collagen volume fraction and a higher expression of MMP-1 (collagenase) than those with diastolic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/49\">",
"       49",
"      </a>",
"      ]. The increases in MMP-1 expression and collagen degradation were directly correlated with end-diastolic volume and inversely correlated with LVEF.",
"     </li>",
"     <li>",
"      MMP-9 (gelatinase B) is markedly overexpressed after myocardial infarction and may be a mediator of collagen accumulation and remodeling. Mice with targeted deletion of MMP-9 or those given an MMP inhibitor have less collagen accumulation in the infarcted areas and less LV dilation than wild-type or control mice [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. A similar benefit from MMP inhibition on attenuating remodeling was seen in another animal model of chronic volume overload [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, lack of MMP-9 function may increase susceptibility to viral myocarditis. Mice with a targeted deletion of MMP-9 were found to be more susceptible to cardiac infection by coxsackie virus as evidenced by increased viral titer and cardiac fibrosis and decreased cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B-type natriuretic peptide (BNP) is another protein overexpressed in HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .) Studies in BNP knockout mice reveal increased cardiac fibrosis in response to ventricular pressure overload, suggesting that the release of BNP from myocytes in the failing heart may protect against pathologic remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that increased apoptosis with loss of myocytes contributes to progressive LV dysfunction in chronic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/29\">",
"     29",
"    </a>",
"    ]. The importance of this type of cell death in human cardiac remodeling is not firmly established. However, in myocardial samples from patients who underwent heart transplantation, apoptosis was increased more than 200-fold in the failing heart [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Likewise, increased apoptosis is associated with the maladaptive response to sustained pressure overload (increased afterload) in the rat [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/30\">",
"     30",
"    </a>",
"    ]. Furthermore, in a mouse model of HF, specific inhibition of apoptosis was beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/55\">",
"     55",
"    </a>",
"    ]. Additional evidence that apoptosis is involved in adverse remodeling and HF post-myocardial infarction comes from mice in which the proapoptotic protein Bnip3 was ablated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FACTORS INFLUENCING CARDIAC REMODELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of factors that can influence remodeling, including LV hemodynamics, hypertension, and neurohormonal activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Changes in hemodynamic load",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early LV dilation in patients with anterior wall infarction may be progressive; on the other hand, compensatory ventricular hypertrophy appears to be a delayed and limited adaptation during the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/24\">",
"     24",
"    </a>",
"    ]. The net effect of progressive ventricular dilation with insufficient reactive ventricular hypertrophy is a considerable increase in global LV wall tension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/24,58\">",
"     24,58",
"    </a>",
"    ]. A number of mechanisms may be stimulated by increased wall stress which, in the absence of effective therapy, may lead to further dilation of the heart and progressive HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/26,59\">",
"     26,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated blood pressure induces structural changes in the LV (hypertrophy, interstitial changes), which may result in diastolic dysfunction that may progress to heart failure. The functional impact of pressure overload hypertrophy may be dependent on the nature of the remodeling process. When remodeling is eccentric (left ventricular enlargement with normal relative wall thickness, but increased wall stress) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/60\">",
"     60",
"    </a>",
"    ], a functional impairment leading to heart failure was observed. In contrast, heart failure did not occur in animals with concentric remodeling (normal chamber size, increased relative wall thickness, and normal wall stress). There was no difference between the two groups in myocardial mass or contractile function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antecedent hypertension may be associated with greater adverse remodeling and development of HF after myocardial infarction (MI). This was demonstrated in a series of 1093 patients, 68 percent of whom underwent serial neurohormonal sampling and evaluation of LV function one to four days and three to five months post-MI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/61\">",
"     61",
"    </a>",
"    ]. Compared to normotensives, hypertensive patients had significantly higher plasma levels of neurohormones at both time periods and a significantly greater increase in LV volumes (ie remodeling) at five months. Normotensives, but not hypertensives, had an improvement in LVEF at five months. Antecedent hypertension was associated with an increased risk of heart failure requiring hospitalization at a mean follow-up of two years (12.4 versus 5.5 percent in normotensives).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neurohormonal activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive HF is associated with neurohumoral activation that may be viewed initially as compensatory but may contribute to progression of the structural abnormalities. The net effect is progressive increases in the release of the three \"hypovolemic\" hormones &mdash; renin, norepinephrine, and antidiuretic hormone &mdash; that is generally proportional to the severity of the ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. High plasma norepinephrine, renin activity and antidiuretic hormone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/64,65\">",
"     64,65",
"    </a>",
"    ] are markers for poor survival in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although initially adaptive, neurohumoral activation may be deleterious over the long-term, in part by contributing to pathologic remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/63\">",
"     63",
"    </a>",
"    ]. The data are most compelling for activation of the renin-angiotensin-aldosterone system. Plasma BNP concentrations are also increased in progressive HF and correlated with prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/67\">",
"     67",
"    </a>",
"    ]. However, in contrast to the deleterious effect of angiotensin II and norepinephrine, the release of BNP from myocytes in the failing heart may protect against pathologic remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Role of angiotensin II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observations in large trials in humans that ACE inhibitors improve survival in HF and can slow and in some cases even reverse, certain parameters of cardiac remodeling indicate the importance of angiotensin II in pathologic remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .) There is an increasing experimental literature as to how this might occur.",
"   </p>",
"   <p>",
"    Both systemic and locally generated angiotensin II may participate in this process. The following observations are consistent with a role for local generation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link&amp;anchor=H18#H18\">",
"     \"Actions of angiotensin II on the heart\", section on 'Cardiac renin-angiotensin-aldosterone system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical stretch directly increases angiotensin II release from cardiac myocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In human myocardial tissue, angiotensin converting enzyme is markedly increased at the edge of the infarct scar [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/69\">",
"       69",
"      </a>",
"      ] while, in an animal model, there is increased expression of AT1 receptor mRNA in noninfarcted areas [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the whether angiotensin II is generated locally or systemically, it may directly promote remodeling as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AT1 receptors have been identified on human fibroblasts cultured from cardiomyopathic and ischemic hearts and on cardiac myocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. These fibroblasts respond to angiotensin II with AT1 receptor-mediated collagen synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/37,73,74\">",
"       37,73,74",
"      </a>",
"      ], an effect that can be reduced by ACE inhibition [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/44\">",
"       44",
"      </a>",
"      ]. Also acting via the AT1 receptor, angiotensin II increases protein synthesis and induces hypertrophy in cardiac myocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/37,68\">",
"       37,68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An animal study evaluated remodeling after a myocardial infarction in both wild-type and AT1A receptor knockout mice [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/70\">",
"       70",
"      </a>",
"      ]. At four weeks after infarction, wild-type mice had more marked remodeling, with further progression of left ventricular enlargement, ventricular dysfunction, and fibrosis. All wild type mice developed HF compared to none of the knockout mice. On the other hand, transgenic mice with overexpression of the AT1 receptor limited to the cardiac myocyte develop cardiac hypertrophy and remodeling without change in the systemic blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both ACE inhibitors and angiotensin II receptor antagonists can reverse remodeling in HF [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/6-8,76-78\">",
"       6-8,76-78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aldosterone, the secretion of which is enhanced by angiotensin II, also may participate in remodeling. The heart contains mineralocorticoid receptors and extracts aldosterone after a myocardial infarction, contributing to post infarction remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/79\">",
"     79",
"    </a>",
"    ]; in addition, the secondary hyperaldosteronism commonly seen in HF may contribute to cardiac hypertrophy and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Part of the survival benefit associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    , which compete for the mineralocorticoid receptor, may come from reduced fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link&amp;anchor=H10#H10\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors can also contribute to remodeling including endothelin, cytokines (tumor necrosis factor-alpha and interleukins) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/83\">",
"     83",
"    </a>",
"    ], oxidative stress, matrix metalloproteinases, and peripheral monocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endothelins are potent vasoconstrictor peptides, the circulating concentrations of which are increased in HF. Long-term endothelin blockade can, in animal models, impair pathologic remodeling [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/85,86\">",
"       85,86",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11592?source=see_link\">",
"       \"Role of endothelin in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Circulating concentrations of tumor necrosis factor-alpha (TNFa) are increased in patients with HF in proportion to the severity of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. Infusion of pathophysiologic concentrations of TNFa can produce changes similar to those seen in remodeling [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/89\">",
"       89",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=see_link\">",
"       \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oxidative stress refers to an imbalance between production of oxygen free radicals and antioxidant defenses. There is an increasing literature on its potential importance in progressive HF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/44/27337?source=see_link\">",
"       \"Role of oxidative stress in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Matrix metalloproteinases (MMPs) contribute to tissue remodeling in a number of disease states, such as an abdominal aortic aneurysm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"       \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"      </a>",
"      .) MMPs have also been implicated in cardiac remodeling [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/90,91\">",
"       90,91",
"      </a>",
"      ], and in animal models remodeling can be attenuated by MMP inhibition [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/51,52,92\">",
"       51,52,92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peripheral monocytosis, which occurs two to three days after an acute MI, reflects monocyte and macrophage infiltration of the necrotic myocardium. A higher peak monocyte level is associated with a larger left ventricular end-diastolic volume and lower left ventricular ejection fraction. A peak monocyte count",
"      <span class=\"nowrap\">",
"       &ge;900/&micro;L",
"      </span>",
"      independently predicts HF, LV aneurysm formation, and cardiac events [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CARDIAC REMODELING AND HEART FAILURE PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with major remodeling demonstrate progressive worsening of cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/18,24\">",
"     18,24",
"    </a>",
"    ]. However, mechanisms other than remodeling also can influence the course of heart disease, and disease progression can occur in the absence of remodeling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adaptive versus maladaptive disease processes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, cardiac remodeling is both an adaptive and a maladaptive process. The adaptive component enables the heart to maintain function in response to pressure or volume overload in the acute phase of cardiac injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/93\">",
"     93",
"    </a>",
"    ]. As an example, an increase in ventricular load (preload), as in mitral insufficiency, modulates remodeling of the ventricle to maintain forward flow. In addition, approximately 25 percent of patients with a first myocardial infarction develop limited left ventricular dilatation within four weeks after first infarction, which helps to restore cardiac index at rest and to preserve exercise performance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, progressive remodeling is deleterious and associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/18,28\">",
"     18,28",
"    </a>",
"    ]. There are no data to indicate when the transition from possible adaptive to maladaptive remodeling occurs or how this might be identified in patients. The occurrence of such a transition and its time course may be expected to vary greatly. However, once established beyond a certain phase, it is likely that remodeling actually contributes to HF progression. As mentioned above, an important factor in patients with a myocardial infarction is the size of the infarct. Progressive remodeling is common after an initial, moderately large anterior wall Q wave infarction, but is unusual after an initial small inferior wall infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19865/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5487520\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remodeling is defined as an alteration in the structure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      function of the heart in response to hemodynamic load",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac injury. Remodeling may be an adaptive or maladaptive process. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and definitions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Adaptive versus maladaptive disease processes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three general patterns of remodeling are concentric left ventricular remodeling (most often in response to pressure overload), eccentric left ventricular hypertrophy (most often in response to volume overload), or mixed",
"      <span class=\"nowrap\">",
"       concentric/eccentric",
"      </span>",
"      hypertrophy as may occur following myocardial infarction. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The process of cardiac remodeling includes structural, functional, cellular and molecular changes involving cardiac myocytes and the interstitial collagen matrix.",
"     </li>",
"     <li>",
"      Systemic factors influencing cardiac remodeling include changes in hemodynamic load, neurohormonal activation, and metabolic status.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/1\">",
"      Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/2\">",
"      Dorn GW 2nd, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res 2003; 92:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/3\">",
"      Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008; 358:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/4\">",
"      Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006; 367:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/5\">",
"      Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/6\">",
"      Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992; 86:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/7\">",
"      Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993; 88:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/8\">",
"      Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995; 91:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/9\">",
"      Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/10\">",
"      Groenning BA, Nilsson JC, Sondergaard L, et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/11\">",
"      Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006; 355:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/12\">",
"      Kramer DG, Trikalinos TA, Kent DM, et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010; 56:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/13\">",
"      Hochman JS, Bulkley BH. Expansion of acute myocardial infarction: an experimental study. Circulation 1982; 65:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/14\">",
"      Weisman HF, Bush DE, Mannisi JA, Bulkley BH. Global cardiac remodeling after acute myocardial infarction: a study in the rat model. J Am Coll Cardiol 1985; 5:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/15\">",
"      Korup E, Dalsgaard D, Nyvad O, et al. Comparison of degrees of left ventricular dilation within three hours and up to six days after onset of first acute myocardial infarction. Am J Cardiol 1997; 80:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/16\">",
"      Giannuzzi P, Temporelli PL, Bosimini E, et al. Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy. Am Heart J 2001; 141:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/17\">",
"      McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986; 74:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/18\">",
"      Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993; 87:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/19\">",
"      Bosimini E, Giannuzzi P, Temporelli PL, et al. Electrocardiographic evolutionary changes and left ventricular remodeling after acute myocardial infarction: results of the GISSI-3 Echo substudy. J Am Coll Cardiol 2000; 35:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/20\">",
"      Ning XH, Zhang J, Liu J, et al. Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction. J Am Coll Cardiol 2000; 36:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/21\">",
"      Cohen MV, Yang XM, Neumann T, et al. Favorable remodeling enhances recovery of regional myocardial function in the weeks after infarction in ischemically preconditioned hearts. Circulation 2000; 102:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/22\">",
"      Douglas PS, Morrow R, Ioli A, Reichek N. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1989; 13:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/23\">",
"      Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 1992; 19:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/24\">",
"      Rumberger JA, Behrenbeck T, Breen JR, et al. Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans. J Am Coll Cardiol 1993; 21:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/25\">",
"      Anversa P, Olivetti G, Capasso JM. Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 1991; 68:7D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/26\">",
"      Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/27\">",
"      Jugdutt BI. Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model. J Am Coll Cardiol 1995; 25:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/28\">",
"      White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/29\">",
"      Sharov VG, Sabbah HN, Shimoyama H, et al. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996; 148:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/30\">",
"      Teiger E, Than VD, Richard L, et al. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996; 97:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/31\">",
"      Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/32\">",
"      Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/33\">",
"      Villarreal FJ, Kim NN, Ungab GD, et al. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993; 88:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/34\">",
"      Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979; 128:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/35\">",
"      Weber KT, Pick R, Silver MA, et al. Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation 1990; 82:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/36\">",
"      Reiss K, Capasso JM, Huang HE, et al. ANG II receptors, c-myc, and c-jun in myocytes after myocardial infarction and ventricular failure. Am J Physiol 1993; 264:H760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/37\">",
"      Sadoshima J, Izumo S. Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/38\">",
"      Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension 1994; 23:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/39\">",
"      Francis GS, McDonald KM. Left ventricular hypertrophy: an initial response to myocardial injury. Am J Cardiol 1992; 69:3G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/40\">",
"      Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/41\">",
"      Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999; 138:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/42\">",
"      La Vecchia L, Mezzena G, Zanolla L, et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000; 19:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/43\">",
"      Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/44\">",
"      van Krimpen C, Smits JF, Cleutjens JP, et al. DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril. J Mol Cell Cardiol 1991; 23:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/45\">",
"      Volders PG, Willems IE, Cleutjens JP, et al. Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol 1993; 25:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/46\">",
"      Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/47\">",
"      Olivetti G, Capasso JM, Sonnenblick EH, Anversa P. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res 1990; 67:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/48\">",
"      Iwanaga Y, Aoyama T, Kihara Y, et al. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 2002; 39:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/49\">",
"      L&oacute;pez B, Gonz&aacute;lez A, Querejeta R, et al. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/50\">",
"      Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/51\">",
"      Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/52\">",
"      Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 2002; 105:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/53\">",
"      Cheung C, Marchant D, Walker EK, et al. Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 2008; 117:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/54\">",
"      Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000; 97:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/55\">",
"      Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest 2005; 115:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/56\">",
"      Diwan A, Krenz M, Syed FM, et al. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J Clin Invest 2007; 117:2825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/57\">",
"      Whelan RS, Mani K, Kitsis RN. Nipping at cardiac remodeling. J Clin Invest 2007; 117:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/58\">",
"      Rumberger JA. Ventricular dilatation and remodeling after myocardial infarction. Mayo Clin Proc 1994; 69:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/59\">",
"      Aikawa Y, Rohde L, Plehn J, et al. Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis. Am Heart J 2001; 141:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/60\">",
"      Norton GR, Woodiwiss AJ, Gaasch WH, et al. Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol 2002; 39:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/61\">",
"      Richards AM, Nicholls MG, Troughton RW, et al. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol 2002; 39:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/62\">",
"      Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/63\">",
"      Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/64\">",
"      Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/65\">",
"      Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998; 19:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/66\">",
"      Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/67\">",
"      Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/68\">",
"      Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/69\">",
"      Hokimoto S, Yasue H, Fujimoto K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 1996; 94:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/70\">",
"      Harada K, Sugaya T, Murakami K, et al. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999; 100:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/71\">",
"      Hafizi S, Wharton J, Morgan K, et al. Expression of functional angiotensin-converting enzyme and AT1 receptors in cultured human cardiac fibroblasts. Circulation 1998; 98:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/72\">",
"      Matsusaka T, Katori H, Inagami T, et al. Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice. J Clin Invest 1999; 103:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/73\">",
"      McEwan PE, Gray GA, Sherry L, et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/74\">",
"      Kawano H, Do YS, Kawano Y, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000; 101:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/75\">",
"      Paradis P, Dali-Youcef N, Paradis FW, et al. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A 2000; 97:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/76\">",
"      van Kats JP, Duncker DJ, Haitsma DB, et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 2000; 102:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/77\">",
"      Tamura T, Said S, Harris J, et al. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation 2000; 102:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/78\">",
"      Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002; 40:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/79\">",
"      Hayashi M, Tsutamoto T, Wada A, et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001; 38:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/80\">",
"      Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 32:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/81\">",
"      Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994; 28:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/82\">",
"      Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/83\">",
"      Hwang MW, Matsumori A, Furukawa Y, et al. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 2001; 38:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/84\">",
"      Maekawa Y, Anzai T, Yoshikawa T, et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. J Am Coll Cardiol 2002; 39:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/85\">",
"      Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/86\">",
"      Mishima T, Tanimura M, Suzuki G, et al. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2000; 35:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/87\">",
"      Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/88\">",
"      Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/89\">",
"      Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/90\">",
"      Miyamoto S, Nagaya N, Ikemoto M, et al. Elevation of matrix metalloproteinase-2 level in pericardial fluid is closely associated with left ventricular remodeling. Am J Cardiol 2002; 89:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/91\">",
"      Fedak PW, Moravec CS, McCarthy PM, et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 2006; 113:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/92\">",
"      Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001; 103:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19865/abstract/93\">",
"      Sabbah HN, Goldstein S. Ventricular remodelling: consequences and therapy. Eur Heart J 1993; 14 Suppl C:24.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3480 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19865=[""].join("\n");
var outline_f19_25_19865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5487520\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIC CONCEPTS OF CARDIAC REMODELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Functional changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cellular and molecular changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cardiac myocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Collagen synthesis and degradation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FACTORS INFLUENCING CARDIAC REMODELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Changes in hemodynamic load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neurohormonal activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Role of angiotensin II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CARDIAC REMODELING AND HEART FAILURE PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adaptive versus maladaptive disease processes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5487520\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3480\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3480|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/56/33677\" title=\"figure 1\">",
"      Frank Starling curves in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/34/39458\" title=\"figure 2\">",
"      Cardiac remodeling after anterior MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/842?source=related_link\">",
"      Cardiac remodeling: Clinical assessment and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=related_link\">",
"      Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11592?source=related_link\">",
"      Role of endothelin in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/44/27337?source=related_link\">",
"      Role of oxidative stress in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_25_19866="Catheter ablation of cardiac arrhythmias: Overview and technical aspects";
var content_f19_25_19866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19866/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19866/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19866/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/25/19866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/25/19866/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/25/19866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter ablation has revolutionized the management of patients with tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/1\">",
"     1",
"    </a>",
"    ]. Having evolved from arrhythmia surgery, catheter ablation was initially performed using high voltage direct current (DC); however, since the late 1980s, radiofrequency current has supplanted DC as the energy source of choice and has made catheter ablation a first-line therapy for many tachycardias [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/2\">",
"     2",
"    </a>",
"    ]. More recently, cryoablation and other energy sources have been used in some specific clinical settings.",
"   </p>",
"   <p>",
"    The topic review will discuss the historical development of catheter ablation techniques, review the technical aspects of radiofrequency energy and ablation, describe the various arrhythmias amenable to catheter ablation techniques, discuss practical aspects of catheter ablation procedures, review the mapping techniques used to target various tachyarrhythmias, and highlight future directions in catheter ablation. A more detailed discussion of the role of catheter ablation in the treatment of specific arrhythmias is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link&amp;anchor=H29#H29\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\", section on 'Catheter ablation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=see_link&amp;anchor=H15#H15\">",
"     \"Restoration of sinus rhythm in atrial flutter\", section on 'Ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter ablation as a cure for arrhythmias resulted from the combination of electrophysiologic studies and arrhythmia surgery. The technique of programmed electrical stimulation to induce tachyarrhythmias was first described in 1967 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In 1969 the His bundle potential was reproducibly recorded transvenously using an electrode catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/5\">",
"     5",
"    </a>",
"    ]. The technique of programmed stimulation while recording multiple intracardiac signals was first applied clinically in 1971 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of cardiac surgery for treating arrhythmias developed at the same time. In 1968, it was first demonstrated that epicardial mapping could be used to identify the site of an accessory pathway in patients with Wolff-Parkinson-White (WPW) syndrome and that surgical interruption of the pathway could cure the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/7\">",
"     7",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Subsequent advances included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgical excision of an arrhythmogenic focus to cure atrial tachycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cryosurgery of the atrioventricular (AV) junction to create complete AV block in patients with refractory supraventricular tachyarrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Surgical dissection of the AV node, without causing AV block to cure AV nodal reentrant tachycardia (AVNRT) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Surgical cure of chronic atrial fibrillation with the use of the Maze procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/11\">",
"       11",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"       \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After it became clear that surgical ablative techniques could cure arrhythmias and that transvenous catheter studies could identify both the tachycardia mechanism and the vulnerable site for surgical ablation, methods for catheter-based tissue destruction, or catheter ablation, were developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     DC energy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first energy source used for catheter ablation was direct current (DC). The catheter tip was positioned at the intended site and a standard external defibrillator was used to deliver a high voltage discharge between the tip electrode and a cutaneous back plate. This high energy discharge, delivered during general anesthesia, caused a small explosion at the catheter tip, with local tissue damage resulting from barotrauma, heat, and electrical energy.",
"   </p>",
"   <p>",
"    DC ablation was initially used to create complete AV block in patients with refractory atrial fibrillation and supraventricular tachycardia. Similar to surgically induced AV block, this approach necessitated permanent pacemaker implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. DC ablation was also applied at other endocardial sites to treat selected patients with WPW syndrome (ablation of the accessory pathway), atrial tachycardia, and ventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/14-19\">",
"     14-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, DC shock ablation, or fulguration, never achieved widespread use because of a high incidence of complications related to the high energy discharge. Risks of the procedure included cardiac rupture, depressed left ventricular function, and death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     RF energy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency (RF) energy source has catapulted catheter ablation to the forefront in the management of patients with tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. RF energy, low voltage high frequency electrical energy (30 KHz to 1.5 MHz), has been used for more than fifty years for surgical cutting and cautery and, by neurosurgeons, to ablate neural tissue responsible for chronic pain syndromes.",
"   </p>",
"   <p>",
"    Delivered from the tip of a catheter to the endocardial surface, RF energy produces controlled focal tissue ablation, as compared with the more extensive damage caused by DC fulguration. In 1987, an animal study demonstrated that RF energy could be safely used to create AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/22\">",
"     22",
"    </a>",
"    ]. Clinical studies confirmed the effectiveness of RF catheter ablation. However, the magnitude and duration of RF ablation were limited by progressive heating of the catheter, leading to the formation of an insulating coagulum of denatured tissue proteins on the catheter tip.",
"   </p>",
"   <p>",
"    In 1995, RF ablation was further refined by the use of saline irrigation to cool the RF catheter tip [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/23\">",
"     23",
"    </a>",
"    ]. This technique prevents tissue coagulum formation and makes larger RF lesions feasible. Saline cooling increased the efficacy of RF ablation in subsequent clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Saline cooled catheters may have a closed (internal cooling) or open (irrigated) design.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other advances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several technical modifications have improved procedural efficacy. A relatively large, bulbous tip electrode reduces the current density and increases cooling by circulating blood, thereby increasing the size of the lesion. Active cooling of the catheter tip is also frequently used in RF catheter ablation. On-line monitoring of electrode tip impedance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temperature reduces the likelihood of coagulum formation and therefore the risk of thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/28\">",
"     28",
"    </a>",
"    ]. Cryoenergy is FDA-approved in some clinical settings; other energy sources (microwaves, ultrasound, etc) remain investigational. Advances in catheter development have made it easier for the electrophysiologist to position the catheter tip at places of interest within the heart. Three dimensional mapping systems and adjunctive imaging techniques have facilitated ablation as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technically, the delivery of RF energy is fairly straightforward [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/29\">",
"     29",
"    </a>",
"    ]. Unmodulated sinusoidal current is delivered between an endocardial tip electrode and a large dispersive skin electrode (ground pad). Unlike DC shock ablation, which causes a large area of damage, resistive heating desiccates tissue directly adjacent to the electrode. Temperatures greater than 46&ordm;C cause permanent tissue damage, while temperatures above 90&ordm;C cause coagulum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    char to form at the catheter tip, creating a high impedance barrier to further ablation and increasing the risk of thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lesions are typically 7 to 8 mm in diameter and 3 to 5 mm deep, well suited for the ablation of focal arrhythmogenic sites. Since RF energy does not directly stimulate nerves or myocardium, the procedure is usually relatively painless and general anesthesia is not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency catheter ablation has become an important therapy in the management of patients with various types of tachyarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/1,2,30,31\">",
"     1,2,30,31",
"    </a>",
"    ]. It is considered first-line therapy for some arrhythmias and an important technique for others that are refractory to pharmacologic therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/32\">",
"     32",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef78003 \" href=\"UTD.htm?42/28/43468\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    What follows is a listing of the major settings in which RF ablation has been used; the data supporting its use are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrioventricular reentrant tachycardia (AVRT) associated with the WPW syndrome or a concealed accessory pathway (",
"      <a class=\"graphic graphic_waveform graphicRef53644 graphicRef73297 graphicRef65587 \" href=\"UTD.htm?37/10/38058\">",
"       waveform 1A-C",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef58120 \" href=\"UTD.htm?16/49/17176\">",
"       waveform 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef72398 graphicRef78363 \" href=\"UTD.htm?19/8/19594\">",
"       waveform 3A-B",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"       \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      AV nodal reentrant tachycardia (",
"      <a class=\"graphic graphic_waveform graphicRef77513 graphicRef58652 \" href=\"UTD.htm?16/32/16905\">",
"       waveform 4A-B",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"       \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrial tachycardia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link\">",
"       \"Focal atrial tachycardia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrial flutter (",
"      <a class=\"graphic graphic_waveform graphicRef69946 graphicRef60090 \" href=\"UTD.htm?8/2/8234\">",
"       waveform 5A-B",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"       \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Idiopathic ventricular tachycardia and bundle branch reentrant ventricular tachycardia (",
"      <a class=\"graphic graphic_waveform graphicRef68142 graphicRef59988 \" href=\"UTD.htm?10/44/10954\">",
"       waveform 6A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef67679 graphicRef77331 graphicRef66372 graphicRef80017 \" href=\"UTD.htm?40/25/41370\">",
"       waveform 7A-D",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"       \"Catheter ablation for ventricular arrhythmias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=see_link\">",
"       \"Bundle branch reentrant ventricular tachycardia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Catheter ablation of the AV junction with permanent pacemaker implantation to establish rate control in refractory atrial fibrillation (AF) (",
"      <a class=\"graphic graphic_waveform graphicRef74286 graphicRef67363 \" href=\"UTD.htm?16/10/16551\">",
"       waveform 8A-B",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"       \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Catheter ablation to cure AF requires extensive ablation in the left atrium, and is performed with increasing frequency. The best candidates for curative AF ablation are those with paroxysmal AF and no or minimal structural heart disease. The success and complication rates, as well optimal patient selection and specifics of lesion deployment, remain controversial, although the Heart Rhythm Society has issued a consensus statement on this issue [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"       \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As adjunctive therapy for recurrent ventricular tachycardia (VT) due to coronary artery disease (CAD) or arrhythmogenic right ventricular cardiomyopathy (ARVC); catheter ablation is rarely applied as primary therapy in these settings (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"       \"Catheter ablation for ventricular arrhythmias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link\">",
"       \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROCEDURAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter ablation is most frequently performed on an elective basis in patients with recurrent tachyarrhythmias; rarely, this procedure is performed urgently in patients with recurrent, destabilizing VT.",
"   </p>",
"   <p>",
"    In 2000, an",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force on clinical competency published recommendations for technical and cognitive skills needed to perform electrophysiologic study",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Preprocedural evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all patients, the preprocedure evaluation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough history and physical examination",
"     </li>",
"     <li>",
"      Examination of the ECG at baseline and during tachycardia; this is helpful for planning the procedure",
"     </li>",
"     <li>",
"      Event monitoring, which is typically more useful than Holter monitoring in documenting the tachycardia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"       \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An echocardiogram, which is helpful in assessing the possibility of structural heart disease, is reasonable in many patients",
"     </li>",
"     <li>",
"      Exercise testing, which may be useful if there is a history of exercise induced arrhythmia, but is otherwise not routinely indicated",
"     </li>",
"     <li>",
"      Other studies, including radionuclide scintigraphy, cardiac catheterization, and coronary angiography, which are performed only if indicated by the patient's clinical presentation and symptoms; a serum thyrotropin (TSH) concentration to exclude hyperthyroidism is reasonable although of low yield",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since most patients are scheduled for elective catheter ablation, they typically report to the hospital in the fasting state early in the morning of the procedure. In most patients, all AV nodal blocking agents, including beta blockers, calcium blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and class I and III antiarrhythmic drugs are discontinued several days prior to the scheduled procedure. In general, beta blockers should be gradually tapered and discontinued, while other agents can be discontinued without tapering.",
"   </p>",
"   <p>",
"    Because radiation exposure is a necessary component of catheter ablation, it is reasonable to obtain a pregnancy test on all women of childbearing capacity on the morning of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ablation technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic studies and catheter ablation procedures are typically performed using conscious sedation, although some procedures are performed under general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/35\">",
"     35",
"    </a>",
"    ]. Heart rate, blood pressure, and pulse oximetry are routinely monitored throughout the procedure.",
"   </p>",
"   <p>",
"    Multiple venous sheaths are typically placed in the femoral veins for positioning electrode catheters in the right atrium, right ventricle, and in the area of the His bundle. A multielectrode catheter may also be placed in the coronary sinus; this may be accomplished via a femoral, left antecubital, left subclavian, or right internal jugular venous approach. If necessary, the left heart may be accessed in one of two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transseptal catheterization permits placement of a sheath across the interatrial septum so that an ablation catheter may be delivered directly into the left atrium.",
"     </li>",
"     <li>",
"      A retrograde approach may be taken, with the catheter being advanced up the femoral artery, across the aortic valve into the left ventricle, and even across the mitral valve into the left atrium if necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For VT ablation a retrograde aortic approach is frequently employed; the transseptal approach is necessary for ablation of left atrial tachycardia or AF. Either approach may be used for left-sided accessory pathway ablation.",
"   </p>",
"   <p>",
"    Since platelet activation, thrombin formation, and fibrinolytic activation have been observed after ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/36\">",
"     36",
"    </a>",
"    ], systemic anticoagulation with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is necessary while the left heart is instrumented.",
"   </p>",
"   <p>",
"    Procedures typically last one or more hours. A diagnostic electrophysiologic study (EPS) constitutes the initial part of the procedure. Programmed electrical stimulation of the atrium and ventricle, sometimes during catecholamine infusion, induces the tachyarrhythmia, and allows definitive diagnosis of the mechanism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ablation usually immediately follows programmed electrical stimulation and arrhythmia induction. A variety of mapping techniques are used to identify the optimal site for ablation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Mapping techniques'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Steerable ablation catheters with various radii of curvature, sometimes used with preformed guiding sheaths, facilitate positioning at the endocardial site of interest. Following successful ablation, repeat programmed electrophysiologic stimulation is performed to make certain that the target arrhythmia is no longer inducible and that no other tachycardias can be provoked.",
"   </p>",
"   <p>",
"    At the conclusion of the procedure, the access sheaths are pulled, and the patient is put at bed rest for four or more hours. During this period, the patient is clinically monitored carefully to make certain there have been no access or other types of complications. Depending upon the nature of the procedure, the patient may be admitted to the hospital overnight for observation or discharged later the same day.",
"   </p>",
"   <p>",
"    Many clinicians treat patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for four to eight weeks after the procedure to reduce the risk of thromboembolic complications. Patients are typically followed clinically following ablation; routine follow-up studies are commonly performed only in patients with VT related to chronic coronary disease. Echocardiography and blood testing are not routinely performed after ablation unless a complication is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Reuse of ablation catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although electrode catheters are labeled for single use, some institutions routinely resterilize and reuse these catheters. In one series in which 74 deflectable ablation catheters with temperature control were resterilized and reused an average of 7.6 times, there were no major catheter failures or major complications, including local or systemic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/37\">",
"     37",
"    </a>",
"    ]. Forty-one catheters were rejected after an average of 9.1 uses because of inaccurate temperature measurements, electrode fracture, or loss of deflection capability. The United States Food and Drug Administration (FDA) is currently considering this issue. Reuse of catheters is illegal in some countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mapping techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of techniques have been developed to help position the ablation electrode in the proper site to cure the given arrhythmia. \"Mapping\" generally refers to the correlation of anatomic locations with electrophysiologic phenomena (eg, electrogram voltage, timing of electrical activation, or the surface ECG morphology generated by pacing). Some mapping methods are performed during a tachycardia, while others are employed during sinus rhythm. A more complete discussion about mapping and its application is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27305?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Use in specific arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Activation mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation mapping refers to defining the timing of electrical activation across regions of the heart. This is frequently performed during the tachycardia and in this setting involves maneuvering the ablation catheter to a site where the tip records electrical activity generated earlier than at any other endocardial site, which is frequently substantially earlier than the P wave or QRS complex on the surface ECG. The rationale for this approach is that the site of earliest activation is likely to be the origin of the tachyarrhythmia.",
"   </p>",
"   <p>",
"    As an example, focal atrial tachycardias are frequently mapped in this fashion; during atrial tachycardia, one seeks the site at which the local atrial activity precedes all other atrial endocardial activity as well as the onset of the P wave on the surface ECG (",
"    <a class=\"graphic graphic_waveform graphicRef58120 \" href=\"UTD.htm?16/49/17176\">",
"     waveform 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activation mapping with a slightly different rationale is also used in the WPW syndrome. In this setting, mapping is performed during sinus rhythm or atrial pacing along the mitral or tricuspid annulus to identify the site which registers earliest ventricular activity and which precedes the onset of the delta wave on the surface ECG (",
"    <a class=\"graphic graphic_waveform graphicRef72398 \" href=\"UTD.htm?8/25/8598\">",
"     waveform 3A",
"    </a>",
"    ). In addition, activation mapping is used to detect retrograde atrial activity during ventricular pacing or SVT in patients with AVRT that utilizes a concealed accessory pathway (",
"    <a class=\"graphic graphic_waveform graphicRef73297 \" href=\"UTD.htm?34/14/35044\">",
"     waveform 1B",
"    </a>",
"    ). The site of earliest antegrade ventricular activation or earliest retrograde atrial activation should be at the location of the accessory pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pace mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pace mapping involves pacing from the ablation catheter during sinus rhythm in an attempt to match the QRS morphology during pacing with the QRS morphology on the surface ECG during the spontaneous tachycardia. This technique is used most frequently during mapping of ventricular tachycardia (VT) (",
"    <a class=\"graphic graphic_waveform graphicRef68142 graphicRef79938 \" href=\"UTD.htm?38/21/39258\">",
"     waveform 6A, 6C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/39\">",
"     39",
"    </a>",
"    ]. In idiopathic right ventricular outflow tract (RVOT) VT, for example, the ablation catheter is placed in the outflow tract and the tip is used to pace. A twelve lead ECG is recorded and compared to the surface QRS morphology during spontaneous VT. Sites in which the pace map perfectly matches the spontaneous tachycardia are frequently sites of successful ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Entrainment mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Entrainment mapping is a more sophisticated technique employed in the mapping of reentrant tachycardias, most commonly VT in the setting of chronic coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/40\">",
"     40",
"    </a>",
"    ]. This approach is designed to identify sites that are within a reentrant circuit.",
"   </p>",
"   <p>",
"    Entrainment mapping involves pacing from the ablation catheter during tachycardia at a paced rate that is slightly faster than the tachycardia, and then evaluating the response of the tachycardia at the cessation of pacing. Since the tachycardia is caused by an electrical circuit, pacing from sites within the circuit will result in an acceleration of the tachycardia rate during pacing, but the QRS morphology will be identical; pacing at sites remote from the circuit results in a faster tachycardia rate but there is usually a subtle change in QRS morphology (",
"    <a class=\"graphic graphic_waveform graphicRef80942 \" href=\"UTD.htm?19/37/20050\">",
"     waveform 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, the \"return cycle length\" can help to define if the site of pacing is within the reentrant circuit. If the tachycardia resumes immediately after the cessation of pacing, the return cycle length is the time between the final paced beat and the first beat of the tachycardia. If the ablation catheter was pacing from within the circuit, the return cycle length should be identical to the tachycardia cycle length. If the ablation catheter was pacing from outside of the circuit, the return cycle length will be longer than the tachycardia cycle length.",
"   </p>",
"   <p>",
"    Entrainment mapping may also be helpful in the ablation of atrial tachycardias and atrial flutter, particularly in the setting of surgically repaired congenital heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Anatomic localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic approaches to ablation are used when the arrhythmia has a known anatomic course. As an example, in typical or common type I atrial flutter, the wave front must proceed through the isthmus of tissue between the tricuspid annulus (TA) and inferior vena cava (IVC). Thus, ablation is directed largely fluoroscopically, with the goal of delivering a continuous series of RF lesions to create an ablation line of complete conduction block between the TA and IVC (",
"    <a class=\"graphic graphic_waveform graphicRef69946 graphicRef60090 \" href=\"UTD.htm?8/2/8234\">",
"     waveform 5A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several approaches to ablation for management atrial fibrillation (AF). All of these approaches incorporate an understanding of left atrial anatomy, and some are entirely anatomically based. Ablation for AF focuses on the elimination of triggers for AF via electrical isolation of the pulmonary vein ostia from the body of the left atrium, and sometimes also includes additional lesions made in the body of the left atrium to modify arrhythmic substrate. Some methods for pulmonary vein isolation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    substrate modification use only anatomic landmarks to guide lesion placement. This approach is sometimes referred to as wide area circumferential ablation (WACA) or left atrial ablation. Advanced imaging techniques (eg, intracardiac echo, electroanatomic mapping, and three dimensional CT reconstructions) are generally used to facilitate this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Electrogram characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrogram characteristics are frequently sought from the tip of the ablation catheter. In catheter ablation of the AV junction in refractory AF, one typically seeks the largest His potential, and then moves the catheter slightly inferiorly and posteriorly in an attempt to target the compact AV node rather than the His bundle itself (",
"    <a class=\"graphic graphic_waveform graphicRef74286 \" href=\"UTD.htm?31/10/31905\">",
"     waveform 8A",
"    </a>",
"    ). Similarly, a right bundle branch potential is used to target the right bundle branch in patients with bundle branch reentrant VT (",
"    <a class=\"graphic graphic_waveform graphicRef66372 \" href=\"UTD.htm?10/10/10403\">",
"     waveform 7C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients with accessory pathways, potentials from the pathway itself can be recorded. Thus, mapping in these patients might involve both activation mapping and seeking an accessory pathway potential.",
"   </p>",
"   <p>",
"    Ablation of idiopathic left ventricular VT generally involves seeking a Purkinje potential in the vicinity of the left posterior fascicle in the inferoapical LV septum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Scar mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, mapping of VT related to chronic coronary disease has required that the patient remain hemodynamically stable during long periods of sustained VT. This is necessary so that complex and relatively time-consuming mapping can be performed during the tachycardia. In patients with hemodynamically unstable VT, the scar substrate can be mapped in sinus rhythm by measuring voltage amplitude throughout the ventricle. Regions of low voltage are associated with myocardial scar, which is the substrate for VT. After this region has been delineated with voltage mapping, a series of lesions can be placed to disrupt reentry circuits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Combined approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches that combine anatomic information and mapping are used to position the ablation catheter in many types of tachycardia. In AVNRT, using a posterior approach, the catheter is first positioned fluoroscopically in the middle or posterior septal region near the coronary sinus ostium which is the \"slow pathway\" area. The catheter is then manipulated in this region to record a small atrial signal and large ventricular signal with no evidence of a His bundle electrogram [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/42\">",
"     42",
"    </a>",
"    ]. With application of RF energy during sinus rhythm, an accelerated junctional rhythm usually signals an effective site. The presence of a slow potential, with an amplitude over one-half of the atrial amplitude, recorded at the mid-septum of the tricuspid annulus, may be a useful marker for localizing the slow pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In ablation procedures for AF, an alternative to the anatomically based WACA or left atrial ablation is segmental ostial pulmonary vein isolation. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Anatomic localization'",
"    </a>",
"    above.) This approach incorporates both anatomic guidance and mapping techniques. A multielectrode circular catheter is positioned in the pulmonary vein ostia to record pulmonary vein potentials. These potentials identify the muscular (and therefore electrical) connections between the posterior left atrium and pulmonary veins. Selective ablation at these sites seeks to electrically isolate the veins. As with circumferential ablation, advanced imaging techniques are generally used to facilitate this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Epicardial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less commonly performed than endocardial ablation, epicardial ablation is possible both surgically and percutaneously via subxiphoid access of the pericardial space. This procedure is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link&amp;anchor=H7#H7\">",
"     \"Catheter ablation for ventricular arrhythmias\", section on 'Epicardial catheter ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential risks and benefits of the procedure, as well as alternative treatment strategies, should be discussed in detail with the patient prior to proceeding (",
"    <a class=\"graphic graphic_table graphicRef63157 \" href=\"UTD.htm?20/2/20524\">",
"     table 2",
"    </a>",
"    ). Patients must be aware that there is a small risk of heart block requiring a pacemaker as well as emergency cardiac surgery, stroke, and death related to the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several groups have reported on the rate of complications and predictors for complications following catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 1050 patients who underwent catheter ablation using a temperature controlled system, a major complication occurred in 3 percent and a minor complication in 8.2 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/46\">",
"       46",
"      </a>",
"      ]. Predictors for a complication included structural heart disease and the presence of multiple targets for ablation.",
"     </li>",
"     <li>",
"      In a report of 1676 consecutive ablation procedures performed at a single center in 2009 and 2010, major complications rates ranged from 0.8 to 6 percent depending on the ablation procedure (0.8 percent for supraventricular tachycardia, 3.4 percent for idiopathic ventricular tachycardia, 5.2 percent for atrial fibrillation, and 6 percent for ventricular tachycardia with structural heart disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/47\">",
"       47",
"      </a>",
"      ]. Other than procedure type, only renal insufficiency was associated with a higher risk of major complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential risks and approximate incidences are similar in younger and older patients and include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/30,31,48\">",
"     30,31,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Death (approximately 0.1 to 0.3 percent).",
"     </li>",
"     <li>",
"      Heart block requiring permanent pacemaker (1 to 2 percent).",
"     </li>",
"     <li>",
"      Thromboembolism, including stroke, systemic embolism, pulmonary embolism (&lt;1 percent). In a series of 232 patients undergoing RF ablation for atrial fibrillation, de novo left atrial thrombus was seen on intracardiac echocardiography in 24 (10 percent) despite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      anticoagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/49\">",
"       49",
"      </a>",
"      ]. In these cases, additional heparin was administered and the procedure catheter and sheath were withdrawn carefully while the patient was monitored. No clinical thromboembolic events occurred.",
"     </li>",
"     <li>",
"      Complications related to vascular access (2 to 4 percent), including bleeding, infection, hematoma, and vascular injury.",
"     </li>",
"     <li>",
"      Cardiac trauma, including myocardial perforation, tamponade, infarction, valvular damage (1 to 2 percent). The frequency of valvular complications is slightly higher with left-sided ablation using a retrograde aortic technique [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiation exposure. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Radiation exposure'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      After ablation for AF, pulmonary hypertension due to pulmonary vein stenosis occurring near the junction with the left atrium [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early and late coronary artery complications have been reported due coronary dissection, embolic events or radiofrequency catheter induced injury.",
"     </li>",
"     <li>",
"      Phrenic nerve injury can occur with sinus node modification for inappropriate sinus tachycardia (IST) or with AF ablation.",
"     </li>",
"     <li>",
"      Esophagoatrial fistula following left atrial ablation for AF has a reported incidence between 0.01 to 0.2 percent. Symptoms begin within 2 to 41 days and the overall mortality rate is approximately 67 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Radiation exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean duration of fluoroscopy in one report was 41 minutes, with a range of 15 to 67 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/53\">",
"     53",
"    </a>",
"    ]. The mean fluoroscopy time may be longer for paroxysmal atrial fibrillation than for common atrial flutter or accessory pathway ablation: 57 versus 20 to 22 minutes in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/54\">",
"     54",
"    </a>",
"    ] and 130 versus 30 and 17 minutes in another [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/55\">",
"     55",
"    </a>",
"    ]. Patient-specific factors can also affect radiation dose. In a series of 85 patients undergoing pulmonary vein isolation procedures for the treatment of atrial fibrillation, obese patients received more than twice the effective radiation dose of normal-weight patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential long-term risk of radiation exposure has been assessed in a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/55,57,58\">",
"     55,57,58",
"    </a>",
"    ]. One such report included 859 patients undergoing ablation of the AV node or accessory pathway in which the mean duration of fluoroscopy was 53 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/57\">",
"     57",
"    </a>",
"    ]. The radiation dose needed to cause radiation skin injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/59,60\">",
"     59,60",
"    </a>",
"    ] was exceeded during 22 percent of procedures. In this and another study, it was suggested that 53 to 60 minutes of radiation exposure during fluoroscopy would result in 0.7 to 1.4 excess fatal malignancies per 1000 women and 1.0 to 2.6 per 1000 men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/55,57\">",
"     55,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the risks of radiation exposure, clinicians and staff should be vigilant to try and minimize radiation exposure to the patient as well as the staff. Newer imaging and mapping techniques have reduced fluoroscopy times, particularly during complex ablations as for atrial fibrillation. Pulse fluoroscopy and optimization of fluoroscopy exposure parameters also reduces the risk of radiation injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;New arrhythmias are a potential concern, since radiofrequency lesions themselves might serve as arrhythmogenic foci. While this is a possibility, this problem has been seen clinically in only a few settings. New atrial fibrillation has occurred in patients undergoing ablation for atrial flutter; it is possible, however, that this occurs primarily in patients predisposed to atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/61\">",
"     61",
"    </a>",
"    ]. Incomplete ablation lines in patients treated for AF may predispose to left atrial flutter, which can cause more severe symptoms than the original AF.",
"   </p>",
"   <p>",
"    An inappropriate sinus tachycardia may be present in some patients after posteroseptal accessory pathway or AV nodal ablation, suggesting disruption of the parasympathetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sympathetic inputs into the sinus and AV nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. When this occurs, it is typically transient.",
"   </p>",
"   <p>",
"    Ventricular fibrillation has been reported in up to 6 percent of patients with chronic atrial fibrillation after AV nodal ablation when the pacing rate is &le;70 beats per minute [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/65\">",
"     65",
"    </a>",
"    ]. This complication can be minimized by post-ablation pacing for three months at a higher rate, ie, 90 beats per minute. A possible mechanism for post-ablation ventricular arrhythmia is activation of the sympathetic nervous system and a prolongation in action potential duration; pacing at a rate of 90 beats per minute decreases sympathetic nervous system activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Troponin I and BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of myocardial injury is more accurately assessed by serum troponin levels than CK-MB [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Elevated troponin I, present in up to 68 percent of patients undergoing ablation, correlates with the number of radiofrequency lesions applied, the site of lesions (ventricular &gt; atrial &gt; annular), and the approach to the left side (transaortic &gt; transseptal) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/67\">",
"     67",
"    </a>",
"    ]. The prognostic significance of asymptomatic elevations of troponin I remains unclear.",
"   </p>",
"   <p>",
"    Similarly, mild elevations of BNP, also of uncertain clinical significance, have been noted following ablation procedures. In a series of 36 patients undergoing ablation for supraventricular tachycardia, a transient rise in BNP was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/69\">",
"     69",
"    </a>",
"    ]. From a baseline of 11.3",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    BNP peaked three hours post-procedure at 40",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    and approached baseline 24 hours post-procedure. This rise correlated closely with modest troponin I elevations, as well as with the duration of ventricular stimulation and total RF energy application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current research is focused on improving mapping techniques, developing new imaging modalities, creating new catheter designs for enhanced energy delivery, and evaluating new energy sources for catheter ablation. Together, these efforts will undoubtedly extend the indications and improve the efficacy of catheter ablation. At present, they are concentrated on developing better catheter ablation techniques for the treatment of AF and VT related to chronic coronary artery disease.",
"   </p>",
"   <p>",
"    Traditionally, catheter mapping has been performed point by point. Several alternative methods have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multipolar basket catheters allow simultaneous registration of numerous endocardial sites [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/71,72\">",
"       71,72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A novel noncontact mapping system utilizing a 64 electrode balloon catheter uses inverse mathematics to simultaneous calculate and record several thousand virtual electrograms; this may be particularly useful for mapping nonsustained tachyarrhythmias or ventricular tachycardia that is not hemodynamically stable [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/73-75\">",
"       73-75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A nonfluoroscopic electromagnetic or electroanatomic mapping system allows construction of a three-dimensional activation and voltage map [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Integrated 3-phase mapping using body surface mapping from 62 torso sites utilizing unipolar recordings, regional body surface mapping, and local activation sequence mapping [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Real time 3-dimensional localization of intracardiac catheter electrodes using an externally applied electrical field [",
"      <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Improved imaging techniques will expedite catheter mapping and ablation. Intracardiac echocardiography, which uses a 9 to 12.5 MHz transducer mounted on a catheter, appears promising in this regard [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. This technique may be of particular utility in directing catheter ablation procedures for AF. Three-dimensional CT reconstructions have been extremely helpful in left atrial ablation procedures for AF; systems to register these images with three dimensional electro-anatomic maps are now available.",
"   </p>",
"   <p>",
"    New catheter designs are also in development. Circumferential ablation catheters may be more effective than standard \"point ablation\" procedures for pulmonary vein isolation to treat AF. For VT related to coronary artery disease, larger deeper lesions are needed to eliminate reentry circuits which may occupy several square centimeters or more, and may involve the endocardium, myocardium, and even epicardium. Newer catheter designs feature an actively cooled tip electrode, which results in a larger, deeper RF lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/23\">",
"     23",
"    </a>",
"    ]. An irrigated-tip catheter, which permits the use of higher energy, improves the ability to successfully ablate VT related to chronic coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/26,27\">",
"     26,27",
"    </a>",
"    ] and atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/81\">",
"     81",
"    </a>",
"    ] and may be useful in the ablation of accessory pathways refractory to standard ablation approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even though RF energy is vastly superior to and safer than DC energy, efforts continue to identify alternate energy sources for catheter ablation. Microwave energy has been tested in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/82\">",
"     82",
"    </a>",
"    ]. Cryothermal ablation offers the potential benefit of reversible cold mapping; if mild cooling has the intended effect, more profound freezing can inflict permanent tissue damage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. If limited cooling has an untoward effect or no effect at all, the tissue is allowed to thaw without permanent damage.",
"   </p>",
"   <p>",
"    Finally, robotic and computer-assisted systems for catheter movement are in development. These systems offer the potential for automating AF ablation procedures, which are at present extremely time-consuming, and reducing the radiation exposure for patient as well as operator [",
"    <a class=\"abstract\" href=\"UTD.htm?19/25/19866/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18348982\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Catheter ablation as a cure for arrhythmias resulted from the combination of electrophysiologic studies and arrhythmia surgery. After it became clear that surgical ablative techniques could cure arrhythmias and that transvenous catheter studies could identify both the tachycardia mechanism and the vulnerable site for surgical ablation, methods for catheter-based tissue destruction, or catheter ablation, were developed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Historical development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lesions resulting from catheter ablation are typically 7 to 8 mm in diameter and 3 to 5 mm deep, well suited for the ablation of focal arrhythmogenic sites. Since radiofrequency energy does not directly stimulate nerves or myocardium, the procedure is usually relatively painless, and general anesthesia is not necessary. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catheter ablation has become an important therapy in the management of patients with various types of tachyarrhythmia, including atrial fibrillation, atrial flutter, atrial tachycardia, AV nodal reentrant tachycardia, AV reentrant tachycardia associated with accessory pathways, and ventricular tachycardia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preprocedural evaluation prior to catheter ablation should include a history and physical examination along with an electrocardiogram (ideally during the arrhythmia) or strips from ambulatory monitoring that document the arrhythmia in every patient. Consideration of other testing prior to the ablation should be based on the patient's clinical presentation and symptoms but may include echocardiography, stress testing, cardiac magnetic resonance imaging, or coronary angiography to evaluate for underlying structural heart disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Preprocedural evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ablation and mapping techniques vary according to the arrhythmia being targeted and are summarized above. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ablation technique'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Mapping techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major complications following catheter ablation are rare, but patients should be made aware of several potential risks prior to the procedure, including death, heart block requiring permanent pacemaker insertion, thromboembolism, complications related to vascular access, cardiac trauma, and radiation exposure. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/1\">",
"      Morady F. Radio-frequency ablation as treatment for cardiac arrhythmias. N Engl J Med 1999; 340:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/2\">",
"      Guidelines for Clinical Intracardiac Electrophysiological and Catheter Ablation Procedures. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures). Developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 1995; 92:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/3\">",
"      Durrer D, Schoo L, Schuilenburg RM, Wellens HJ. The role of premature beats in the initiation and the termination of supraventricular tachycardia in the Wolff-Parkinson-White syndrome. Circulation 1967; 36:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/4\">",
"      Coumel P, Cabrol,C, Fabiatio A, et al. Tachycardes par rythme reciproque. Arch Mal Coeur 1967; 60:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/5\">",
"      Scherlag BJ, Lau SH, Helfant RH, et al. Catheter technique for recording His bundle activity in man. Circulation 1969; 39:13.",
"     </a>",
"    </li>",
"    <li>",
"     Wellens HJJ. Electrical stimulation of the heart in the study and treatment of tachycardias, Stenfert Kroese, Leiden 1971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/7\">",
"      Cobb FR, Blumenschein SD, Sealy WC, et al. Successful surgical interruption of the bundle of Kent in a patient with Wolff-Parkinson-White syndrome. Circulation 1968; 38:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/8\">",
"      Coumel P, Aigueperse J, Perrault MA, et al. [Detection and attempted surgical exeresis of a left auricular ectopic focus with refractory tachycardia. Favorable outcome]. Ann Cardiol Angeiol (Paris) 1973; 22:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/9\">",
"      Harrison L, Gallagher JJ, Kasell J, et al. Cryosurgical ablation of the A-V node-His bundle: a new method for producing A-V block. Circulation 1977; 55:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/10\">",
"      Pritchett EL, Anderson RW, Benditt DG, et al. Reentry within the atrioventricular node: surgical cure with preservation of atrioventricular conduction. Circulation 1979; 60:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/11\">",
"      Sundt TM 3rd, Camillo CJ, Cox JL. The maze procedure for cure of atrial fibrillation. Cardiol Clin 1997; 15:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/12\">",
"      Gonzalez R, Scheinman M, Margaretten W, Rubinstein M. Closed-chest electrode-catheter technique for His bundle ablation in dogs. Am J Physiol 1981; 241:H283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/13\">",
"      Scheinman MM, Morady F, Hess DS, Gonzalez R. Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. JAMA 1982; 248:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/14\">",
"      Gallagher JJ, Svenson RH, Kasell JH, et al. Catheter technique for closed-chest ablation of the atrioventricular conduction system. N Engl J Med 1982; 306:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/15\">",
"      Weber H, Schmitz L. Catheter technique for closed-chest ablation of an accessory atrioventricular pathway. N Engl J Med 1983; 308:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/16\">",
"      Morady F, Scheinman MM. Transvenous catheter ablation of a posteroseptal accessory pathway in a patient with the Wolff-Parkinson-White syndrome. N Engl J Med 1984; 310:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/17\">",
"      Haissaguerre M, Warin JF, Lemetayer P, et al. Closed-chest ablation of retrograde conduction in patients with atrioventricular nodal reentrant tachycardia. N Engl J Med 1989; 320:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/18\">",
"      Hartzler GO. Electrode catheter ablation of refractory focal ventricular tachycardia. J Am Coll Cardiol 1983; 2:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/19\">",
"      Scheinman MM, Evans-Bell T. Catheter ablation of the atrioventricular junction: a report of the percutaneous mapping and ablation registry. Circulation 1984; 70:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/20\">",
"      Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991; 324:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/21\">",
"      Calkins H, Sousa J, el-Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med 1991; 324:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/22\">",
"      Huang SK, Bharati S, Graham AR, et al. Closed chest catheter desiccation of the atrioventricular junction using radiofrequency energy--a new method of catheter ablation. J Am Coll Cardiol 1987; 9:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/23\">",
"      Ruffy R, Imran MA, Santel DJ, Wharton JM. Radiofrequency delivery through a cooled catheter tip allows the creation of larger endomyocardial lesions in the ovine heart. J Cardiovasc Electrophysiol 1995; 6:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/24\">",
"      Ja&iuml;s P, Shah DC, Ha&iuml;ssaguerre M, et al. Prospective randomized comparison of irrigated-tip versus conventional-tip catheters for ablation of common flutter. Circulation 2000; 101:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/25\">",
"      Yamane T, Ja&iuml;s P, Shah DC, et al. Efficacy and safety of an irrigated-tip catheter for the ablation of accessory pathways resistant to conventional radiofrequency ablation. Circulation 2000; 102:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/26\">",
"      Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coll Cardiol 2000; 35:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/27\">",
"      Soejima K, Delacretaz E, Suzuki M, et al. Saline-cooled versus standard radiofrequency catheter ablation for infarct-related ventricular tachycardias. Circulation 2001; 103:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/28\">",
"      Dinerman JL, Berger RD, Calkins H. Temperature monitoring during radiofrequency ablation. J Cardiovasc Electrophysiol 1996; 7:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/29\">",
"      Nath S, DiMarco JP, Haines DE. Basic aspects of radiofrequency catheter ablation. J Cardiovasc Electrophysiol 1994; 5:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/30\">",
"      Kay GN, Epstein AE, Dailey SM, Plumb VJ. Role of radiofrequency ablation in the management of supraventricular arrhythmias: experience in 760 consecutive patients. J Cardiovasc Electrophysiol 1993; 4:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/31\">",
"      Chen SA, Chiang CE, Tai CT, et al. Complications of diagnostic electrophysiologic studies and radiofrequency catheter ablation in patients with tachyarrhythmias: an eight-year survey of 3,966 consecutive procedures in a tertiary referral center. Am J Cardiol 1996; 77:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/32\">",
"      Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995; 332:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/33\">",
"      European Heart Rhythm Association (EHRA), European Cardiac Arrhythmia Scoiety (ECAS), American College of Cardiology (ACC), et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/34\">",
"      Tracy CM, Akhtar M, DiMarco JP, et al. American College of Cardiology/American Heart Association 2006 update of the clinical competence statement on invasive electrophysiologystudies,catheterablation,andcardioversion: a report of the American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training developed in collaboration with the Heart Rhythm Society. J Am Coll Cardiol 2006; 48:1503.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations, Lea and Febiger, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/36\">",
"      Michelucci A, Antonucci E, Conti AA, et al. Electrophysiologic procedures and activation of the hemostatic system. Am Heart J 1999; 138:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/37\">",
"      Blomstr&ouml;m-Lundqvist C. The safety of reusing ablation catheters with temperature control and the need for a validation protocol and guidelines for reprocessing. Pacing Clin Electrophysiol 1998; 21:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/38\">",
"      Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias. Results and mechanisms. Circulation 1994; 89:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/39\">",
"      Coggins DL, Lee RJ, Sweeney J, et al. Radiofrequency catheter ablation as a cure for idiopathic tachycardia of both left and right ventricular origin. J Am Coll Cardiol 1994; 23:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/40\">",
"      Stevenson WG, Sager PT, Friedman PL. Entrainment techniques for mapping atrial and ventricular tachycardias. J Cardiovasc Electrophysiol 1995; 6:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/41\">",
"      Cosio FG, Arribas F, Lopez-Gil M, Gonzalez HD. Radiofrequency ablation of atrial flutter. J Cardiovasc Electrophysiol 1996; 7:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/42\">",
"      Wu D, Yeh SJ, Wang CC, et al. A simple technique for selective radiofrequency ablation of the slow pathway in atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1993; 21:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/43\">",
"      Haissaguerre M, Gaita F, Fischer B, et al. Elimination of atrioventricular nodal reentrant tachycardia using discrete slow potentials to guide application of radiofrequency energy. Circulation 1992; 85:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/44\">",
"      Jackman WM, Beckman KJ, McClelland JH, et al. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry, by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med 1992; 327:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/45\">",
"      Yamabe H, Okumura K, Tsuchiya T, et al. Slow potential-guided radiofrequency catheter ablation in atrioventricular nodal reentrant tachycardia: characteristics of the potential associated with successful ablation. Pacing Clin Electrophysiol 1998; 21:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/46\">",
"      Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation 1999; 99:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/47\">",
"      Bohnen M, Stevenson WG, Tedrow UB, et al. Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias. Heart Rhythm 2011; 8:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/48\">",
"      Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/49\">",
"      Ren JF, Marchlinski FE, Callans DJ. Left atrial thrombus associated with ablation for atrial fibrillation: identification with intracardiac echocardiography. J Am Coll Cardiol 2004; 43:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/50\">",
"      Olsson A, Darp&ouml; B, Bergfeldt L, Rosenqvist M. Frequency and long term follow up of valvar insufficiency caused by retrograde aortic radiofrequency catheter ablation procedures. Heart 1999; 81:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/51\">",
"      Robbins IM, Colvin EV, Doyle TP, et al. Pulmonary vein stenosis after catheter ablation of atrial fibrillation. Circulation 1998; 98:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/52\">",
"      Siegel MO, Parenti DM, Simon GL. Atrial-esophageal fistula after atrial radiofrequency catheter ablation. Clin Infect Dis 2010; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/53\">",
"      Perisinakis K, Damilakis J, Theocharopoulos N, et al. Accurate assessment of patient effective radiation dose and associated detriment risk from radiofrequency catheter ablation procedures. Circulation 2001; 104:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/54\">",
"      Macle L, Weerasooriya R, Jais P, et al. Radiation exposure during radiofrequency catheter ablation for atrial fibrillation. Pacing Clin Electrophysiol 2003; 26:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/55\">",
"      Lickfett L, Mahesh M, Vasamreddy C, et al. Radiation exposure during catheter ablation of atrial fibrillation. Circulation 2004; 110:3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/56\">",
"      Ector J, Dragusin O, Adriaenssens B, et al. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. J Am Coll Cardiol 2007; 50:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/57\">",
"      Rosenthal LS, Mahesh M, Beck TJ, et al. Predictors of fluoroscopy time and estimated radiation exposure during radiofrequency catheter ablation procedures. Am J Cardiol 1998; 82:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/58\">",
"      Kovoor P, Ricciardello M, Collins L, et al. Risk to patients from radiation associated with radiofrequency ablation for supraventricular tachycardia. Circulation 1998; 98:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/59\">",
"      Koenig TR, Wolff D, Mettler FA, Wagner LK. Skin injuries from fluoroscopically guided procedures: part 1, characteristics of radiation injury. AJR Am J Roentgenol 2001; 177:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/60\">",
"      Koenig TR, Mettler FA, Wagner LK. Skin injuries from fluoroscopically guided procedures: part 2, review of 73 cases and recommendations for minimizing dose delivered to patient. AJR Am J Roentgenol 2001; 177:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/61\">",
"      Paydak H, Kall JG, Burke MC, et al. Atrial fibrillation after radiofrequency ablation of type I atrial flutter: time to onset, determinants, and clinical course. Circulation 1998; 98:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/62\">",
"      Kocovic DZ, Harada T, Shea JB, et al. Alterations of heart rate and of heart rate variability after radiofrequency catheter ablation of supraventricular tachycardia. Delineation of parasympathetic pathways in the human heart. Circulation 1993; 88:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/63\">",
"      Psychari SN, Theodorakis GN, Koutelou M, et al. Cardiac denervation after radiofrequency ablation of supraventricular tachycardias. Am J Cardiol 1998; 81:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/64\">",
"      Hamdan MH, Page RL, Wasmund SL, et al. Selective parasympathetic denervation following posteroseptal ablation for either atrioventricular nodal reentrant tachycardia or accessory pathways. Am J Cardiol 2000; 85:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/65\">",
"      Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 1997; 20:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/66\">",
"      Hamdan MH, Page RL, Sheehan CJ, et al. Increased sympathetic activity after atrioventricular junction ablation in patients with chronic atrial fibrillation. J Am Coll Cardiol 2000; 36:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/67\">",
"      Manolis AS, Vassilikos V, Maounis T, et al. Detection of myocardial injury during radiofrequency catheter ablation by measuring serum cardiac troponin I levels: procedural correlates. J Am Coll Cardiol 1999; 34:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/68\">",
"      Katritsis D, Hossein-Nia M, Anastasakis A, et al. Use of troponin-T concentration and kinase isoforms for quantitation of myocardial injury induced by radiofrequency catheter ablation. Eur Heart J 1997; 18:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/69\">",
"      Chen L, Wei T, Zeng C, et al. Effect of radiofrequency catheter ablation on plasma B-type natriuretic peptide. Pacing Clin Electrophysiol 2005; 28:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/70\">",
"      Schilling RJ, Davies DW, Peters NS. Clinical developments in cardiac activation mapping. Eur Heart J 2000; 21:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/71\">",
"      Rodriguez E, Man DC, Coyne RF, et al. Type I atrial flutter ablation guided by a basket catheter. J Cardiovasc Electrophysiol 1998; 9:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/72\">",
"      Schmitt C, Zrenner B, Schneider M, et al. Clinical experience with a novel multielectrode basket catheter in right atrial tachycardias. Circulation 1999; 99:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/73\">",
"      Schilling RJ, Peters NS, Davies DW. Simultaneous endocardial mapping in the human left ventricle using a noncontact catheter: comparison of contact and reconstructed electrograms during sinus rhythm. Circulation 1998; 98:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/74\">",
"      Schilling RJ, Peters NS, Davies DW. Feasibility of a noncontact catheter for endocardial mapping of human ventricular tachycardia. Circulation 1999; 99:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/75\">",
"      Strickberger SA, Knight BP, Michaud GF, et al. Mapping and ablation of ventricular tachycardia guided by virtual electrograms using a noncontact, computerized mapping system. J Am Coll Cardiol 2000; 35:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/76\">",
"      Smeets JL, Ben-Haim SA, Rodriguez LM, et al. New method for nonfluoroscopic endocardial mapping in humans: accuracy assessment and first clinical results. Circulation 1998; 97:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/77\">",
"      Peeters HA, SippensGroenewegen A, Wever EF, et al. Clinical application of an integrated 3-phase mapping technique for localization of the site of origin of idiopathic ventricular tachycardia. Circulation 1999; 99:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/78\">",
"      Wittkampf FH, Wever EF, Derksen R, et al. LocaLisa: new technique for real-time 3-dimensional localization of regular intracardiac electrodes. Circulation 1999; 99:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/79\">",
"      Fisher WG, Pelini MA, Bacon ME. Adjunctive intracardiac echocardiography to guide slow pathway ablation in human atrioventricular nodal reentrant tachycardia: anatomic insights. Circulation 1997; 96:3021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/80\">",
"      Kalman JM, Olgin JE, Karch MR, Lesh MD. Use of intracardiac echocardiography in interventional electrophysiology. Pacing Clin Electrophysiol 1997; 20:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/81\">",
"      Atiga WL, Worley SJ, Hummel J, et al. Prospective randomized comparison of cooled radiofrequency versus standard radiofrequency energy for ablation of typical atrial flutter. Pacing Clin Electrophysiol 2002; 25:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/82\">",
"      Jumrussirikul P, Chen JT, Jenkins M, et al. Prospective comparison of temperature guided microwave and radiofrequency catheter ablation in the swine heart. Pacing Clin Electrophysiol 1998; 21:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/83\">",
"      Skanes AC, Klein G, Krahn A, Yee R. Cryoablation: potentials and pitfalls. J Cardiovasc Electrophysiol 2004; 15:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/84\">",
"      Rodriguez LM, Leunissen J, Hoekstra A, et al. Transvenous cold mapping and cryoablation of the AV node in dogs: observations of chronic lesions and comparison to those obtained using radiofrequency ablation. J Cardiovasc Electrophysiol 1998; 9:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/85\">",
"      Skanes AC, Dubuc M, Klein GJ, et al. Cryothermal ablation of the slow pathway for the elimination of atrioventricular nodal reentrant tachycardia. Circulation 2000; 102:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/86\">",
"      Rodriguez LM, Geller JC, Tse HF, et al. Acute results of transvenous cryoablation of supraventricular tachycardia (atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, atrioventricular nodal reentry tachycardia). J Cardiovasc Electrophysiol 2002; 13:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/87\">",
"      Pappone C, Vicedomini G, Manguso F, et al. Robotic magnetic navigation for atrial fibrillation ablation. J Am Coll Cardiol 2006; 47:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/25/19866/abstract/88\">",
"      Reddy VY, Neuzil P, Malchano ZJ, et al. View-synchronized robotic image-guided therapy for atrial fibrillation ablation: experimental validation and clinical feasibility. Circulation 2007; 115:2705.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1007 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19866=[""].join("\n");
var outline_f19_25_19866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18348982\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - DC energy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - RF energy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other advances",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROCEDURAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Preprocedural evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ablation technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Reuse of ablation catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mapping techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Activation mapping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pace mapping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Entrainment mapping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Anatomic localization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Electrogram characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Scar mapping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Combined approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Epicardial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Troponin I and BNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18348982\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1007\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1007|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/28/43468\" title=\"table 1\">",
"      Indications for RF ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/2/20524\" title=\"table 2\">",
"      Complications EP study",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1007|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?37/12/38086\" title=\"waveform 1A\">",
"      EP study tracings AVRT concealed pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?34/14/35044\" title=\"waveform 1B\">",
"      EP study tracings concealed pathway ventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?16/54/17254\" title=\"waveform 1C\">",
"      EP study tracings post RF ablation concealed pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?16/49/17176\" title=\"waveform 2\">",
"      EP study tracings during atrial tachycardia mapping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/25/8598\" title=\"waveform 3A\">",
"      EP study tracings preablation mapping WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?19/5/19543\" title=\"waveform 3B\">",
"      EP study tracings post RF ablation WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?15/63/16373\" title=\"waveform 4A\">",
"      EP study tracings mapping slow AV nodal pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?4/62/5092\" title=\"waveform 4B\">",
"      EP study tracings RF ablation AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?16/5/16470\" title=\"waveform 5A\">",
"      EP study tracings RF ablation atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?7/47/7926\" title=\"waveform 5B\">",
"      EP study tracings bidirectional isthmus block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?18/4/18503\" title=\"waveform 6A\">",
"      ECG pace mapping RVOT tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/28/42436\" title=\"waveform 6B\">",
"      EP study tracings RF ablation RVOT tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/26/41385\" title=\"waveform 6C\">",
"      ECG pace map ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?32/12/32967\" title=\"waveform 7A\">",
"      ECG bundle branch reentrant ventricular tachcardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?29/21/30035\" title=\"waveform 7B\">",
"      EP study tracings bundle branch reentrant VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?10/10/10403\" title=\"waveform 7C\">",
"      EP study tracings BBRVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?29/54/30563\" title=\"waveform 7D\">",
"      EP study tracings RBB ablation for BBRVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/10/31905\" title=\"waveform 8A\">",
"      EP study tracings AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/44/21186\" title=\"waveform 8B\">",
"      EP study tracings RF catheter ablation of the AV junction in AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?19/37/20050\" title=\"waveform 9\">",
"      EP study tracings entrainment concealed fusion VT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=related_link\">",
"      Bundle branch reentrant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=related_link\">",
"      Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27305?source=related_link\">",
"      Electrophysiologic cardiac mapping: Use in specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=related_link\">",
"      Maintenance of sinus rhythm after cardioversion in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=related_link\">",
"      Restoration of sinus rhythm in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_25_19867="Objectives of mechanical vent";
var content_f19_25_19867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Objectives of mechanical ventilation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physiologic objectives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Support pulmonary gas exchange based on alveolar ventilation and arterial oxygenation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce the metabolic cost of breathing by unloading the ventilatory muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimize ventilator-induced lung injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical objectives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reverse hypoxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reverse acute respiratory acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relieve respiratory distress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prevent or reverse atelectasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reverse ventilatory muscle fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Permit sedation and/or neuromuscular blockade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease systemic or myocardial oxygen consumption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stabilize the chest wall",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Slutsky, AS, Chest 1993; 104:1833.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19867=[""].join("\n");
var outline_f19_25_19867=null;
var title_f19_25_19868="Vancouver and ILAR criteria for juvenile psoriatic arthritis";
var content_f19_25_19868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vancouver and ILAR criteria for juvenile psoriatic arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Vancouver",
"       </td>",
"       <td class=\"subtitle1\">",
"        ILAR (Edmonton revision)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        <strong>",
"         Inclusion",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Arthritis plus psoriasis or arthritis plus at least two of",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Arthritis plus psoriasis or arthritis plus at least two of",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dactylitis",
"       </td>",
"       <td class=\"sublist1\">",
"        Dactylitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nail pits",
"       </td>",
"       <td class=\"sublist1\">",
"        Nail pits or onycholysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        FHx of psoriasis in a first- or second-degree relative",
"       </td>",
"       <td class=\"sublist1\">",
"        FHx of psoriasis in a first-degree relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Psoriasis-like rash",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Exclusion",
"        </strong>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        <ol>",
"         <li>",
"          Arthritis in an HLA-B27-positive male beginning after the sixth birthday",
"         </li>",
"         <li>",
"          AS, ERA, sacroiliitis with IBD, reactive arthritis, or acute anterior uveitis, or a history of one of these disorders in a first-degree relative",
"         </li>",
"         <li>",
"          The presence of IgM RF on at least two occasions at least three months apart",
"         </li>",
"         <li>",
"          The presence of systemic JIA in a patient",
"         </li>",
"         <li>",
"          Arthritis fulfilling 2 JIA categories",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For both criteria sets, arthritis must be of unknown etiology, begin before the sixteenth birthday, and persist for at least six weeks. Under the Vancouver criteria, \"definite\" disease is arthritis plus psoriasis or arthritis plus three minor criteria, while \"probable\" disease is arthritis plus two minor criteria.",
"    <div class=\"footnotes\">",
"     ILAR: International League of Associations for Rheumatology; FHx: family history; AS: ankylosing spondylitis; ERA: enthesitis-related arthritis; IBD: inflammatory bowel disease; JIA: juvenile idiopathic arthritis;&nbsp;RF: rheumatoid factor.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19868=[""].join("\n");
var outline_f19_25_19868=null;
var title_f19_25_19869="Cancer risk Lynch genotypes";
var content_f19_25_19869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lifetime cancer risk related to Lynch genotypes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Cancer site",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        MLH1",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        MSH2",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        MSH6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2\">",
"        Women",
"       </td>",
"       <td class=\"subtitle2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2\">",
"        Women",
"       </td>",
"       <td class=\"subtitle2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Any Lynch cancer",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         76 percent*",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         80 percent*",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         73 percent*",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colorectal",
"       </td>",
"       <td>",
"        58 to 65 percent",
"       </td>",
"       <td>",
"        50 to 53 percent",
"       </td>",
"       <td>",
"        54 to 63 percent",
"       </td>",
"       <td>",
"        39 to 68 percent",
"       </td>",
"       <td>",
"        36 to 69 percent",
"       </td>",
"       <td>",
"        18 to 30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometrial",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        27 percent",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        40 percent",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        71 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        6 percent",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        12 percent",
"       </td>",
"       <td colspan=\"2\">",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper urologic tract",
"       </td>",
"       <td>",
"        2.1 percent",
"       </td>",
"       <td>",
"        0.4 percent",
"       </td>",
"       <td>",
"        20 percent",
"       </td>",
"       <td>",
"        9 percent",
"       </td>",
"       <td colspan=\"2\">",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric",
"       </td>",
"       <td colspan=\"2\">",
"        6 percent*",
"       </td>",
"       <td colspan=\"2\">",
"        5 percent*",
"       </td>",
"       <td colspan=\"2\">",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small bowel",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        3 percent",
"       </td>",
"       <td>",
"        6 percent",
"       </td>",
"       <td>",
"        3 percent",
"       </td>",
"       <td>",
"        6 percent",
"       </td>",
"       <td colspan=\"2\">",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biliary/pancreatic",
"       </td>",
"       <td colspan=\"4\">",
"        4 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain tumors (gliomas)",
"       </td>",
"       <td colspan=\"2\">",
"        1.7 percent",
"       </td>",
"       <td colspan=\"2\">",
"        2.5 percent",
"       </td>",
"       <td colspan=\"2\">",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sebaceous gland tumors",
"       </td>",
"       <td colspan=\"2\">",
"        42 percent of families",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        44 percent of families",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        0 percent of families",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable; ?: unknown.",
"     <br>",
"      * Not reported separately by sex.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Not reported separately by genotype.",
"       <br>",
"        &Delta; Percent of Lynch families with one or more members with sebaceous gland tumors.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Hampel H, Stephens J, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005; 129:415.",
"       </li>",
"       <li>",
"        Watson P, Vasen HFA, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123:444.",
"       </li>",
"       <li>",
"        Koessler T, Ostergaard MZ, Song H, et al. Common variants in mismatch repair genes and risk of colorectal cancer. Gut 2008; 57:1097.",
"       </li>",
"       <li>",
"        Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004; 127:17.",
"       </li>",
"       <li>",
"        South DC, Hampel H, Comeras I, et al. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 2008; 100:277.",
"       </li>",
"       <li>",
"        Barrow E, Alduaij W, Robinson L, et al. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 2008; 74:233.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19869=[""].join("\n");
var outline_f19_25_19869=null;
var title_f19_25_19870="Rhythm versus rate control AF AFFIRM";
var content_f19_25_19870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Rate control versus rhythm control in AFFIRM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 312px; background-image: url(data:image/gif;base64,R0lGODlh7gE4AeYAAP///4CAgAAAAEBAQMDAwKCgoPDw8ODg4NDQ0DAwMHBwcCAgIP8AABAQEFBQUGBgYLCwsAAz//+goJCQkP/AwKCz/4CZ//+AgP8gIEBm/xBA///w8P9AQODm/3CN//+wsP9QUPDz//8QEGCA/yBN/9DZ/8DN/7DA/1Bz/zBZ/5Cm//8wMP9gYP/Q0P+QkP/g4P9wcF8fn68PT98GH58TX9+mwH85n18/vw8v77+Mvz9W788JLyA8729Mv+8DD79soO+jsM8pT3A8r59jr6+Av28cj8C87+/T4M+Zv3Asn+4jMI9mv1Azv58yf38Zf++Dj6Bzv8Ct32Bw77Cw7zA5368wcCAyf3B8708jr0BQj98mPz8mvwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADuATgBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09ekIEwEFBoIGBfr87AkcSHCQgIMCBghKkFBAgoIQI8YrAODAQQAQBDgA4EAAhEEEAogcGYCAxJMouRFQICAAgAAtX8YUFJJkgAEuU+rcKa3AAAEKZLqEmRORSJ5IkzL7SWACUAAsJyg6qrSqVV8EEgRgKeCAxQUEFnSdWvSq2bOzDjAUsOAjgAJi/xdQJIu2rt1iVO/q3asrL9+/gAcpmJvvlN/AiO0ayPqAAAEHCk0dTkz5KgGECB8YLlu5s9IDARbgDDAhYKnJnlPvRHBgFWrVsCUigDxgQFDJnGPrhigWYeTTuXcLt6fRdfDhyOM5uJ3qdfLn7B40qG17M/Tr8H76to69O2Xn3sN/Q8AwrFTc4tOTS9CgwcrfpMCrn2/N44CQ8EfJp88/WoMJA0CwgGbo9WfgNTAhZFKBBzY4DYAOuMWggxQ2A4FLoCHAXYUcKrNATgNsNGGHJBIjwII3bVjiisEMaIABCRAIHIs0ApPgQQvOWOOOvPgUYSg1kYQTj0TiUsBcogQ50v+QRTY5C2TGOSklLHA5RoCGI06p5SnaHZSfKPttKSYn/4yEZHzHjalmJxdmqOKacHLC1WMyohnnPBS4QMFADTyQAH5v3pnOByyswMAKLOwp0In3PfBlKGEK+s0GIlygaEEDJLBAR+fpKGk6IIBwEgINHJSAaXZ+is4HImyQ0pXNpanqNx98gJIBCoQooaezTirBpSl16VGgvWbTAgsirAAsSjHB+CgokRbrjAQriMBCC0n9+JKIvEprjQQMuOCqUg+INsACojEHpqzeTsuABFcJ62W37UYDLrwNRluvMRLgmy+7+wacqsDOULDsgfoS/AsLF+iFKr0K84sBBrZKcsL/CRCFFcDDkAIccS8STOxvJB1ogHFBB/zUwK4df1zMBiFjMLIkKXiAkmMQu7wLBSAwwMHMkniQQkEPBNBarDr7IoGtFEgwLiQneGDB1BZ4oEEHmB7kwJmNHJBPaf38s88iCSetSswVS9JBBiRQTfXJBUEgnQANKHA0I10+BABDP+mdSNlmlwKzyJSEYEEEFoTAk9yYPWsIBC+KRUBGG3XEciGABw4KzD3/XEkFJGSANU/aJVDAAQWo24hYoMVEFEg23eSx5qPwzAAITn9OAglw8/SA3ZU4FdTrr9MUO5O0t9L005OATkIFVhWwIASXL8ISgcJDJUCnh2Se/CW1YuI8//Tx5pQrJB19WNJXYY319+zfb3KBCGk3vzv5Vl2GWXGP7O8SXGzhmiG8F79IbAAEK8BWJUqgARWgBQEDaIC5HIClnBWQEy1YAQiYJ4kQpMACd5FelC4YClY17BIoQIFdCGAABFgJVlkiYSYOSD9MWCAFiqsLoxpHLBlaglUbbEQFpOY2t1mtBHcxWplEIsCW+XAT4RNiBIhYxLexiIBPpEQFIoC/ylDni6pbVxYvYbBHbLGLldnfvGI4Rke0AAQnZMQZx4TFghjMYOOSAAcU2IgWeM4WMODA5j5wAQ4wAAOJkiIaU2OAfDCxh1dhgCQlaasLMOBghbDknijAgDiSwv9njjAkJl7wK0FQgAUY8NkFPsBBRcxxNx3ZDhsjyQAAgEuQlnQBCzhgK0K+wJYX8CMDWPArBsAgkCeUwCo5AIMN7JKPgtiACzjAARcA4FjMdNULVolMWx7yAqQEpwt+OU0QVEyUlKAADKoFAkXlCZpm5OJwgMIo+GGijgSRJABcMEwAWFIEhmQAKcMFABFgoAWpXAEMOOkzEbwLAIacGAMAeshCGPKYInhBsua3AgAwlAMOlQAMJrpHQzpUncbsma3QCQk9JmuhmnilcE7UANA4zhP4HMgkD+UqTQJgpBSg1Ao+QFCfcrJhRG2YKI8K0VoOogX9BMAL+GmrkbaAqUn/BQAomzquZAFgA7drKiQ+ILJfbkKmwmlAARywgOlA0iqSHCkGenpJf9aVBYdiAF032UmP9nWpf3WqKfsqCJ9qkqlM3SpLtwpKljbiA0ATnzyTcyRSNaCCA7OLPg0pKsPWlaGisqulEBtYvypVsIIQAf0+kMDbUQADIjCtbA9JgRewVKW5FGsrSnC4Re6GNYIA7izhWkuNvsuzikplxV6Qynb2lamAPW0h3ihJQYbsUNgibcMsyQBhDuKAE4WBIByLiChqogQqQIEGNJAB3+6GSSkaLmLAioFm0LB+lOhAeteLAhUg8ToQlGBt3CrfwPDTk8eAmQiCWLgTjIAEGujv/3+9oz+ErOytCjtWsvD7CBPcMAIfNEF/BjNCs1GgWteaxAkyoAESjOAEOTSQAsJoQYItT4sasMDoKOSoEkeslJc4Iokm0AAzYbhXG7gABpR1iRGkYMIcEtZNO5FTJ70AWe28hAdxuCIXWgmz+rHnmnhmLbNaogMpGEGMD2GCNptgzbjwQAbmgQDS3K3GgjoxBi7QykkwcASMiICgBd07QhxOxJ+IwJwbkYEIyKMAFgazGHu1NFNGlmQmOIEFNODeQggaAFuccwdGkIEMeCAEa4vACKA36gyMAMoA6ICcUYCxEpD61ADwsIMzgLEttq0DFdCxCrCmggzQWhCNlkcDHP8wuQRwqxNKEgnyJIW2SoQg2KXWQATYa+pOe9rRKlB1rjNggRGougQkALEHSvbB9RIiBOstt+g00O6hHY69gpb1tjNQgkZr2wQemCIKIoCxZMfjRIKIryeiLbtPxezSjTDBCNhrgROYYMeRGDSIc1gBUisaAIcGQLhHYIFGI1rkk9UvwQEQcN5GQMQBF/HHAdDoHNIbACGIgAoNDg9NbaVuR27S4GSWXxXsbt2ZEHTASaC4gHvABB8P+eFIPrUdh1wQUn951mW+aJ7P/OM8fwepTMUxJ6rJdn+URAUG/mJOfLrROyd4qEGOOBOUAMQW98CE754CE6z97igwAYTpLuL/kEeABBfn+cA1HQEHhh0eMAw6j24siRJYLQUqgHPSHV0yLjJQ0R/vQLpVeIIUCDoFGC+9oEEIOhAjcet0j0C/HS2IEAxcAzajOe3h0UgjF5hG5u2gClKAe1jHqTdrxDOLbEsxFZsbBd5ek0a+LHkOJbmTfVaErHc3bG8poE7Vd1ALXIABDpjZESvWwAhO7i1Iy1L5DiIzQDnMiBC0TfPSoht1aAwtMfPnnZVQcgrzIT5mfUB2CSXDfvuiAOqjD+EXHhrGZJgwAoCmMFL2gNhBLdYCT5VgAlcTMV7mGJJmdgfycNlHCeTWRppQZZ5BVkTHCZbHdCqYCSyYGJUGWZuA/17qFWGFNoOUUIOAUW0xxWIR5l8+uAlAuBcPxwlbZAHGpzO4MgCzUT39B4Hk94JnNVnJE0sE8ADPFmbYIX9pl4XR9zHbcx8Kl1nJAYCfgFbJYx8EECIYGIT0twkqV4YuIx0SJABNVIXDIYSdYHmm114yZAAdAXRzeBdLyAnXNnEk4AE9WEBlB39/sYjnVWyKZoRtlCljMwmR5w8AQTb+dxYUoGRYiAlRA2Grhn9PxBUC0BiQUGcJMQh84xCiSBkw404wAHGQAGwDVzNPOIMGAAE/MWWFoB2RQTkcMSzvExic41p2OHw6VwEYd4SDgAAMeBDgxwiXERnEMxNGMYoo8f+MuHOCkRCD6lcBrGiNAPATC6AAI7gI3ZhwrgOODDdtpHgBPVOOmuBgu9N27LgIE0CFjTCPAJA9UQE7NoGPZlGKuYMJjdhieheQ3NhCLxSPiIAPDsFC7MM6dGEWubgJ1/aL3UeRjbBD79cIwmISACQXt2gVEYhJFjNw7VWNJkk2qEMSffgJSYgOGphil+Bg9FaSNykJwiVclDgQ4CIulxCDj2iTRQkJ8GWMSCiO8XAvZ2YBEDaRUVkJAWYuBJaU9YCVk6BfxAeQXWkJFXYQF/Z7AtEvHbR205iWcrKTk/YXZjmN60iXlNB7j+SW8RCSj8BbxAd9e8mXlRBLyaeGAkH/jjJZCOiIloj5CfQUh1YpCT2ZDeT4kIoglI+ogJNJmQRQU2kIhvZgO/yoCBEJjKFpCmrFVmHJmPFAeYkwkiBGlK1ZCpXVHhiJU5fpDQfYmeZWk7mJIL+pDduULI8JAJbXYrhZnLhhE3ZJZcd5Dac0TI+pX1sZjNBJCmo0i4AJnNUCTogAbI0mmd2pCi9EfeHJDUuJCIKol+kZC0vkgO2pDWQ5CBH5iJE4n61wgfeZDXApCOjVaBmgif5JCyGoVok4DZU2CKmYjoeZoLEghwEaDaQ0MR9gm6xJobpQJixBlStYncigTtXyM7bGXtToob0gLATpm95AZgpFASFgdE/J/6K/EIJ3JpsOii9N80snMHDHhqPtkJm3IE0PJQjbRwKZR6TCQGQpaZrUcErJAi/6xWKv5qQmMh21wX88SaK5sE0TcwFH0HEQZphaWgwEqApG+goUAFIsQARCo2hOmKbIoDF/uXDHA6a2gAQ2oAPq1p92OgxrsZiccI98CgswkwPq5WLqOKjNMH0i2KC08Iwy0APPCanL8H0FGAyWGgNXAJqauhQ8dKGwYDsyEAM8oGOjOg25sn+U6go1YAM4kAJ42Kr10KackIsSp2qiiqvP8KpdGqumoEcMIANMkGNQCazQAKBiuQohMwO0aqvM2g1tQayhEK0x4KvV6g0JIKI0mP+omkBWMxADytqt2/CqDPGFdwkLcNkBQxAD1Iqu3NAlC9Cb1BkLSPoD5rZ+9HoWuroIVLoD5sqq/6oSASIIxJgjPEoKYjoDTkAF0Hew3yAdhNAn2BoJNcABPkADPWABv0qx2VAbhECypgoJecKoGnADP2AEEyqy1xBBAWEAsSmlnZAnhcIAO0ADS5CpMAsOkKY+YsE9NosJp2QoSkADRbAFaPqz6PAApXqyhkABTwAFQvqoTrsOdRYAL/qll5CLttm0WVsZmWOpNyCfY5saCfOpPCC2aau28IOqMaADT/e2wiEfSwNwN5AEUrCidjsczvGmM4AFNROyfwsbqPECIOD/A03gt4ebGKDYic1ICBswUlUwBY/rGbXoN+FICPMTBFGQuZ6hjJbzkUCAAVpQA6KrtvUoKyJxAiQgBLy4un/xjUVxjwOQBVYQO7zbu777u8AbvMI7vMRbvMZ7vMibvMq7vMzbvM5LvAx7Fwi5PQq5kKPxvNjbu7WRvdx7PNfbveC7veAbvt87vtnLkHXRke4zub0QsCNqI+JKgrzgvu7QktP5EvHrh+2bv/o7v/zrtchBv/f0v/n6CwJ8CQeMwAS8EwlcCQ38gwvMCQ88CRNMwRGcEhUcCRkMCRvMwRccrvCbHB3sCCPcCCVswh88wCGMHDiDFdGrCy3swr8Qw71A/8O0e8M4nMM6vMNJE7mTeAuRlwteQxo/rKD5ILm84EI7agvrORyb2wuyCK7/iRCcmwtRuwtjl8KTsD/CQbrMqAvIyAuQYwCS0yMVcRG9sBZaLAk4YsOqYbs1DJ694JG8sBLg2Bd1c8e34CXMdretG8dS7ArZ0ws+8RRY7BHFkwsOEABQW1O7Mb1EiwsGuQvXEwxMsQs3chBrPAmXrBvqu8S2oJF/UsSwkD4i8cK1kBVbcRCgTAsH4BhQ+wCtHAuq3MiknBj226KYgcqz4D+7oBYHca2+kMi3AMwOga88nMzKvMzMTGEEcDRK3My6ARMKQbMNcMvS/BdkjMjUawA3of8tr/oAGhISCCBCAGIbs5zNJ5ERYqE37BEADKEhH6IAEiQTpcLIQAHPvKzOKKEdGoIACYHPLvEepSITbtERi7zP/HwSBtmNIzE5GgEBDCETC2IAfnIQXbvQBTHJ7SE9E/APLSEgAkDRgvAAE2DHkazRDC3HsxHMkMMQ6DLSMIEipYKIKn3TOJ3TOr3TPN3TPv3TQB3UQj3URF3URn3USJ0UjsEPi5HOjGDR1WEI5yMJPoHMn7LUANDUnOyl16E1AHAZlwm1JGYIP/EIZU3SAuPVYL3FgdwKcuwOCrLWB6kriRCF4vzVYmE0hECMbDXSXw0ZCsAPj1EbUtE+JQETE+D/KG5xzsCjKnEdE/8gCJEdEhDgAA7gzQMwFwHNJJj9I+QsQoYQEo9BQTQB2PzwD17TGmtlGy/yzR8BGhCQK//DFnoN1+zRFjHBEgpQuofwzuyBOqUihYOQEVohFhihESyxEYx8E3xYAMEN0tPBymKtz7PiEBKUES5x1mUNEw3AEN1dKq1BN7tNvb4tALJ4z90T0O1x3MtRHCpzIjCxyGBR3i7kJaWSOvpn1eKQEJD2Ey7R3VnNP4UA0EGREVJx1oPQEa1R1h0hEsbdSA7AENnt1zOtPY+hESXRK/zdEBMuCNuNcLNY4bNoAAkB0DgBtSLxxQOEcCxx4Q4+0j8REPWc/9UOjeJrjd0A8NbtMIva4RLgqeM0ERNrjeAe7tdl7d8jsTf/4RQdTtIzbdFrkdFbwuOa3I5GLtMgrhAiHhkJ4dCnXOFGgXAzjeRHgeBy7OUlsdZrDeTrMIv64xKWg9hWXggSdOEaQuRCIdIHOX1yk+NgwRITDgGyaBIzbdIoXd0K8ebLuBwFveUkvZFQKxUd3RQgvSAAXRaIDQHr7RTM1ucIzimPMZpqRelqHhNs8czvAJ4ontWHeBt4Th4BVOSFYADuaNwv0Rsb4X7+jRGlkg9iDt81zdVqouoxgQBiEeFYbhIhDuKlYsgtzRYXgnB7fmcwERdYEhpejeAWXSoLcP8Az94WpT4UB6HfSe0MDgB+YF7uOuEAO5ru6v7u8B7va8Jw5lvv9n7v+J7v+r7v/N7v/j6+Cq0J9P7vBF/wBn/wCJ/wCr/wxhvw8v7wEB/xEq8lLxQQVf0IEHS/qzDVXUPEsvAPEhISTWSImGUSJJ8KFdTE+CsSO3ryXgM2UKHxilBnE3A0QUIRr2wlLU/awTUIkSvZwo7xLE8IktZChnDyPQ87Y5M6l7C1Nu97F4LE/UDaQwxmXvEWQU+ZmPER7p7eJiHXpcDmh4Dndd0WAFKhJbHIX/0nRTNA3AO1wdXWXsnxJOHXJ4LVhEAaFdEWcMHUp2IJEeLc/MDIkxok+Kj/9xUBaYMwASf9O4LQx5gQIQLSGqjj1z7/rW4vCJU/CAHAbPEF+ZQg+d3+Eo0BKyvxHpkf8wKSI6SSE6B/ChfR3zKR2AnbJm8RABD0itIDFLIt2VzL2o4CZo1E2ACAAI4S2BXBtb0ftEpkNDU/19pC9ojQ5wCwANg8CgIg2ApBYmox65w7ASwxCLComz1WCAVAIJbv/YIA/iU9F5GNCfeBv4gw+pcPO+mvsCKSMpyQAOMMCAECAISEDgoDhYQGCYUEgoUDEISDAAeJipmam4QJCAABAZyVhYyaoYsJD6KWmJyvsLGUgxMCD6ACDQMCAgcFAhMADQsICwIJCgS8Aw0C/wUAuwvGugILmbsKCg0HDQkB3QDKAszOCrkDCLvNBOYKDgKTu7KEqNAE8/j5pwsFD/H3AEgRgsAKQL+AjhToW6iJgKtF2ygNcACwEEFCExSCKtiIYSYDEQMsGBDAgKIAtxRdVCQQlINPhAaY9JiJwCqWih4UcJhpZSFSEBaEKiiTJiGbrESSnHnUmsqCkZ4ZQFcPGlOjC3nxSmBS0D1zBEAmgAAM1z1losiKkocWmkAEtggdqDXJHIK2agNi2jUTnAEBDtziqzegItbDCiZMSPCsMKVMAQCmMynw4WFZPE+mtBRuwYGTAA0syOYt0uWbnA080AgA5GfQmVqyYx35sv8lCAleIyR0MHOh2jh5KygwgLZhhgdwf/6smjWj48ALESekc+Pv47Zj8TK3oKuAe14BPDgmwPtZAaLaskUv2BF7et/Ntm07Liap+nrby5rACl12owh0BBIAFBHSAGQABZDAALu4Ytl/m/jWWkTXGBZdOAj4YxpWD2zmiCsonXJcS4/Rg51RVZHC4AAJNMAaKCMW0sBMnph4WVXhYMLIMwgqUgBXBjIoDY8XQvgKL24FFl544gSGS2TzsbfeWi010AAEuMFF0QIHRilKNQRcQso7BJUlzzwBTmikR9yYVAwAGQEAgZPS8RicJR6uWdNDIcrF3Iw+2knImxvS1KEiCWr/5JomBQi6WzhNFfKAbjQd8NoAdpIooUGOkrLAPaK9Nmmllz6TaGuMbdKodEBCVtCoeh45CDfOLBkfAMZMYokxFLGn3iC/ZoLAO/UVYEyNXuIiQDqkGPCOi/blo0ACqcaqz48MfjIVizAVcokmpATgqLXT6qIthZYsWK23rjwwUbc2GaXMis8omIADM/WZybe8NVivujCZctgB6mpE3DiCbsqvQf4CECCDPArMZsH0UIsvKLpkq8jCxzD4Yj0SW2vUX06JbPLJKHPywImopnway9BQ6jJ1MJ8y7sw05yMuzjnVDNnNPHNSC1RBF220PgcQowkjuh6NT9Ld5vQiz1DP//Oj03IpLcvVRle9dUdYhy322GSXbfbZaKet9tpst+3223DHjRkBdF+FNiLWHhDABHYXTfffR4nbt7NRg/oSzlEPOpPeE8jc2ksG/E3AJ8MdhsDelEbN+OCHD7rvTAVMDSDmR0lOz1AyE15I4gTdE7rloehWwIWXj6v6XAFoDrroKGvFS9OQ3bomfrKcuaZoEEzwYNBDQRIARQE8uHdOlaTjMgJ4+xgfAWMZa/f0eofiLqp96+MABAUA6kuzCyQvfTCW/FJKUBUVeNn56Xc1VCXf1Q0Z/OtTBEkmZwifxeJ8QfkMSriXIIpgZ3oAGA79WjPBAvIMSb9IxAHcVRwDiP+pOhscwAMSdwBEnM9h7lKASR4BAXdN4hdC8UUA5vIZ5Z1QP0ZqISG6M7aDSKJEpQAbnMwhKQNmpx8PeRh4NOKYIGqiOgYhGk0c8wigpISHTgwcKfT2KXZBqIm8SQmJUuEISIRxX8tjSI1yYxCFJI0TITudJURSkYW5DEm1uIVDUGKLYhxDAdzwhpUUAZIGoGQAgfxGIwRBjV6Yw1zq+E47yIRDCBHGiChbVFCG0pOCHIQU7HCZbybjmKT5wzI+iVQhhEiTRQHxkk+JTYUEWD6PuHJCrxmH/SxCtDG5a5dFkRdqKsETG2Kqk5o4ZkwME8w7aqVVSKxPePIYPeHVgkf/c4FHBJcVHrDkxy19acRfAmM8I8EybH0KHXGmBpzJPAoaotSRfxwzrBY2E0bXEFQa9YGaV/bHQjESIECz009QbOYzBPAMbO40gGAUI1+Y5ERy2EjMRKDEAM9ZqHQeAkZ8zmw71TBJO+ZlFlysIna/EZ6tqgie+ODHePipTzkhxJ+YJK5orgQUAGp0nYoxiHj7XFNmEsqgbtSTEInRaGeucZhD3amm0IhakVrS0SIZykO3jMRAGQqQJlqVIag4UDiUlBSoXOhHV6lqRLODpF2QEx4ZfNLkjgEBdnQLLgkgQAFeApiEHmilAfmUmApBJkEEY6b/SdOA0LmZLoYqUODy/1aeRLYpe4iHFQ4Q1KqiwlSjOPVOihVrnWQp0Jw4jiGfpcdB/3SVzf6kEBO4BUhmAivklIpAdXGoU344Wt60SqumxRmSaFUABDSjQbsCjJwSsBVK4YYXojDWMT4BWEEsy3jOygUTx5idaa3raLd8mDK9SFpQAG1N5fIPcJ21oKktLKE1mWw+5gUxhiEMqdRy1MIOdsx0dENRrPQIfY95S4KxSL+u4C+PpqXMOCKNYg5bUDCx5V5XdKw4DmMGMsgotw57GBYrg2OA0RZiTiDSaCWex86clmJZrDhoLY7Fiz9MYxp7jZBjcduNpXa0Hb+Ca07zMSeAHDQhq2rENU6ykoaXzOQmO/nJUI6ylKdM5Spb+cpYzrKWt8zlLnv5y2AOs5jHTOYym/nMaE6zmtfM5ja7+c1wjrOc50znOtv5znjOs573zOc++/nPgA60oAdN6EIb+tCITrSiF83oRjv60ZCOtKQnTelKW/rSmM60pjfN6U57+tOgDrWoR03qUpv61KhO9akDAQA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of the AFFIRM trial in which 4060 patients with atrial fibrillation (AF) that was likely to be recurrent were randomly assigned to rhythm or rate control. The primary end point was overall mortality. There was an almost significant trend toward lower mortality with rate control (21.3 versus 23.8 percent, hazard ratio 0.87, 95 percent CI 0.75 to 1.01).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Wyse DG, Waldo AL, DiMarco JP, et al. N Engl J Med 2002; 347:1825.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19870=[""].join("\n");
var outline_f19_25_19870=null;
var title_f19_25_19871="Divertics virtual colonoscopy";
var content_f19_25_19871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Virtual colonoscopy of colonic diverticulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 191px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Diverticula as seen on routine colonoscopy (arrows). Panel B: 3-D reconstruction of the diverticuli (arrows) is shown by virtual colonoscopy in which air insufflation of the colon is performed in conjunction with CT scanning.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of AK Hara, CD Johnson, JE Reed, Mayo Clinic, Rochester, MN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_25_19871=[""].join("\n");
var outline_f19_25_19871=null;
